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In chemical biology, there are many tools widely used for cell imaging, 
target/inhibitor identification, target screening and other functions, such as 
chemical probes or microarray technology. Chemical probes are mainly 
functioned in proteome study and bio-imaging, most of which are selective 
and accurate at cellular levels; however, microarray is mainly used in high 
throughput target screening and followed by target identification processes, 
which was highly efficient. This thesis mainly discussed about the 
development of novel chemical biology tools for interrogation of cellular drug 
targets at molecular and cellular levels. In this thesis, three projects were 
included. In Chapter 2, the development of a small molecule activity-based 
probe (ABP) of DNA methyltransferases 1 (DNMT1), T1, was described. The 
probe was a clickable analog of tryptophan and was able to covalently label 
endogenous DNMT1 and inhibit its enzymatic activity more effectively than 
previously known DNMT1 inhibitors (RG108 and its maleimide analogue 
1149). In addition, a new type of small molecule DNMT inhibitors based on 
tetrazole-containing compounds (Gn) which were analogs of 1149 was also 
discovered. Amongst these compounds, G6 possessed reasonable inhibitory 
activity against DNMT1 in both in vitro enzymatic assays and cell growth 
proliferation experiments. Both T1 and G6 showed effective labeling of 
endogenous DNMT1 from mammalian cells by using in vitro competitive 
pull-down and live-cell bioimaging experiments. Thus, in Chapter 3, we 
xi 
 
continued studying a protein methyltransferase, named DOT1L, a sole histone 
H3 lysine 79 (H3K79) methyltransferase, which is a promising drug target 
against mixed lineage leukemia. In this study, two photoreactive and ‘clickable’ 
probes P1 and P2 based on FED1were designed and synthesized. P1 is an 
exact mimic of FED1 hence less interference with protein-probe interaction is 
expected. P2 on the other hand, contains a minimalist linker extended towards 
a solvent exposed area of DOT1L which is advantageous for cellular imaging 
purposes. Here, the binding and inhibition efficiency of the two probes were 
examined both in vitro and in situ; the probes were used for localizing the 
target protein DOT1L via bio-imaging and proteome profiling assays. The 
target proteins were also validated. At last, Chapter 4 presents another 
chemical biology tool; the small molecule microarray used for controlled 
release of immobilized bioactive compounds and carrying out cell-based 
screening directly on this platform. In this project, PC-3 cells were grown 
on a functional peptide-bioactive compounds modified hydrogel microarray, 
and then controlled release of functionally active compounds enabled 
their cellular uptake and direct screening of their biological activities in 
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1.1 Overview of chemical biology tools 
In chemical biology, there are many tools widely used for multi chemical 
biology functions such as bio-imaging, target/inhibitor identification and high 
throughput screening. Among those tools, chemical probes or microarray 
technology, as examples, are broadly applied in the chemical biology studies. 
Chemical probes are mainly employed in proteome and bio-imaging studies, 
and most of them are selective and accurate at cellular levels. In contrast, 
microarray technology is mainly used in high throughput target screening 
followed by target identification processes, which was highly efficient. 
Besides, other chemical biology tools such as biosensors and imaging agents 
are also widely developed in the interrogation of proteomics and cellular drug 
targets.
[1]
 As those previous methods also suffer some limitations, researchers 
keep on exploring novel chemical biology tools for further addressing 
chemical biology issues. In this thesis, activity-based proteome profiling 
(ABPP) and small molecule microarray (SMM) will mainly be discussed; 
other chemical biology tools will only be briefly introduced. In addition, as an 
important part of proteomics study and cellular drug discovery, some of the 
most widely used biorthogonal reactions and bio-imaging technology will also 
be briefly elaborated. 
1.1.1 Activity-based proteome profiling (ABPP) 
After completing human genome sequencing, researchers intended to 
further study the cellular protein functions in complex biological systems, so 
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that proteomics was developed. Proteomics aims to accelerate the 
development of functional assignment by exploiting analytical methods for 
thousands of proteins in biological systems. Recently, to study specific protein 
properties, various technologies have been employed, such as liquid 
chromatography-mass spectrometry (LC-MS), microarray techonology and 
yeast two-hybrid assays. However, those methods only provide limited 
insights into the performance states of proteins in the native proteome.
[2]
 
Therefore, activity-based protein profiling (ABPP) has become an important 
method for cell-based proteome study. In recent years, ABPP has been widely 
used and matured as a standard method for the fast, sensitive, and selective 
identification of enzyme activity and inhibitors in proteomes.
[3]
 
Figure 1.1 General working scheme of activity-based proteome profiling (ABPP). 
Two types of bioactive molecules are chemically modified to provide the 
corresponding activity-based probes (ABPs) or affinity-based probes (AfBPs). 
Thorugh probe incubation of live cells or cell lysates, the proteins are covalently 
captured directly with the ABPs, or indirectly with the AfBPs via the aid of a 
photo-crosslinker. After labelling, a reporter is next covalently attached to the 
protein-probe complex via a bioorthogonal reaction. The captured proteins are then 
profiled and identified. 
Activity-based protein profiling (ABPP) was pioneered by Cravatt and 
Bogyo, and has become a promising chemical biology tool for the study of 
functional states of proteins in complex proteomics.
[4]
 ABPP is a chemical 
strategy utilizing active site-directed probes to profile the functional state of 
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enzymes in complex proteomes.
[5]
 To date, ABPP have been used in studying 
many enzyme classes, like phosphatases, kinases, methyltransferases, 
proteases, glycosidases and oxidoreductases. Based on the differences in 
targeting mechanisms, the corresponding ABPP probes can be roughly 
classified into two big categories, including the activity-based probes (ABPs) 
and affinity-based probes (AfBPs). The probes are normally built up by three 
fundamental building blocks (Figure 1.1): 1) an moderately reactive moiety 
called warhead (WH) that are reactive groups or affinity binding groups 
targeting the conserved mechanistic or structural feature of a set of proteins; 2) 
a click handle which subsequently links to a reporter for target protein 
identification and purification; and 3) a linker which modulates the reactivity 
and specificity of the reactive moiety and binding group, as well as providing 
enough space between the reporter and the warhead.
[2]
 During the design of 
these probes, one of the most important considerations is the installation of a 
chemical “traceable” tag to the original bioactive compounds under mild 
chemical conditions without introducing inefficient target binding; the tag 
must be small enough to decrease the disruption of the drug bioactivity and 
protein-ligand interactions, at the same time provide a click handle for 
subsequent protein enrichment and other downstream proteome assays. 
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Figure 1.2 Structures of activity-based probes (ABPs) generated from covalent 
bioactive small molecules. 
For activity-based probes (ABPs), the reactive moiety (warhead, WH) 
will covalently bind to the target protein at a specific position. This covalent 
modification is irreversible and helps report on protein-ligand interactions 
directly.
[6]
 Generally speaking, when designing a ABP, a terminal alkyne/azide 
handle will be introduced to the original bioactive compound because of its 
small size, chemically inert properties and ease of modification by clicking 
with a variety of azide/alkyne-containing reporters via the well-known copper 
(I)-catalyzed azide-alkyne [3+2] cycloaddition (CuAAC) reaction. To date, 
many ABPs have been developed for both in vitro and in situ applications as 
shown in Figure 1.2. Our group also made some contributions to the 
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development of activity-based probes. In a recent study, we developed an ABP 
of DNA methyltransferase (DNMTs) named probe T1 (probe 1 in Figure 
1.2).
[7]
 This probe is a clickable analogue of tryptophan and was able to 
covalently label endogenous DNMT1 with better inhibition efficiency than 
previously known DNMT1 inhibitors (RG108 and its maleimide analogue 
1149). In addition, in this study, we also discovered a new type of small 
molecule DNMT inhibitors based on tetrazole-containing compounds which 
were analogues of 1149. Amongst these compounds, which we called Gn, one 
of them (G6) possessed reasonable inhibitory activity against DNMT1 in both 
in vitro enzymatic assays and cell growth proliferation experiments. Both 
probe T1 and G6 showed effective labeling of endogenous DNMT1 from 
mammalian cells by using in vitro competitive pull-down and live-cell 
bioimaging experiments. 
In an earlier example reported by our group, we studied 
Tetrahydrolipstatin (THL or Orlistat), an FDA-approved anti-obesity drug with 
potential antitumor activities was explored and its on- and off-targets as well 
possible side effects were investigated. During the study, several 
alkyne-containing Orlistat analogues were designed and synthesized (Figure 
1.2, probe 2, 3 and 4),
[8]
 which, to our knowledge, were the first reported 
cell-permeable drug-like probes to demonstrate the feasibility of in situ 
proteome- -lactone parts are the 
warheads of these probes which covalently bind to their cellular targets 
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through a nucleophilic reaction.  
In 2010, a potent acyl protein thioesterase 1 (APT1) inhibitor named 
palmostatin B was identified by the Waldmann group.
[9]
 Palmostatin B, also a 
-lactone, has strikingly similar structure to THL. It was found that 
Palmostatin B can induce partial phenotypic reversion in oncogenic fibroblasts. 
Preliminary in vitro and cell-based experiments indicated that the cellular 
target of palmostatin B likely to be APT1.
[9]
 Therefore, in one extension study, 
an in situ proteomic approach was applied by making use of two “clickable”, 
alkyne-containing probes 5 and 6, both of which were found to have similar 
biochemical potency as the wildtype inhibitor palmostatin B.
[10]
 Based on their 
results, compared to probe 6, probe 5 was found to perform better in a 
proteomic experiment and was able to identify both APT1 and APT2 (an 
isoenzyme of APT1) as the cellular targets of palmostain B. That is 
presumably due to better accessibility of its alkyne handle to click reaction. 
A known anti-parasitic compound, K11777 (N-Mpip-Phe- Hph-VSPh) is 
a potent inhibitor against a variety of parasites (e.g. T. brucei) and currently in 
the late-stage preclinical trials for Chagas disease. To study parasites and 
corresponding diseases, series of chemical probes based on K11777 were 
developed, including a diazomethyl ketone (7), an azanitrile (8), and a vinyl 
sulfone (9).
[11, 12]
 Each of these probes contains an electrophilic warhead (WH) 
which could covalently label their target proteins in live parasites. The probes 
were then used in subsequent biological assays to identify potential unknown 
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K11777 cellular targets. With the newly developed probes in hand, for the first 
time, potential unknown cellular targets of K11777 in both BSF (bloodstream 
form) and PCF (procyclic form) of T. brucei were revealed and the new 
information could provide new clues for further investigation of K11777 as an 
anti-parasitic drug in both parasites and human cells.  
Another example is the development of monoamine oxidase (MAO) 
probes. On the basis of known irreversible MAO inhibitors, pargyline’s and 
deprenyl’s structures, probe 10 and 11 were developed by the Sieber’s group 
for the proteome study of MAO-A/B’s activities.[13] To our knowledge, 
pargyline and deprenyl have currently been used in clinical applications 
against Parkinson’s disease, therefore probe 10 and 11 have some significance 
in the therapy of Parkinson’s disease. Different from MAO-A, MAO-B’s 
activity has been associated with neurode-generative disorders. In the probes’ 
structures, the N-propargylamine group is essential to form a stable covalent 
bond via FAD cofactor-catalyzed oxidation and subsequent Michael addition. 
According to their results, both of the probes (10 and 11) were able to 
selectively label the target proteins (MAO-A and MAO-B) over other proteins 
in brain cancer cells. However, their probes cannot efficiently distinguish the 
two isoforms of monoamine oxidases. 
Besides the ABPs mentioned above, several protein kinases’ ABPs were 
also developed in recent years. Protein kinases (PKs) are important enzymes in 





A number of covalent inhibitors against different subclasses of PKs have been 
discovered, and some of the most promising ones have already been used in 
different stages of clinical trials.
[14, 15]
 Based on the previous research, some 
activity-based probes were applied in proteome study, for example, probe 12 
was used for isolation and enrichment of endogenous RSK.
[16]
 Then, the same 
group continued to design and synthesized two Src-directed probes 13 and 14, 
both of which contain structural elements from FSBA and the Src-family 
inhibitor PP1.
[17]
 The two probes were found to be cell-permeable, capable of 
covalently binding to the catalytic lysine
295
 and a poorly conserved proximal 
cysteine
277
 of c-Src expressed in mammalian cells respectively. However, in 
their study there were no further proteome-based experiments carried out to 
investigate the potential cellular targets of theses probes. 
Another example is using Showdomycin analogues as ABPs to decipher 
the cellular targets of Showdomycin. In 2010, probe 15 was developed by 
modifying Showdomycin with a 5- hexynoic acid tag.
[18]
 The probe has been 
proven to prossess identical MIC values as the original wildtype drug. In 
addition, there were 13 potential targets discovered (including MurA1 and 
MurA2), which are all important enzymes and function in bacterial cell wall 
biosynthesis. The prodrug probe 16 contains a chloromethyl group which can 
form a cyclopropane moiety in situ upon reacting with endogenous 
-D-galactosidase.
[18]
 During the proteome studies using this prodrug probe, 
ALDH1A1 was identified as its true cellular targets. 
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Figure 1.3 Structures of affinity-based probes (AfBPs) generated from covalent 
bioactive small molecules. 
Different from those enzyme classes can be targeted with ABPs above; 
there are also a majority of protein classes that do not have a known pocket 
containing conserved residues for covalent binding to inhibitors. In this case, 
the AfBPs are developed and employed in the study of those proteins that  
cannot react covalently.
[2]
 However, the transient protein-probe complex may 
not strong enough to survive the in vitro affinity purification conditions 
needed for enriching proteins as well as downstream target identification 
experiments. To address this problem, some suitable photo crosslinking 
reactions which can generate stable covalent protein-probe linkage were 
employed in the affinity protein capture using AfBPs (Figure 1.3). 
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Photo affinity labeling (PAL) has been around for decades to study 
different types of non-covalent interactions by utilizing a photo-reactive 
moiety or a masked electrophile, including protein-protein, protein-nucleic 
acid, protein-carbohydrate, protein-peptide and protein-small molecule 
interactions.
[6, 19-21]
 In 2012, one example reported that Dasatinib, a 
FDA-approved protein tyrosine kinase inhibitor, was converted to its 
corresponding cell-permeable probes, numbered 17 and 18 in Figure 1.3.
 [22]
 
By replacing the non-essential part of the original drug with a terminal 
alkyne-containing photo-cross-linker (diazirine for 17 or benzophenone for 
18), the resulting probes were able to retain most of the biological activities of 
the original drug. The probes were then applied into live cancer cells to bind to 
their potential cellular targets. After affinity protein capture, UV irradiation 
was employed to initiate the photo-crosslinking reaction and led to the 
covalent bond formation between proteins and probes. Subsequently, several 
proteome study and target identification experiments were carried out. This 
study is the first demonstration that a small molecule kinase inhibitor can be 
used for comprehensive profiling in live cells. 
In 2010, Yao’s group used a similar strategy on Imatinib which is another 
FDA-approved kinase drug, but the corresponding affinity-based probe was 
not active enough for downstream in situ proteome profiling.
[23]
 Thus in 2011, 
the same group developed probe 19 based on a natural product named 
staurosporine (STS) which is one of the most potent inhibitors against 
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numerous PKs with little selectivity.
[24]
 During the design of AfBPs, one of the 
most essential considerations is that when modifying the bioactive compounds, 
it is necessary to use the smallest photo crosslinkers containing a terminal 
alkyne or other suitable tags to minimize the interference on binding to the 
intended protein targets. To achieve this goal, the same group then designed 
“minimalist’ linkers” and used them in their following studies, such as the 
study of probes 20-23,
[25]
 as well as the most recent one, probe 33 (Figure 1.3). 
These probes can preserve most of the original compounds’ biological 
activities. More importantly, in the in situ proteome studies, these new probes 
can label their endogenous targets in mammalian cells more selectively and 
sensitively than the previous ones. 
Besides above, AfBPs based on type-II kinase inhibitors were also 
developed recently.
[26, 27]
 Based on the structures of known type-II kinase 
inhibitors which could only identify the inactive ATP-binding sites of certain 
PKs, Maly et al. identified two general scaffolds and generated two 
corresponding probes 24 and 25 (Figure 1.3).
[26]
 In their study, after chemical 
synthesis, the probes were used in subsequent proteome profiling and target 
identification assays. According to their results, a diverse set of PK targets 
were labelled, and some of them were also selectively labelled in in situ 
experiments. It should be noted that the probes were found to selectively label 
the so-called DFG-out inactive conformation of PKs, thus making the two 
probes useful for monitoring conformational changes occurring in certain 
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kinases during the signal transduction processes. In one of their more recent 
work in 2013, probe 26 was designed and synthesized (Figure 1.3) which is a 
Halo-tag conjugated Dasatinib probe enabling rapid and quantitative profiling 
of PKs’ active sites both in vitro and in situ.[27] Other probes based on 
Src-family kinases’ inhibitors were employed to study different mutations of 
Src and Hck, which led to a better understanding of the regulatory domain 
interactions’ effect on the ATP-binding site of kinases. 
Long time before the application of AfBPs in in situ cell-based proteome 
profiling, the PAL approach have already been used in endogenous protein 
labeling. In 2007, a classical example was reported by Taunton’s group.[28] On 
the basis of cyclodepsipeptide HUN-7293, probe 27’s potential cellular targets 
were identified. However, they didn’t conduct the cell-based proteome 
profiling in this study. In a more recent work, a clickable cell-permeable probe 
28 was developed, which was designed based on 3-Deazaneplanocin A 
(DzNep, a global histone methylation inhibitor) and synthesized to investigate 
the true cellular targets of DzNep (Figure 1.3). In addition to 
methyltransferases, other enzyme classes like kinases, phosphatases and 
ATPases were also identified.
[29]
 These findings might have significant 
implications in the consideration of developing DzNep as a validated chemical 
probe for further epigenetic and proteomic research. In recent years, similar 










Of course, AfBPs approaches are pretty useful in the study of epigenetics 
and proteomics at molecular and cellular levels, but there is no one experiment 
approach that can be perfect. One of the drawbacks that AfBPs suffer is the 
often unavoidable photo crosslinking of a probe to unrelated proteins, thus 
giving rise to the false positive labelling hits. To fix this limitation and get 
more accurate target identification results in the future studies, a number of 
AfBP strategies have been developed (Figure 1.4). One common used method 
is competitive labelling, in which the original bioactive compound or its 
analogues as control probes are used as competitors. 
Figure 1.4 Recent strategies for improved target identification 
Those improved strategies using competitors have already been used in 
actual studies. One example is the study of Sal-AMS which is a bisubstrate 
inhibitor that has potent antitubercular activity under both iron-rich and 
iron-deficient conditions. To explore its cellular functions, based on 
Sal-AMS’s structure, an affinity-based probe (29, Figure 1.3) was designed by 
the Aldrich group together with a control probe by replacing the 
benzophenone moiety with a phenyl group.
[33]
 The researchers noted that 
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MbtA was the target in mycobacteria. By combining the information of other 
off-targets of the probes, the overall picture provided might assist in 
developing further improved muti-target inhibitors or even corresponding 
probes with more potent activity and less drug resistance in further 
investigation.  
Another example was reported by Inoue’s group. They developed an 
active/inactive dual-probe approach to control the selectivity of PAL reactions 
toward detecting the specific small molecule-binding protein hCAII.
[34]
 This 
work proved that it was workable to tune the selectivity of an active probe in a 
complex proteomics system by employing an inactive probe simultaneously as 
a scavenger of nonspecific-binding proteins. 
In order to identify the potential cellular targets of an anti-proliferative 
compound, in 2012, the Park’s group reported the fluorescence difference in 
two-dimensional gel electrophoresis (FITGE) approach making use of an 
active AfBP 30 and an inactive AfBP 31(Figure 1.3) labelled with two different 
fluorophores.
[35]
 Their subsequent proteome profiling of the two probes using 
2-D gel electrophoresis allowed rapid identification of proteins which were 
only labelled by the active probe. 
In our most recent work, two affinity-based probes of DOT1L protein 
were developed named 32 and 33 here. DOT1L is the sole protein 
methyltransferase that methylates histone H3 on lysine 79 (H3K79), and a 
promising drug target against cancers. In this study, we designed and 
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synthesized photo-reactive and “clickable” affinity-based probes (AfBPs), P1 
and P2 based on FED1’s structure, which were excellent cell-permeable and 
structural mimics of FED1, one of the potent DOT1L inhibitors. Both the 
binding and inhibition efficiency of the two probes against DOT1L protein 
were thoroughly examined in vitro and in live mammalian cells (in situ). The 
probes were subsequently used, in live-cell imaging experiments, to study 
their cellular uptake and sub-cellular localization properties. The potential 
cellular off-targets of FED1 were also identified through large-scale cell-based 
proteome profiling experiments with P1/P2, followed by quantitative 
LC-MS/MS (SILAC). Amongst the potential off-targets identified, putative 
ribosomal RNA methyltransferase NOP2 was further confirmed to be likely a 
genuine off-target of FED1 by preliminary validation experiments including 
pull-down/Western blotting (PD/WB) and cellular thermal shift assay 
(CETSA). 
Over the past years, ABPP has developed into a mature, standard 
technology for rapid, sensitive and selective protein activity identification in 
complex proteomes.
[3]
 It is well known that the development of novel 
therapeutic compounds is important for the treatment of human diseases. 
Recent advance studies for proteome-wide characterizations of potential 
protein-drug interactions and drug candidates have shown great promises to 
collect information on both on- and off-targets at molecular or cellular levels 
in native cellular environments. In recent years, the technological 
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advancements in ABPP have accelerated these developments and will also be 
relevant for the success of other chemical biology approaches. 
1.1.2 Microarray technology 
In the past two decades, high-throughput screening methods using 
microarray technology have enabled thousands of biochemical interactions to 
be analyzed simultaneously in a single step, resulting in a paradigm shift in 
biology, medicine and drug discovery. In 1991, microarray-based technology 
was first introduced by Fodor et al.
[36]
 in the form of a peptide microarray, 
later which was adopted by Affymetrix and the Brown group
[37]
 to create the 
highly popular DNA microarray. Subsequently, small molecule and protein 
microarrays were developed by MacBeath et al.
[38]
 Early microarrays 
consisting of regularly repeating arrays of DNA were used to measure changes 
in gene expression,
[37]
 but more recently, microarrays have been extended to 
the high-throughput analysis of proteins, peptides, carbohydrates, small 
molecules, even live cells and tissues, with each technology possessing 
distinctive characteristics while providing unique opportunities.
[39,.40]
 In this 
thesis, only small molecule microarray and mammalian cell-based array will 
be discussed.  
Small molecule libraries provide a rich source for microarray screening 
because of their diverse biological properties.
[39a]
 Therefore small molecule 
microarray (SMM), as a high throughput screening (HTS) method becomes a 
powerful tool for the discovery of new protein-small molecule interactions, 
18 
 
which may generate potential lead compounds for drug discovery. By printing 
thousands small molecules on a single slide, the selectivity and drug potency 
of tested small molecule ligands against the target proteins can be rapidly 
screened and evaluated. 
 
Figure 1.5 General working flow of Small Molecule Microarray (SMM) technology 
(Copyright © 2015, Royal Society of Chemistry, license number is 3767401328220). 
Small molecule microarray consists of miniaturized assemblies of many 
small molecules immobilized across a planar glass slide, which has been 
extensively used for high-throughput studies of protein-small molecule 
interactions with minimal sample consumption. Immobilization strategies for 
SMM necessitate that the diverse molecular species and scaffolds are 
uniformly presented so as to maximize protein/enzyme–ligand interactions. 
Considerable effort has been expended to develop mild and selective methods 







synthesis step. In recent years, many chemical reactions under mild conditions 
have been applied in the small molecule microarray fabrication, such as the 
Staudinger ligation reaction,
[41]
 and other bioorthogonal reactions which will 
be discussed later in this thesis. 
Figure 1.5 explains the general working flow of a small molecule 
microarray (SMM). Once a small molecule library is obtained and 
immobilized on a standard glass slide to form a SMM, on which the 
target-contained complex is applied. After the targets capture, the whole slide 
is screened and the target hits could be identified. Subsequently, the hits are 
further validated via other specific biological assays more specifically and 
selectively. 
Different from the functionalization of in situ synthesized microarray, on 
which the biomolecules are immobilized while being synthesized on the array, 
the fabrication of spotted SMM needs a separate important immobilization 
step to complete the library synthesis processes, which is done by spotting the 
small molecules or biomolecules in small droplets onto suitable surfaces, 
normally a standard glass slide using a robotic dispensing system. The 
molecules can link to the pre-functionalized slides covalently or 
non-covalently, depending on the different immobilization strategy used. 
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Figure 1.6 Examples of Immobilization Strategy in SMM Fabrication 
Generally speaking, slide immobilization is the heart of most microarray 
technologies and can affect downstream microarray screening quality 
significantly. Many immobilization methods have been discovered with the 
development of microarray technologies. Several essential factors must be 
considered to choose a suitable immobilization method, such as molecular 
orientation, linkage chemistry as well as molecule stability.
[39a]
 In some 
previous reviews, the authors have extensively discussed the immobilization 
methods developed in recent years
[40b, 41a]
 and summarized some key methods 
based on different types of molecules, which can be broadly classified into 
three categories, including noncovalent immobilization, random covalent 




Different types of noncovalent interactions have been successfully 
employed in the small molecule immobilization on glass slides, like fluorous 
interaction and biotin/avidin interaction. In 2007, Schreiber’s group 
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constructed a small molecule library containing a fluorous tag and they 
anchored the library onto glass slides to form a SMM using the fluorous 
interactions. They used this array to screen potent inhibitors of the HDAc 
protein family.
 [42]
 In more recent work, Jeon and coworkers developed a 
fluorescent-tag-containing system by combining the fluorous interaction and a 
coumarin fluorophore. This design provided an opportunity for the evaluation 
of microarray fabrication in a stepwise manner via fluorescence detection.
[43]
 
Besides the fluorous interaction, Valles-Miret and Bradley presented a novel 
generic approach to immobilize any given compound libraries to form SMMs. 
This was achieved by spotting fluorous-tagged photo-reactive 
3-aryl-3-trifluoromethyldiazirine, which undergoes non-selective insertion into 
compounds through the UV-activation, onto fluorous-functionalized glass 
slides (Figure 1.6a). 
[44]
 
Random covalent immobilization 
Different from noncovalent immobilization, the covalent bonds formed 
between molecules and slide surfaces are more stable and robust. Therefore, in 
principle, covalent modification may lead to higher resistance ability to resist 
harsh washing conditions. Commercially available epoxy-, aldehyde- and 
N-hydroxysuccinimide (NHS)-coated slides are common choices for further 
immobilization, the pre-functionalized slides can also be prepared by 
researhcers to satisfy specific requirements. In 2006, Schreiber and his 
coworkers came up with several immobilization strategies, such as silyl 
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chloride/alcohol, diazobenzyldiene/phenol as well as acidic compounds. Those 
chemistries were employed to covalently anchor diversity-oriented 
synthesized small molecules onto microarrays. Subsequently, Bradner and his 
coworkers successfully applied isocyanate reaction to capture small molecules 
containing different functional groups (i. e. alcohols, amines, carboxylic acids, 
thiols and phenols).
[45]
 Five years later, Park’s group used pyridine vapor 
activation to immobilize a potential tyrosinase inhibitors library onto a 
isocyanate-functionalized slide and identiﬁed 2,4,4’-trihydroxychalconea as a 
new small-molecule binder named to tyrosinase with K
[46]
 The 
same team also discovered that compared to other molecules functionalized 
slides, poly(propyleneoxide) amine (also named Jeffamine) pre-coated slides 
could display higher signal-to-noise ratio. 
Site-specific immobilization 
This method is an important advance in the development of microarray 
fabrication because it allows the molecules to be immobilized in uniform 
orientations, which facilitate further molecular recognitions. To achieve the 
site-specific immobilization, a number of classical chemical reactions were 
employed in the small molecule library immobilization on glass slides, 
including Diels-Alder reaction, Staudinger ligation, thiol-ene reaction, native 
chemical ligation and so on. For instance, in 2012, Prof. Arumugam and Popik 
developed a Michael addition reaction-based reversible light-directed 
approach for surface functionalization and patterning.
[47]
 The unique 
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reversibility of o-naphthoquinone methide/thiol light-induced click chemistry 
not only allows various substrates to undergo patterned immobilization on a 
surface, but also provides a light-directed release or replacement of the 
immobilized substances (Figure 1.6b). Furthermore, the high stability and 
robustness of the reactive groups and the compatibility of the reaction with 
aqueous solutions makes it suitable for biological applications. In another 
example, Wittmann’s group proved that dienophile-containing carbohydrates 
are able to covalently bind to tetrazine-functionalized slides.
[48]
 In order to 
immobilize unfunctionalized carbohydrates on the slides, they continued to 
devise a bifunctional linker to install a dienophile moiety on the carbohydrates 
via a oxime reaction; the modified carbohydrates can bind to the 
tetrazine-functionalized slides directly (Figure 1.6c). In their study, these 
immobilization methods have been proved homogeneous and superior to 
previous reported amine- or thiol-based methods. 
However, as mentioned in the ABPP section, there are no perfect 
experimental procedures; each of these discussed small molecule 
immobilization approaches has its own limitations. For the noncovalent 
immobilization, the noncovalent interactions between small molecules and the 
slides may not be strong enough to survive in subsequent washing and 
screening processes. The random covalent immobilization approach provides a 
convenient way to modify microarrays without introducing extra tags in the 
original small molecules, which is also helpful to relieve the time and effort 
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for small molecule library synthesis. However, with the application of 
photo-assistant reactions, some key functional groups in the small molecule 
structures may react with the molecular handles on slides’ surfaces 
nonspecifically, which lead to blocking of protein binding sites. Finally, 
compared to other immobilization approaches, site-specific immobilization 
approach provides the most effective way for microarray functionalization, but 
using the immobilization method, a specific chemical tag should be introduced 
to the target molecules during library synthesis, which becomes the limitation 
of site-specific immobilization approach. Nevertheless, this limitation is still 
useful in retaining the protein biological activities.
[39a]
 
To date, small molecule microarray technology has been employed in the 
study of protein-small molecule or protein-protein interactions (PPI). For 
example, a recently developed SMM was used to rapidly and quantitatively 
screen hundreds of small molecule-based PPI inhibitors, and a potent inhibitor 
of the protein BRCA1 (a breast cancer-related protein) was successfully 
identified which showed good cellular activity in disrupting the association 
between BRCA1 and its binding proteins.
[49a]
 Actually, as early as 2010, the 
same group reported a Microarray-Assisted High-Throughput Identification of 
a Cell-Permeable Small Molecule Binder of 14-3-3 Proteins.
[49b]
 In that study, 
the researchers developed the first small-molecule PPI inhibitor of 14-3-3 
proteins. They carried out extensive biochemical assays to confirm their 
compounds’ potency against the target proteins and their cellular functions. 
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Subsequently, the same group continued to report several SMM-based work to 
study the protein-protein interactions
[49c-e]
 of different enzyme classes, which 
has great significance in the drug targets identification of different protein 
classes.  
Figure 1.7 General working flow of Cell-based microarray 
Besides the above microarrays, in recent years, researchers have started 
to focus on cell-based arrays (Figure 1.7). Cell-based screening is able to 
provide simultaneous information on multiple parameters for a given target, 
sometimes even multiple target proteins in a complex biological system.
[50]
 
With the improvement of quality and quantity of prilimery data, cell-based 
arrays may become a critical factor giving the increased number of emerging 
new targets. Until now, there are many studies on cell-based arrays reported. 
In 2004, Bailey et al. developed a microarray-based system for screening 
small molecules in mammalian cells, which is compatible with image-based 
screens and requires fewer than 100 cells per compound.
[51]
 In this study, the 
array consisted of biodegradable polymer spots containing small molecules, on 
which a monolayer of mammalian cells were placed and cultured. This method 
ensured each compound can only affect the proximal cells. Although this 
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method is seemed simple, there are still several barriers needing to be 
overcome in the future studies, e.g. drug diffusion and cross contamination. 
The subsequent studies conducted by Dordick and co-workers reported a 
miniaturized 3D cell-culture array for high-throughput (HT) toxicity screening 
of drug candidates.
[52] By using a ‘‘stamping’’ method to control the transfer 
of small molecules from one surface to another surface on which cells were 
grown, the authors effectively converted an SMM platform into an HT 
cell-based assay with minimal cross contamination between compounds. Most 
recently, our group reported controlled proliferation and screening of 
mammalian cells on a hydrogel-functionalized small molecule microarray.
[53]
 
In this study, A hydrogel-functionalized small molecule microarray has been 
developed, on which PC-3 cancer cells were selectively grown. Subsequent 
controlled release of immobilized bioactive compounds enabled cell-based 
screening to be directly carried out on this platform. 
Small molecule microarray technology has been extensively used for 
high-throughput studies of protein–small molecule interactions with minimal 
sample consumption.
[49]
 It offers a flat screening surface and the samples are 
readily applied using coverslips. It is also easy to wash and carry out following 
screening/data analysis procedures. Mammalian cell-based arrays enable to 
provide simultaneous information on multiple parameters for a given target, 
sometimes even multiple target proteins in complex biological systems. 
However, one of the greatest limitations of microarrays is the high cost of 
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instrument and small molecule library resources. The quality of array 
fabrication and the consistency of data are important factors that need to be 
improved. Even so, small molecule microarrays or even cell-based arrays have 
continued to remain a highly specialized chemical biology tool for researchers 
who have interests in drug discovery as well as proteomic and epigenetic 
studies at molecular and cellular levels. 
1.1.3 Other chemical biology tools 
Except activity-based proteome profiling (ABPP) and small molecule 
microarray mentioned before, in the discovery and interrogation of cellular 
drug targets studies, some other chemical biology tools such as molecular 
sensors, agonists and antagonists, protein modulators, and imaging agents 
were also employed. Some of the real examples are shown (Figure 1.8).
[1b]
 
Considering that each of the tools comes down to a broad research field, 
therefore among those, only reactive oxygen species (ROS) sensors, GPR30 
agonists and antagonists as well as β-amyloid PET imaging agents will be 
briefly introduced in this section as specific examples of those chemical 
biology tools (molecular sensors, agonists and antagonists, protein modulators, 
and imaging agents etc.). 
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Figure 1.8 Some examples of other chemical biology tools
[1b]
 (Copyright © 2013, 
American Chemical Society). 
Reactive oxygen species (ROS) sensors 
In cellular environment, the presence of reactive oxygen species (ROS) 
and reactive nitrogen species (RNS) will reflect the balance of the need for 
energy (ATP) generation via the oxidative phosphorylation (OxPhos) pathway, 
regulatory feedback mechanisms for oxygen metabolism as well as the 
biochemical functions of transition metal cofactors. In general, the 
mitochondria generates most of the intracellular ROS which can be triggered 
by radiation, aging, exposure to microbial toxins, hemorrhagic shock or 
activation of membrane associated death receptors.
[1b]
 Except genetically 
encoded redox sensors,
[54]
 using small molecules to detect ROS provides an 
active field of research focused on improving our understanding of cellular 
energy conversion and signaling pathways.
[55, 56]
 In addition, the commercial 
developments in ROS detection and regulation have been inspired by the 
opportunities to correlate the redox environment to the regulation of cell 
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division, immune response, circadian rhythms and cell apoptosis. Many 
fluorescent signaling ROS sensors have been developed, such as the one in 
Figure 1.8, the triple ROS/RNS fluorescent sensor. Some sensors also have 
additional cellular targeting capabilities. To design an efficient and 
mitochondria specific ROS sensor, it is often and sufficient to introduce a 
positive charge to the fluorescent probe. The specific ROS sensor should be 
able to offer information about morphology, number, or even membrane 
potential of these energy producing organelles. 
GPR30 agonists and antagonists 
As receptors, Orphan G-protein-coupled receptors (GPCRs), whose 
natural ligands are still unknown, can often be identified via sequence analysis. 
However, the study on the biology of novel GPCRs is limited because of the 
lack of selective tools. The identification of selective orphan and deorphaned 
GPCRs ligands (both agonists and antagonists) provides a valuable biological 
tool and may cause significant impact on academic research. In 2006, 
researchers screened a 10000-compound library designed to contain GPCR 
privileged structures. Based on their screening results, a robust hit compound 
(Figure 1.8, GPR30 probe) was identified, which inhibites the binding of 
estrogen to gene GPR30 (G-protein-coupledestrogen receptor, GPER1).
[57]
 
This tool compound was the first one to differentiate GPR30 from the classical 
 After this study, a number of other improved 
tools were discovered, in addition, the factors contributed to the successful 
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identification and characterization of GPR30 tools are widely used by 
researchers. The study on GPR30 modulators (agonists and antagonists) has 
never stopped since. 
β-amyloid PET imaging agents 
Alzheimer’s disease (AD) is the most prevalent form of dementia, which 
affects more than 18 million people worldwide. Different from other causes of 
dementia, the feature of AD is the presence of neuronal plaques consisting of 
-amyloid peptide 
[1b]
 Due to the lack of useful biomarkers, AD 
diagnosis in patients depends on a battery of complex exams and tests. One 
noninvasive method to detect the presence 




Among the imaging agents, one of the first of which called Pittsburgh 
compound B (PiB, Figure -amyloid fibrils) was 
developed in 2003.
[59]
 PiB is a carbon-11-radiolabeled analogue of 




imaging agents are still questionable because of their low therapeutic 
efficiency in an early stage of disease discovery.
 [1b]
 Therefore the 
-amyloid-targeting imaging agents is urgent and still 
needs further exploration.  
On the way of studying cellular drug targets at molecular and cellular 
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levels or even the chemical biology field, people cannot rely on one 
technology or old technologies. It is necessary to use multiple tools and keep 
on developing novel chemical biology tools to understand the chemical 
biology system deeper. 
1.2 Bioorthogonal chemistry and bio-imaging technology 
In proteomics study and cellular drug discovery, bioorthogonal reactions 
and bio-imaging are two important methods for target validation. In this thesis, 
the two biological assays will be briefly introduced as essential assistant target 
identification technologies. 
1.2.1 Bioorthogonal chemistry 
Bioorthogonal chemistry has been widely used in chemical biology, 
which normally displays the following properties
[61]
: 1) the reaction involved 
should proceed rapidly in aqueous media under bio-compatible conditions (pH 
and temperature); 2) being applied in biological environments, the reagents 
should be nontoxic to live cells or organisms; 3) the participating functional 
groups should not engage endogenous biological functionalities in competing 
side reactions, also called abiotic; 4) in terms of chemistry, the second reaction 




. It should be noted that 
the properties of bioothogonal reactions relate closely to the “click” chemistry 
concept (for example, both of them are highly selective and have good 
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functional group tolerance) and any other reactions that meets the demands of 
the former could be probably classified as an example of the latter.
[62]
 
During the last decade, bioothogonal chemistry has great development 
and applications in chemical biology, Figure 1.9 lists some hot examples of 
bioorthogonal reactions, including Staudinger-Bertozzi ligation, copper (I) 
catalyzed cycloaddition (CuAAC) between azide and terminal alkyne, 
strain-promoted cycloaddition between cyclooctyne and azide (SPAAC), 
strain-promoted inverse-electron-demand Diels-Alder cycloaddition 




Figure 1.9 Representatives of bioorthogonal chemistry 
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1.2.2 Bio-imaging technology 
In recent years, fluorescent-based bio-imaging has become a powerful 
tool in modern chemical biology; it is able to provide several advantages in the 
study at molecular and cellular levels, such as high sensitivity, non-invasive, 
safe detection and drastic modulation of fluorescent signals. Bio-imaging also 
allows the real-time detection and tracking of enzyme activities in live cells or 
whole organisms with high resolution as well as spatial and temporal control, 
which can help people obtain a better understanding of natural biochemical 
processes. Cellular imaging is becoming more relied on the development of 
novel fluorescent-based tools, among which, one of the most widely used is 
the genetically encoded fluorescent biosensors utilizing Green Fluorescent 
Protein (GFP) and its variants.
[64, 65] 
These have contributed remarkably to the 
important molecules in imaging and sensing as well as the key events in live 







 protein activities (i. e. kinases and protease),
[68-70]
 methylations as well as 
post-translational modifications.
[67, 71-74]
 This GFP-based approach is 
extremely powerful in the tracking of protein expression and localizations in a 
wide range of biological samples with lower photodynamic toxicity and 
photobleaching. However, it also suffers some limitations, for example: 1) 
GFP is a macromolecule which is difficult to be modified with less 
interference of its original fluorescent property; 2) the samples need to be 
genetically engineered; 3) GFP does not allow covalent capture of the target of 
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interest for further analysis and identification. Considering the inconvenience 
of using GFP, small molecule-based fluorescent probes have been 
comprehensively reported in recent years in the research of cellular-based 
studies both in vitro and in situ. One of the traditional methods is the 
development of fluorogenic substrates which contains synthetic short peptides 
attached to a fluorogenic or colorimetric molecule. Using these complex 
molecules, the in-cell target information can be obtained via the release of 
fluorophores/dyes after substrate cleavage.
[75]
 Furthermore, Fluorescence 
Resonance Energy transfer (FRET) is widely applied in the development of 
imaging-capable chemical probes, such as activity-based fluorescent probes as 
well as quenched activity-based fluorescent probes. Each of the existing 
approaches has its own limitations, such as weak signal, high background 
fluorescence and photobleaching, which lead to the further improvement of 
the whole bio-imaging technology. 
1.3 Objectives 
This thesis aims to discuss the development of novel chemical biology 
tools for the interrogation of cellular drug targets at molecular and cellular 
levels; it consists of two main parts to present activity-based proteome 
profiling (ABPP) and small molecule microarray (SMM) technology. In the 
first part, both of the novel developed activity-based probes of DNA 
methyltransferase 1 (chapter 2) and affinity-based probes of DOT1L, a type of 
histone methyltransferase (chapter 3) were introduced. Using those probes we 
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conducted series of biological assays to identify the cellular drug targets, 
tested the inhibition efficiency of the newly designed probes and their target 
capture efficiencies. In the second part (chapter 4), small molecule microarray 
technology was employed on a hydrogel-based matrix for the selective growth 
of live PC-3 cells and controlled drug release. In this study, mammalian cells 
were cultured directly on the SMM-based hydrogel matrix with highly 
cell-type selectivity followed by the caged-small molecule drug release to 
affect cell behaviors. In general, in this thesis, several novel developed 
chemical biology tools are presented. Further study on this field will proceed 
continuously. 
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DNA methylation is an important epigenetic modification catalyzed by 
DNA methyltransferases (DNMTs). Abnormal expression of endogenous 
DNMTs in human causes alterations in the genome methylation patterns which 
subsequently lead to the development of cancers. Thus detection of 
endogenous DNMT activities and efficient inhibition of DNMTs have 
important therapeutic significance. In this work, a small molecule 
activity-based probe (ABP) of DNA methyltransferases 1 (DNMT1), T1, was 
developed. The probe was a clickable analog of tryptophan and was able to 
covalently label endogenous DNMT1 and inhibit its enzymatic activity more 
effectively than previously known DNMT1 inhibitors (RG108 and its 
maleimide analogue 1149). In addition, we also discovered a new type of 
small molecule DNMT inhibitors based on tetrazole-containing compounds 
which were analogs of 1149. Amongst these compounds, which we called Gn, 
one of them (G6) possessed reasonable inhibitory activity against DNMT1 in 
both in vitro enzymatic assays and cell growth proliferation experiments. Both 
T1 and G6 showed effective labeling of endogenous DNMT1 from 
mammalian cells by using in vitro competitive pull-down and live-cell 
bioimaging experiments. 
2.2 Introduction 
DNA methylation is an epigenetic modification that leads to the addition 
of a methyl group at the C-5 position of cytosine residues of DNA without 
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interfering with usual base pairings. The process prevents gene expression, 
stabilizes DNA-protein complexes and promotes normal DNA expression.
[1-3]
 
In mammalian genes, the principle targets of DNA methylation are CpG 
sequences, ~60-90% of which have been methylated. However, there are some 
unmethylated regions called “CpG islands” which occur predominantly in the 
promoters of mammalian genes.
 
Hypermethylation of CpG islands is regarded 
as a common character of cancer cells because it will cause the silencing of 
tumor suppressor genes. Failure in maintaining normal DNA methylation 
patterns is associated with mis-expression of certain proteins, which may lead 
to cancers or other diseases. The abnormal DNA methylation has become an 
interesting and promising cancer therapeutic target. 
[4-6]
 
DNA methylation is catalyzed by DNA methyltransferases (DNMTs). 
This enzyme family mainly contains two categories, including the 
maintain-type DNMT1 and the de novo-type DNMT3.
[1,7-11]
 DNMT1 is the 
most abundant enzyme of human DNMTs expressed in somatic cells, which 
has high affinity for hemi-methylated DNA and helps to maintain the 
methylation patterns of DNA. DNMT3 presents in small quantities in somatic 
cells and has no differential affinity between unmethylated and 
hemi-methylated CpG sites; its main role is in de novo methylation. The 
catalytic mechanism of DNMTs has been studied extensively (shown in Figure 
2.1a).
[12] 
During the methylation processes, DNMTs first bind to the C-6 
position of cytosine residues of DNA, then transfer a methyl group from 
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S-adenosyl methionine (SAM; a methyl group donor) to the C-5 of cytosine, 
followed by the concomitant release of S-adenosyl-L-homocysteine (SAH). 
Subsequently, the proton at the C-5 position is removed and the free enzyme is 
released via -elimination to generate the methylated cytosine. 
Since the alteration in genome methylation and mis-DNA methylation are 
caused by the mis-expression of DNMTs, based on the catalytic mechanism of 
these enzymes, many small molecule DNMT inhibitors have been developed, 
including nucleoside analogues (5-Azacytidine and Zebularine), 
non-nucleoside analogues (Procaine, Procainamide, Hydralazine, Curcumin 
and RG108) and other SAH analogues.
[5,11,13]
 However, their relatively poor 
inhibitory activities towards DNMTs coupled with significant cytotoxicity 
make such compounds unsuitable as potential therapeutic agents. New potent 
and highly selective DNMT inhibitors are urgently needed. 
Activity-based protein profiling (ABPP) technology has become an 
important method for cell-based proteome profiling. Recently, its 
corresponding probes, activity-based probes (ABPs) and affinity-based probes 
(AfBPs) have also become promising chemical tools that enable reliable and 
comprehensive identification of potential “on” and “off” cellular targets of 
drug candidates.
[14-18]
 With such probes, proteome-wide assessment of 
bioactive compounds and their cellular mechanism-of-action can now be 
investigated at the earliest stages of drug development, thus potentially 
providing a better success rate in subsequent clinical trials.
[15]
 These so-called 
48 
 
“in situ drug profiling” strategies have in recent years been successfully 
applied to a number of biologically important drug candidates, including the 
FDA-approved anti-obesity drug Orlistat,
[19]
 several anti-cancer small 
molecule kinase inhibitors,
[20-24]
 and the newly developed epigenetic 
protein-protein interaction (PPI) inhibitor JQ-1.
[2]
 
Herein, we extend this approach to the study of DNMTs (Figure 2.1b-d). 
Inspired by two known DNMT1 inhibitors 1149 and RG108,
[26-28]
 two types 
of activity-based probes T1 and Gn were designed and synthesized (Figure 
2.1b). To design these compounds as potential covalent DNMT inhibitors, the 
maleic moiety in 1149 was strategically retained, which should result in 
covalent interaction between the compound and the active-site cysteine 
residue in DNMT1. In addition, a terminal alkyne and a tetrazole moiety were 
introduced into T1 and Gn, respectively, which would serve as click handles 
for reaction with azide- and alkene-containing reporters under copper 
(I)-catalyzed azide-alkyne [3+2] cycloaddition (CuAAC) conditions,
[29-32]
 and 
light-induced tetrazole-alkene-1,3-dipolar cycloaddition (LITAC) conditions, 
respectively (Figure 2.1c & 2.1d).
[33-35]
 In the case of Gn, we envisaged that 
the tetrazole moiety not only served as a well-known “photo-click” handle, it 
could also be an effective aromatic mimetic to introduce compound diversity 
(i.e. G1 to G12; see Table 2.1). The tryptophan analogue probe T1 was 
designed via conversion of a known DNMT1 inhibitor, 1149. The chemical 
structures of the two previously reported, azide-containing reporters are shown 
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in Figure 1d (TER-PEG-N3 & TER-Biotin-N3), and would be used to “click” 
to T1-labeled mammalian proteomes for subsequent in-gel fluorescence 
scanning, pull-down (PD)/Western blotting (WB) and bioimaging 
experiments. 
Figure 2.1 A) Schematic showing DNA methyltransferases (DNMTs) catalyze DNA 
methylation. SAM acts as the methyl group donor; B) Overall strategy of our probe 
(T1) and the inhibitor library (Gn) derived from known DNMT1 inhibitors 1149 and 
RG108; C) Workflow of ABPP and the corresponding competitive ABPP technology 




2.3 Results and Discussion 
2.3.1 Chemical synthesis of activity-based probes 
Probe T1 was a derivative of 1149, containing an additional small alkyne 
handle at the 5-position of the tryptophan indole ring. The probe was 
synthesized in five steps from the commercially available 
L-5-hydroxytryptophan as shown in Scheme 2.1a. Briefly, both the carboxylic 
acid and the primary amine group in L-5-hydroxytryptophan were first 
protected with a methyl and a tert-butyloxycarbonyl group, respectively. The 
resulted compound 1a was reacted with propargyl bromide under basic 
conditions to generate compound 1b (99% yield). Deprotection of the Boc 
group by TFA gave the free primary amine which was further reacted with 
maleic anhydride under refluxing conditions to afford the final probe T1 in 31% 
yield (two steps). 
 




The 12 tetrazole-based compounds Gn (n = 1-12) were synthesized in 
several steps as shown in Scheme 2.1b. Starting from the commercially 
available 4-nitro-3-phenyl-L-alanine, the carboxylic acid moiety was protected 
by a methyl group, followed by amine protection to give the corresponding 
Cbz-protected methyl ester, 2a. Subsequently, the nitro group in 2a was 
reduced by tin (II) chloride under acidic conditions to give 2b in 81% yield. 
Next, the diazonium salt was prepared by slowly adding a cold NaNO2 
solution into a cold solution of 2b (dissolved in 1:1 ethanol/water). 
Independently, 12 commercially available common aldehydes, N1-12, were 





A /% B /% A /% B /%
R1 86 35 R7 74 44
R2 88 43 R8 69 17
R3 84 48 R9 33 22
R4 37 35 R10 27 27
R5 24 9 R11 35 29
R6 57 51 R12 77 18
Table 2.1. Yield of reaction A & B
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at room temperature. Upon solvent evaporation, the corresponding 2cn (n = 
1-12) were obtained. Subsequently, they were re-dissolved in pyridine and 
cooled in an ice/NaCl bath to minus 10-20 
o
C for 20 min, then used to react 
with the above-described, freshly prepared diazonium salt (Reaction A). The 
resulting mixtures were allowed to warm to room temperature, thus affording 
the corresponding tetrazole compounds 2dn in acceptable yields (24-89%). 
Subsequently, the Cbz group in each compound was removed by H2/Pd-C 
treatment to afford compound 2en. Finally, further reaction of the primary 
amine in each compound with maleic anhydride in acetic anhydride/sodium 
acetate under refluxing conditions delivered the desired products Gn in 
acceptable yields (9-52% over two steps). The 12 analogues of Gn (n= 1-12) 
were so chosen based on their structural diversity and the commercial 
availability of their aldehyde precursors, thus delivering a variety of diverse 
aromatic groups linked to the core inhibitor structure via the centrally located 
tetrazole moiety (see summary Table in Scheme 2.1b). 
2.3.2 Biological Evaluation 
With all compounds in hand, we next confirmed the biological properties 
of these two types of probes via side-by-side comparison with known DNMT 
inhibitors. As mentioned earlier, the 12 Gn compounds were initially designed 
as covalent modifiers of DNMT1 (via the maleic amide moiety). Upon 
covalent reaction with endogenous DNMT1, we had planned to subsequently 
carry out LITAC reaction with a suitable reporter tag to detect the 
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probe-bound DNMT1 by taking advantage of the presumably bioorthogonal 
nature of the photo-induced tetrazole-alkene ligation reaction. To our great 
surprise, we found that this reaction was not as “bioorthogonal” as expected 
(Figure 2.2);
[33-35]
 by taking G6 as a model substrate, we found the compound 
rapidly reacted upon UV irradiation for 2 min under published conditions
[36]
 
with a variety of biological nucleophiles including acids, amines, thiols and 
others, yielding highly fluorescent products which were distinctly different 
from the nitrile imine intermediate initially released from UV irradiation. 
Upon further checking in the literature, we found that several reports had 
previously documented that the nitrile imine generated from a UV-irradiated 
tetrazole indeed readily react with different nucleophiles.
[37,38]
 Thus, Gn were 
not employed as activity-based probes in our subsequent experiments. They 
were nevertheless found to act as novel covalent inhibitors of DNMT1 from 
our present study (Table 2.1, Figure 2.3 & Figure 2.4). Overall, we assessed 
T1 and Gn’s ability to inhibit recombinantly purified DNMT1 in an in vitro 
enzyme inhibition assay. We subsequently evaluated their effects in inhibition 
of mammalian cell growth in an XTT anti-proliferation assay. Finally, we 
carried out in vitro cell-based proteome profiling experiments with T1 and 
competitive ABPP with Gn followed by cellular bioimaging. 
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2.3.2.1 Solution-phase photoclick property test of the tetrazole 
inhibitors Gn 
Because of the nonspecific ligations between tetrazoles and nucleophilies 
as reported before, 
[38, 39]
 we designed to test the photoclick properties of the 
tetrazole inhibitors in solution phase, here G6 was taken as a model substrate. 
Three nucleophiles were applied, including acetic acid, isopropylamine and 
glycine, which represent acid, base and amino acid classes respectively. To a 
solution of tetrazole inhibitor G6 in acetonenitrile (2 mM, 25 L), an aqueous 
solution of acetic acid, isopropylamine or glycine (100 mM, 25 L) was added 
(G6:nucleophile = 1:50, final solvent, ACN:H2O = 1:1). Using high compound 
concentration is to obtained better fluorescence signals. Then the mixture was 
irradiated under a 302 nm handheld UV lamp for 2 min with ice cooling. 
Sample which only contains G6 as a control was tested simultaneously. Based 
on Figure 2.2, before UV irradiation, there is no fluorescence showing up 
(samples 1, 3, 4, 5). However, after UV irradiation, the tetrazole was first 
activated to generate nitrile imine intermediate (sample 2) showing weak 
fluorescence signal, then nitrile imine can subsequently react with the 
nucleophiles existing in the reaction solution and yield highly fluorescent 




Figure 2.2 Photoclick test of tetrazole inhibitor G6. G6: 1 mM; Nucleophiles: 50 
mM (AcOH: acetic acid; iPA: isopropylamine; Gly: Glycine); UV source: 302 nm 
handheld UV lamp. 
2.3.2.2 Enzymatic inhibition against T1  
First, T1 and Gn library were evaluated for their inhibition efficiency 
against pure DNMT1 using DNMT Activity/Inhibition Assay Ultra Kit 
(Fluorometric, EpiQuik
TM
). Generally, with an increase in the inhibitor 
concentrations, a concomitant decrease in the enzyme activity was observed 
until a saturation point was reached (Figure 2.3a, left). For T1, when compared 
to RG108 or 1149, it appeared that introduction of the terminal alkyne in 
5-hydroxytrptophan did not have significant impact toward the inhibition of 
DNMT1. Interestingly, all tetrazole-based inhibitors, Gn (n = 1-12), appeared 
to possess reasonable inhibitory property against DNMT1 (Figure 2.3a, right); 
among them, G6 possessed the highest inhibitory activity against DNMT1 and 
inhibited the enzyme even more effectively than the two known DNMT1 
inhibitors, RG108 and 1149. This thus provides the first direct evidence that 
the tetrazole moiety in these compounds indeed served as a good mimic to the 
indole ring of tryptophan and could effectively bind to the DNMT1 active site 
via non-covalent interactions. Encouraged by these preliminary results and due 
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to high cost of the DNMT1 enzymatic assay, we subsequently carried out 
cell-based assays, ABPP and cell-based imaging experiments to further assess 
selected compounds. 
 
Figure 2.3 a) Left: dose-dependent inhibition assay of T1, Gn as well as the positive 
controls (RG108 and 1149) against recombinant DNMT1; Right: Inhibition assay of 
different inhibitors at 2 M; b) GI50 plot of several inhibitors against MCF-7 cells; c) 
Fluorescence-activated cell sorting (FACS) results of MCF-7 cells treated with 10 
M probes (T1, G6, 1149 and RG108). 
2.3.2.3 Cell proliferation 
Inhibition of DNMT1 induces cell death and apoptosis of human cancer 
cells that harbor abnormal active DNMTs, such as MCF-7 breast cancer cell 
line.
[1]
 In the XTT cell proliferation assay (Figure 2.3b, 2.4 & Table 2.2, 2.3), 
we observed the corresponding dose-dependent inhibition of T1 and Gn 





two known inhibitors (RG108 and 1149) were subsequently determined and 
summarized in Table 2.2 & 2.3. According to the results, it was obvious that 
T1 showed better inhibition than both 1149 and RG108. The results once 
again confirmed that the tetrazole-based compounds had reasonable GI50 
against MCF-7. G6, the smallest-size tetrazole amongst the 12 compounds, 
showed the best inhibition efficiency which was consistent with the earlier in 
vitro DNMT1 enzyme inhibition results. It is also noted that T1 showed much 
better inhibition properties than 1149, which may be due to its better solubility 
and cell permeability. The good inhibition potency of T1 and G6 against 
MCF-7 was further determined by Fluorescence-Activated Cell Sorting (FACS) 
experiments (Figure 2.3c); by using a BD Pharmingen 
TM
 FITC Annexin V 
Apoptosis Detection Kit I to stain the inhibitor-treated cells with FITC Annexin 
V (detecting apoptosis) and propidium iodide (PI; detecting cell death), the 
fluorescence signals were quantified. Based on the data histogram, it was 
observed that after treating live MCF-7 cells with inhibitors at a concentration 
of 10 μM, both T1 and G6 showed a noticeable increase in the number of 
Annexin V labelled cells (Figure 2.3c). T1 caused 61~62% cell apoptosis and 
death; the value was higher than that of the known DNMT1 inhibitor RG108. 
These results thus indicate that both T1 and G6 indeed were relatively potent 






Table 2.2 Structures and GI50 values of probe T1 
and control inhibitors 1149 & RG108 
 
Table 2.3 Structures and GI50 values of the tetrazole-based inhibitors Gn 
 
Probe Structure GI50/M Probe Structure GI50/M 
G1 
 
0.38 ± 0.06 G7 
 
1.10 ± 0.06 
G2 
 
1.16 ± 0.07 G8 
 
6.15 ± 0.07 
G3 
 
0.48 ± 0.06 G9 
 
1.86 ± 0.05 
G4 
 
0.87 ± 0.06 G10 
 
0.73 ± 0.07 
Probe Structure GI50/M Mark 
T1 
 






7.31 ± 0.07 Control inhibitor 
RG108 
 





1.08 ± 0.06 G11 
 
1.77 ± 0.06 
G6 
 
0.30 ± 0.06 G12 
 
0.78 ± 0.05 
 
 
Figure 2.4 FACS plots of MCF-7 cells treated with the probe and inhibitors 
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2.3.2.4 Target profiling with T1 and competitors 
T1 showed better potency against DNMT1 than both RG108 and 1149, 
and as a covalent modifier of the enzyme, its terminal alkyne could serve as a 
clickable tag for subsequent cell-based proteome profiling and target 
identification.
[15,19]
 To do so, we first obtained the optimized T1-proteome 
labeling conditions: 100 g of freshly prepared MCF-7 cell lysates were 
incubated with 10 M of T1 for 1 h at room temperature, followed by 2 h of 
CuAAC click chemistry with previously reported protocols (using 
TER-PEG-N3 or TER-Biotin-N3).
[19]
 Subsequently, the same conditions were 
used for dose-dependent, competitive ABPP by using lysates of mammalian 
cells pretreated with either G6, 1149 or RG108 (Figure 2.5a, b); in-gel 
fluorescence scanning results showed some distinctly fluorescent bands at < 
70 kDa, but not at ~183 kDa, where the labeled endogenous DNMT1 was 
expected to appear. This indicates T1 was not able to directly profile the 
presence of endogenous DNMT1 under such experimental conditions, 
presumably due to the low endogenous expression level of the enzyme in 
mammalian cells and insufficient detection sensitivity of the probe. We 
therefore carried out profiling experiments by using an alternative strategy, the 
competitive ABPP followed by click chemistry with TER-Biotin-N3, then 
protein enrichment by pull-down (PD) followed by DNMT1 visualization with 
Western blotting (WB) analysis (Figure 2.5c, d); successful detection of the 
endogenous DNMT1 (~183 KDa) in T1-labeled proteomes, but not in the 
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unlabeled proteome clearly showed that T1 indeed was a novel activity-based 
probe of DNMT1 capable of covalent labeling of endogenous DNMT1 from 
complex mammalian protein lysates, albeit with a low sensitivity (thus 
rendering the labeled target detectable only upon enrichment and signal 
amplification). When the same labeling/PD/WB experiments were carried out 
on lysates of mammalian cells pre-treated with increasing concentrations of G6, 
1149 or RG108, we observed concomitant decreases in the signals of the 
labeled DNMT1, indicating all three inhibitors effectively competed for 
binding to the active site of DNMT1 even under complex cellular 
environments. The success of competitive ABPP also confirmed that the 
covalent labeling of DNMT1 by T1 was indeed activity-based, making it the 
first known ABP of DNMT1 to our knowledge. 
 
Figure 2.5 a) In gel-fluorescence scanning profile of MCF-7 cell lysates labeled with 







concentrations. The corresponding Coommassie Blue stained gels were shown (right). 
b) ~ d) In vitro competitive PD-WB targets validation experiments with probe T1 and 
competitors (G6, 1149 and RG108). b) In gel fluorescent scanning profile of the PD 
samples; c) WB validation of the target DNMT1; d) competitive PD-WB results. 
2.3.2.5 Bioimaging 
Bioimaging is another interesting way to report endogenous enzyme-drug 
interactions, including drug uptake amount and target localizations.
[40-49]
 In 
recent years, small molecule-based activity-based probes have been used to 
successfully image endogenous cellular targets.
[24,25,45,46-49]
 Since T1 appeared 
to possess better cellular activities than both RG108 and 1149, and it was also 
a more potent DNMT1 inhibitor, we reasoned that it might serve as a potential 
DNMT1 imaging probe as well. To confirm this hypothesis, we carried out 
cellular imaging experiments (Figure 2.6). MCF-7 cells were first treated with 
an optimized amount of T1 (5 M) for 30 min in a cell culture incubator. 
Subsequently, cells were fixed with 3.7% formaldehyde, permeabilized by 0.1% 
Triton X-100, and clicked with TER-PEG-N3 by following previously 
optimized protocols.
[19, 24]
 The same cells were further treated with 
anti-DNMT1 antibodies by following standard immunofluorescence (IF) 
protocols, then stained with Hoechst to visualize their nuclei. Finally, cells 
were imaged by fluorescence microscopy under four different imaging 
channels (Figure 2.6); no fluorescence was detected in cells treated with 
DMSO alone. Strong T1 fluorescence signals were detected throughout the 
nuclei of the cells (green), which co-localized reasonably well with signals 
obtained from the immunofluorescence with anit-DNMT1 antibodies (IF; red;), 
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clearly indicating that T1 was able to bind to endogenous DNMT1 in live 
mammalian cells. 
A competitive imaging experiment was developed to test whether our 
newly developed, tetrazole-based DNMT1 inhibitors, e.g. G6, were indeed 
able to bind to the same DNMT1 active site in live mammalian cells as T1, 
thus directly competing with T1 for binding to the enzyme. Live MCF-7 
mammalian cells were pre-treated with either G6, RG108 or 1149 (100 M) 
for 1 h prior to incubation with T1 as earlier described, then imaged (Figure 
2.4; panels 7-24); a significant decrease in the fluorescence signals was 
detected in T1-labeled cells pre-treated with G6. Interestingly, neither RG108 
nor 1149 were as effective as G6 in competitively decreasing the fluorescence 
signals of labeled cells, once again indicating G6 was a better DNMT1 
inhibitor than both RG108 and 1148 under native cellular environments. 
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with Hochest 33342. Panel (5~8): cells were treated with DMSO as negative control. 
Panel (9~12): cells were treated with 5 µΜ T1. Panel: (13~16): cells were pretreated 
G6 (50 µΜ); Panel (17~20): cells were pretreated G6 (100 µΜ); Panel (21~24): cells 
were pretreated with G6 (500 µΜ); Panel (25~28): cells were pretreated 1149 (50 
µΜ); Panel (29~32): cells were pretreated with 1149 (100 µΜ); Panel (33~36): cells 
were pretreated 1149 (500 µΜ); Panel (37~40): cells were pretreated with RG108 (50 
µΜ); Panel (41~44): cells were pretreated with RG108 (100 µΜ); Panel (45~48): 
cells were pretreated RG108 (500 µΜ). Insert: Probe/IF/BF images merged with 
nuclei images (NU). Scale Bar: 10 µm. 
2.4 Conclusion 
We have successfully developed two types of novel chemical tools for the 
study of DNMT1, an small molecule, activity-based probe (T1) and twelve 
tetrazole-containing small molecule covalent inhibitors (Gn; n = 1-12). We 
found T1 could serve as an effective activity-based profile for cell-based 
profiling of endogenous DNMT1 expressed in mammalian cells, albeit with 
relatively low detection sensitivity. The taget should also be validated via 
LC-MS/MS to ensure the target DNMT1 and potential off-targets. Further 
improvement will clearly be needed on this probe in order to make such 
profiling experiments a routine endeavor for future chemical and cellular 
studies of DNMT1 biology. As tetrazole-derived tryptophan analogs, G6 was 
found to be a novel small molecule inhibitor of DNMT1, with better inhibitory 
activities than well-known DNMT1 inhibitors such as RG108 and 1148 under 
both in vitro and cellular settings. G6 was initially designed to serve not only 
as a covalent inhibitor, but also a potential activity-based probe of DNMT1. 
Unfortunately, throughout our preliminary studies, we found the so-called 





 and the UV-irradiated tetrozole intermediate (nitrile imine) 
appeared to react with many common biological nucleophiles.
[37, 38] 
More 
extensive studies are underway to better understand such reactions and results 
will be reported in due course. We caution however, the bioorthogonality of 
“photo-click” chemistry needs to be carefully scrutinized before it is used in 
other chemical biological applications. Nevertheless, based on our in vitro 
DNMT1 inhibition assay, XTT anti-cell proliferation assay, FACS, in situ 
competitive APBB as well as cellular imaging results, we could confirmed that 
G6 was indeed a reasonable DNMT1 inhibitor and may be further developed 
into a useful chemical tool for the study of DNMT1 biology. 
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DOT1L is the sole protein methyltransferase that methylates histone H3 
on lysine 79 (H3K79), and a promising drug target against cancers. Small 
molecule inhibitors of DOT1L such as FED1 are potential anti-cancer agents 
and are useful tools to investigate the biological role that DOT1L plays in 
human diseases. FED1 showed excellent in vitro inhibitory activity against 
DOT1L, but its cellular effect was relatively poor. In this study, we designed 
and synthesized photo-reactive and “clickable” affinity-based probes (AfBPs), 
P1 and P2, which were excellent cell-permeable and structural mimics of 
FED1. Both the binding and inhibition efficiency of the two probes against 
DOT1L protein were thoroughly examined in vitro and in live mammalian 
cells (in situ). The probes were subsequently used, in live-cell imaging 
experiments, to study their cellular uptake and sub-cellular localization 
properties. These results revealed that, while both P1 and P2 readily entered 
mammalian cells, most of them were not able to reach the cell nucleus where 
functional DOT1L resided. This offers a plausible explanation for the poor 
cellular activity of FED1. Finally, potential cellular off-targets of FED1 were 
identified through large-scale cell-based proteome profiling experiments with 
P1/P2, followed by quantitative LC-MS/MS. Amongst the > 100 candidate 
off-targets identified, NOP2 (a putative ribosomal RNA methyltransferase) 
was further confirmed to be likely a genuine off-target of FED1 by 
preliminary validation experiments including pull-down/Western blotting 
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(PD/WB) and cellular thermal shift assay (CETSA). 
3.2. Introduction 
Protein methyltransferases (PMTs) play essential roles in epigenetics by 
the regulation of gene expression and chromatin-dependent signaling via the 
methylation of chromatin-associated substrates (e.g. histones). There are 60 
PMTs encoded in the human genome, including 51 protein lysine 
methyltransferases (PKMTs) and 9 protein arginine methyltransferases 
(PRMTs).
[1]
 Abnormal activities of PMTs lead to many diseases, especially 
cancers. Selective inhibition of protein methyltransferases is a promising new 
approach in drug discovery.  
Most of the PKMTs have a conserved SET domain, except DOT1L, 





is the only PKMT that methylates histone H3 on 
Lysine 79 (H3K79),
[1,3]
 a chromatin mark associated with active chromatin 
and transcriptional elongation.
[4]
 DOT1L is a key enzyme involved in 
tumorigenesis and an attractive target for potential cancer treatments. For 
example, in mixed lineage leukemia (MLL), the translocation of the MLL gene 
generates fusion proteins with AF10, AF4 and ENL proteins in which DOT1L 
is recruited.
[5-7]
 This causes mis-regulation of DOT1L’s activity culminating in 
an increase in the methylation level of H3K79 at hox genes which are 
well-recognized markers for MLL-rearranged leukemia.
[2,8]
 Due to DOT1L’s 





 Among them, FED1, a SAM analogue, is a potent DOT1L 
inhibitor (IC50 = 2.9 ± 0.2 nM
[1]
; Figure 1) capable of selectively inhibiting 
DOT1L methylation of H3K79 by occupying the S-adenosylmethionine (SAM) 
cofactor binding site. Analogues of FED1 (i.e. EPZ-5676) have recently 
entered clinical trials.
[10]
 Relatively poor cellular activities of FED1 and its 
analogues (e.g. 4- day incubation of cells with FED1 was typically needed in 
cell-based experiments
[11]
), have thus far restricted these novel chemical 
agents to be used more widely in the studies of DOT1L and its potential 
therapeutics. Little is known about why these compounds were ineffective in 
situ (e.g. in live cells). Similarly, potential cellular off-targets of these 
compounds have not been comprehensively studies under native cellular 
environments.  
Activity-based protein profiling (ABPP) is an important method that 
enables proteome-wide profiling of target-probe interactions under native 
cellular settings.
[12-16]
 By using the so-called activity-based probes (ABPs) or 
affinity-based probes (AfBPs), derived from bioactive compounds, this 
strategy has recently become a promising tool capable of large-scale 
identification of potential “on” and “off” cellular targets of drug candidates.[13] 
Up to date, we have successfully applied such “in situ drug profiling” 
strategies to a number of biologically important drugs (and candidates), 
including the FDA-approved anti-obesity drug Orlistat,
[17]
 several anti-cancer 
small molecule kinase inhibitors,
[18-22]
 and the newly developed epigenetic 
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protein-protein interaction (PPI) inhibitor JQ-1.
[23]
 Furthermore, a “clickable” 
affinity-based probe (AfBP) derived from 3-Deazaneplanocin A (DzNep), 
which is a global histone methylation inhibitor that also targets many other 
SAM-binding proteins, was recently reported.
[24]
 This probe, named DZ-1, is 
the only known attempted in situ-enabled AfBP against PMTs. Due to 
relatively weak binding and low selectivity of this probe toward most PMTs, 
however, it is not suitable to directly label endogenous PMTs (including 
DOT1L) whose expression levels are maintained at low levels in most cell 
lines. In the present study, we have successfully developed two novel AfBPs, 
P1 and P2, which are “minimalist” probes of FED1 (Figure 3.1). Both in vitro 
and in situ experiments indicated both probes were indeed excellent structural 
mimics of FED1 and possessed good cell-permeability and cellular activities 
in targeting DOT1L protein. The probes were subsequently used, in live-cell 
imaging experiments, to study their cellular uptake and sub-cellular 
localization properties. These results revealed that, while both P1 and P2 
readily entered mammalian cells, most of them were not able to reach the cell 
nucleus where functional DOT1L resided. This offers a plausible explanation 
for the poor cellular activity of FED1. Finally, potential cellular off-targets of 
FED1 were identified by carrying out large-scale cell-based proteome 
profiling experiments with P1/P2, followed by quantitative LC-MS/MS 
(Figure 1a). Amongst the > 100 candidate off-targets identified, NOP2 (a 
putative ribosomal RNA methyltransferase) was further confirmed to be likely 
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Figure 3.1 a) Overall workflow of our probes used in proteome profiling, bioimaging, 
and pull-down analysis for target identification in this study. Reaction of the alkyne 
handle on the probe with TERodamine–azide through click chemistry allowed 
visualization of target proteins by in-gel fluorescence scanning and fluorescence 
microscopy. Target identification was done by pull-down experiments followed by 
quantitative LC-MS/MS (SILAC) experiments with biotin–azide. b) Synthetic 
scheme of probe P1, P2 and control inhibitors FED1, C1 and C2. 
Figure 3.1a illustrates the overall work flow of this study. The cells or 
cell lysate were first incubated with the probes/control inhibitors, then UV 
irradiation was introduced to finish the photo crosslinking processes, so that 
the probes can covalently bind to the target proteins. After labelling, the 
protein-probe complex was clicked with functional reporters such as 
TERodamine-azide (TER-N3) or Biotin-azide (Biotin-N3) therefore following 
biological assays can be carried out (proteome assays, bioimaging and target 
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validation and quantification, etc). With those experiments conducted, we 
want to quantitatively compare the performance differences between the two 
probes P1 and P2 tagging with difference approaches in order to understand 
the influence caused by drug modification approaches. 
3.3 Results and Discussion 
3.3.1 Design and synthesis of P1 and P2 
The probe synthesis part was done by Zhang Hailong, here I want to 
express my appritiation to him. 
As a SAM analogue, FED1 may bind to not only DOT1L but also many 
other potential proteins that require SAM. Thus the target profiling of FED1 
could help to answer its poor cellular activities, which have not been 
comprehensively studied under native cellular environments. Besides, drug 
localization in cells is paramount to deciding its cellular activities. Cellular 
compartmentalization divides proteins into specific organelles where 
biological processes are dynamic and highly regulated. Misplacing FED1 in 
cells will diminish the efficacy of the therapeutic outcome as DOT1L localizes 
in the nucleus. In order to resolve its cellular position, it is imperative that the 
probe reproduce the drug’s structural properties to deceive the cell. Recently, 
two FED1-based probes were reported by Bradner
[11] 
with introduction of a 
biotin or a fluorophore to FED1. Based on their structures, these probes were 




in situ target identification and localization of FED1, but were instead used to 
develop in vitro biochemical and cellular assays to screen activities of 
DOT1L’s inhibitors.  
In order to achieve excellent cell-permeable and structural mimics of 
FED1, we first strategically retained the core structure of FED1 in our AfBPs 
P1 and P2 to maintain its cellular activities (Figure 3.1a). Next, P1 was 
designed by modifying the tert-butyl group of FED1 to trifluoromethyl 
diazirine and the N-isopropyl group to a terminal alkyne. The chemical 
structure of P1 is highly similar to that of the known DOT1L inhibitor FED1, 
which should maintain most of the bioactivities and hence qualify it for an 
alternative “minimalist” tagging. On the other hand, P2 was designed by 
conveniently attaching our “minimalist” linker to FED1. Such 
photo-cross-linker contained both diazirine and a terminal alkyne in 
“minimalist” size, which minimizes interference to the target proteins 
binding.
[19]
 This strategy has been applied to tag a variety of bioactive 
compounds with reasonable success on proteome study, target validation and 
bio-imaging.
[19, 23, 24] 
Since both P1 and P2 were carefully designed to 
resemble FED1’s structure with smaller size of modifications, they should be 
more suitable for predicting FED1’s original bio-activities in live cells. In 
both designs, upon photo-irradiation, the diazirine moiety will generate a 
highly reactive carbene that covalently links to adjacent residues of target 
proteins. Subsequently, the terminal alkyne would serve as an analytical 
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handle that reacts with azide-containing reporters via copper(I)-catalyzed 
azide-alkyne cycloaddition (CuAAC) for visualization or enrichment of the 
captured protein-probe complexes.
[25-28]
 To better assess how the two 
modifications of FED1 to P1 could affect its properties respectively, we 
further designed two control inhibitors C1 and C2 which possessed either a 
terminal alkyne or a diazirine accordingly (Figure 3.1a). 
As shown in Figure 3.1b, the synthesis of P1 started from 1, which was 
installed with a trifluoromethyl ketone by the Grignard reaction. Subsequent 
aromatic substitution of the fluoride with an azide yielded 3. It was then 
condensed with hydroxylamine to form an oxime intermediate, whose OH 
group was tosylated to afford 4. Then liquid ammonia was added to produce 
diaziridine 5. The diazirine 6b was generated by the reduction of the azide and 
oxidation of the diaziridine. After that, utilizing a coupling agent triphosgene, 
6(a,b) was first coupled with 11 to form 7(a, b). Then the acetal de-protection was 
applied to form an aldehyde that cyclizes to generate 8(a, b). The reaction 
between 8(a, b) and 15(c, d) through reductive amination and the following 
removal of the acetal protecting group yielded AfBP P1 and FED1/C1/C2 
(Scheme 3.1). P2 was prepared via another synthetic route using some of the 
intermediates above. The minimalist linker L7 was synthesized as previous 
reported by our group,
[19]
 which was used to alkylate the amino group of 
compound 16 under basic conditions. After alkylation, the azide group was 
reduced with PPh3 to afford the amine form compound 18. Finally, 8a and 18 
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reacted through reductive amination followed by the subsequent removal of 










Scheme 3.1 Synthetic route of P1, P2, C1, C2 and FED1 
3.3.2 Biological Evaluation 
3.3.2.1 Molecular Modeling  
FED1 is a nanomolar inhibitor of DOT1L protein. Since crystal structure 
of FED1 complexed to DOT1L is available, the molecular docking 
experiments were carried out with our probes/controls to gain insights about 
their bindings with DOT1L. As shown in Figure 3.2a, b, although there were 
some differences in the binding modles beween P1/P2 and the wildtype FED1, 
the critical binding sites were still remianed, which suggested that the probes 
could closely mimic FED1’s binding to DOT1L and the modifications in our 
designs are appropriate. As expected, the photoreactive group in P1 matched 
FED1’s tert-butyl group and fitted in the hydrophobic pocket nicely. The 
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terminal alkynes in P1 and P2 were projected towards the solvent-accessible 
surface of DOT1L to minimize disruption to the protein-probe interaction and 
facilitate CuAAC with azide-containing reporter. Similar binding moles were 
also observed for the control inhibitors C1 and C2 (Figure 3.2) 
 
Figure 3.2 Molecular docking results of probes. a) FED1 and P1; b) FED1 and P2; c) 
FED1 and C1; d) FED1 and Ctr1B in the SAM binding pocket of DOT1L. FED1, 
P1, P2, C1 and C2 are shown in yellow, green, red, purple and blue respectively. 
3.3.2.2 DOT1L labelling efficacy and assays of P1 and P2 
The two probes were first examined with the labelling efficacy of 
recombinant DOT1L. For dose-dependent in vitro bacterial lysate labelling, 50 
µg of freshly prepared bacterial lysates overexpressing DOT1L (1-420) were 
incubated with probes/inhibitors at various concentrations for 2h at room 
temperature, followed by 20 min irradiation (~350 nm) on ice and reaction 
with TER-N3 via CuAAC click chemistry for 2h at room temperature 
(referring to published protocols).
[18]
 The labelling events were finally 
separated by SDS-PAGE and analyzed by in-gel fluorescence scanning For 







showed that DOT1L protein (~48 kDa) was well labelled by both probes. The 
fluorescence of this band increased with incremental probe concentrations, but 
decreased significantly with pretreatment of the competitor C1 (Figure 3.3). 
Overall, P1 demonstrated better DOT1L labelling efficiency than P2 under the 
same conditions. Here I’d like to give my thanks to Chenyu for his help on 
bacteria culture, in situ labelling as well as the ITC experimts presented below. 
 
Figure 3.3 In gel-fluorescence scanning profiles of DOT1L 1-420-overexpressing 
bacterial lysates labeled with a) P1 and b) P2, respectively. The labeling experiments 
were done in the presence of 10 times concentrated FED1 also. (top) fluorescence 
gels; (bottom) coomassie gels. 
To confirm the probe binding efficiency, Isothermal titration calorimetry 
(ITC) gives more accurate physical data of the binding constant (Figure 3.4). 
Here pure SAM-free DOT1L (1-420) was employed which were 
overexpressed in E. coli. Based on the titration curves, it is noted that probe 
P1 is the better binder to DOT1L (1-420) compared to probe P2, with the 
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respectively, which is similar to the value of reported FED1 derivatives.
[24]
 I’d 
like to thank Mr. Wang Chenyu for his contributions to this ITC experiment as 
well as the following in situ labelling experiment. 
 
Figure 3.4 ITC of P1/P2 and DOT1L interaction, giving the corresponding Kd value. 
For P1, Kd=100.88±25.70 nM; for P2, Kd=133.77±24.07 nM. 
To further investigate the efficiency of our probes stabilizing the target 
protein DOT1L in situ, a cellular thermal shift assay (CETSA) was applied by 
referring to the published procedures.
[29] 
Considering the poor cell 
permeability of the probes, A431 cells were incubated with probes/inhibitors 
(5 M) in a cell culture incubator for 4 days. Then the cells were UV 
irradiated (~350 nm) on ice and heated at different temperature (40~73 
o
C, 
temperature difference is 3 
o
C for each temperature endpoint). Subsequently 
the cells were lysed with liquid nitrogen; the supernatant of cell lysate was 
analyzed by Western Blotting (WB) analysis to explore the target protein 
P1: Kd=100.88±25.70 nM P2: Kd=133.77±24.07 nM
84 
 
amount. Here DMSO and NP were negative controls while FED1 as a wild 
type DOT1L inhibitor was a positive control. According to the results, both P1 
and P2 show similar or even better stabilizing effect compared to FED1. This 
indicates that similar to FED1, P1 and P2 also engaged in physically binding 
to endogenous DOT1L in live cells (Figure 3.5). 
 
Figure 3.5 In situ Cellular Thermal Shift Assay (CETSA) of probes in A431 cells, 
probe concentration: 5 M, cells were incubated for 4 days. 
3.3.2.3 Cellular H3K79me2 supression assays 
As discussed, DOT1L is the only PKMT that methylates histone H3K79 
to produce H3K79me2. Thus the inhibition of DOT1L activity will lead to the 
suppression of H3K79me2, which can be used as a marker for the DOT1L 



























































FED1/P1/P2 (1, 5, 10 M) for 4 days, harvested and processed with the 
histone extraction. The H3K79me2 expression levels were then determined by 
WB, with the total histone amount as internal loading control. Results showed 
that the H3K79me2 expression levels decreased with increasing 
concentrations of P1/P2 in a similar manner to FED1. This confirmed that our 
newly designed probes P1 and P2 were indeed successful mimics of FED1 
that could induce similar bioactivities in DOT1L inhibition (Figure 3.6a). 
This DOT1L inhibitory efficiency was also measured by the 
immunofluorescence imaging of H3K79me2. A431 cells were first treated 
with DMSO or FED1/P1/P2 (5 M) for 4 days. The cells were then fixed with 
3.7% formaldehyde, permeabilized by 0.1% Triton X-100, and further treated 
with anti-H3K79me2 antibody and the fluorophore-labelled secondary 
antibody. Finally, cells were stained with Hoechst before imaging using a 
confocal fluorescence microscopy. Strong immunofluorescence was detected 
in DMSO treated cells, and the signals reduced with higher concentrations of 
FED1/P1/P2 used (Figure 3.6b). These results clearly indicated that P1 and 
P2 were able to inhibit DOT1L’s activity and prevent the methylation of 
H3K79 to form H3K79me2 in live mammalian cells. This was also consistent 
with the results of CETSA and WB-based H3K79me2 suppression assay, 





Figure 3.6 a) Immunoblot assay of H3K79Me2 to analyse DOT1L’s methylation 
activity in situ in A431 cells. P1, P2 and FED1 were added at 1, 5, and 10 µM and 
the cells were incubated for 4 days; b) Methylation assay of H3K79Me2 to analyse 
DOT1L’s methylation activity using IF, Cells were incubated with probes/inhibitors 
(5 µM) for 4 days. 
3.3.2.4 Cellular imaging 
Cellular imaging is an attractive way to report endogenous enzyme-drug 
interactions, including drug uptake amount and target localizations.
[30-37]
 In 
recent years, small molecule-based probes especially dual-purpose probes 
have been used to successfully image endogenous cellular targets.
[22, 23, 35-38]
 
Since FED1, P1 and P2 appeared to possess similar cellular activities against 
DOT1L, we inferred that they might serve as potential DOT1L imaging probes 
as well. To confirm this hypothesis, A431 cells were treated with DMSO or an 
optimized amount of P1/P2 (2 M) for 4 h, 1 day or 4 days respectively. 






































































3.7% formaldehyde, permeabilized by 0.1% Triton X-100, and clicked with 
TER-PEG-N3 by referring to the published protocols.
[17,22]
 The same cells 
were further treated with anti-DOT1L antibodies for IF and stained with 
Hoechst before the confocal fluorescence microscopy under four different 
imaging channels (Figure 3.7). Under the same conditions, P2 produced 
higher fluorescence signals than P1. As a methyltransferase, DOT1L is 
situated in the nucleus. However, most of the P1/P2 signals are localized 
outside the nucleus. This could be due to several reasons: 1) the presence of 
the nuclear envelope might prevent the probes from entering the nucleus, and 
2) the potential cellular off-targets may cause the non-target binding. If the 
off-targets were mostly located in cytosol, it would be difficult for the probes 
to enter the nucleus with sufficient amount. This assumption could be verified 
by further proteome profiling, target validation and quantification 
experiments. 
 
Figure 3.7 Fluorescence imaging of A431 cells with P1 and P2. A total of four 
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imaging channels were employed, including bright-field (BF), probe-treated channel 
(upon click chemistry with TER-PEG-N3), immunofluorescence (IF) and 
Hoechst-stained channel (NU). Cells were incubated with probes/inhibitors (2 M) 
for 4 h, 1 day and 4 days. Full images were shown in ESI. Scale Bar: 10 µm. 
3.3.2.5 Mammalian cell based proteome profiling and target 
validation of P1 & P2 
Based on the previous results, the mammalian cell (A431, human 
epidermoid carcinoma) based proteome profiling was conducted both in vitro 
and in situ (Figure 3.8) before further target validation. For in vitro labelling, 
100 g of freshly prepared A431 cell lysates were treated with P1/P2 in 
different concentrations (or pretreated with C1 (10X)) following the procedure 
described in the bacterial lysate labelling section.  For in situ labelling, live 
A431 cells were incubated with probes (1 and 5 M, ± C1 (10X)) for 4 days. 
Then the cells were irradiated and lysed. The rest procedures were the same as 
in vitro labelling. In-gel fluorescence scanning results of the in vitro labelling 
showed some distinct fluorescent bands at around 40-70 kDa, but not at ~185 
kDa where the endogenous DOT1L was expected to be. This indicated that P1 
and P2 were not able to directly profile the presence of endogenous DOT1L 
under our experimental conditions, presumably due to the low endogenous 
expression level of the enzyme in mammalian cells, insufficient detection 
sensitivity of the probes and potential cellular off-targets. The results of the in 
situ labelling also showed that the endogenous DOT1L could not be profiled 
by P1/P2. However, the fluorescent bands below 70 kDa may be the potential 
off-targets of the probes, which could be determined by LC-MS/MS. In 
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addition, based on the proteome profiling results, the labelling profiles of the 
two probes were different. It was also observed that P1 possessed better 
labelling ability in the in vitro experiments while P2 performed better in the in 
situ experiments. This may be attributed to our “minimalist” linker used in P2, 
which may give it better cellular permeability. However, the failure of directly 
profiling the cellular target DOT1L may be due to the mis-localization of the 
drugs, as suggested in the live-cell imaging results. 
To validate if P1/P2 could label the endogenous target DOT1L, we 
carried out the protein enrichment by large scale pull-down (PD) both in vitro 
and in situ followed by DOT1L detection via WB in the presence/absence of 
competitor C1 (Figure 3.8d~f). The labelled protein-probe complex was 
prepared as described in previous section and clicked with Biotin-N3 for 
subsequent enrichment on immobilized avidin. Successful detection of the 
endogenous DOT1L (~185 KDa) in the P1/P2-labelled proteomes both in vitro 
and in situ showed that our probes indeed were efficient AfBP of DOT1L 
capable of targeting endogenous DOT1L from complex mammalian protein 
lysates or live mammalian cells. When the same PD/WB experiments were 
carried out with pretreatment of C1 (10X), the signals of the labelled DOT1L 
bands decreased significantly, indicating that C1 effectively competed for the 
probe binding to DOT1L under complex cellular environments. These results 
confirmed the successful labelling of endogenous DOT1L by P1/P2 with good 
efficiency. However, the in situ protein enrichment efficiency was much poorer 
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than that of in vitro experiments, which is another evidence of drug 
mis-localization as presented in the imaging results. The potential off-targets 
could be determined via the subsequent SILAC LC-MS/MS validation. 
 
 
Figure 3.8 In vitro labeling profile of probe a) P1 and b) P2 in A431 cell lysate and c) 
in situ labeling profile of probes in live A431 cells with or without competitor (10X) 
respectively. (left) fluorescence gels; (right) coomassie gels; In vitro PD of probe d) 
P1 and e) P2 in A431 cell lysate and f) in situ PD of probes in live A431 cells with or 
without competitor (10X) respectively. 
3.3.2.6 SILAC target validation and quantification  
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amino acids in cell culture (SILAC) experiment was conducted (refer to the 
published procedures,
[39, 40]
) to quantify the on- and off-targets as well as to 
compare the difference in the performance between P1 and P2. In this 
competitive SILAC experiment, after drug treatment and photo crosslinking, 
the heavy (probe treated, 2 M) and light (probe/C1 treated, 2/20 M) cells 
were lysed separately and mixed in equal amount. The SILAC mixture was 
clicked with biotin-N3, enriched by avidin beads and separated by SDS-PAGE. 
The protein extracts were then subjected to in-gel trypsin digestion, and 
identified by LC-MS/MS (SILAC settings). The complete LC-MS/MS results 
are shown in appendix with selected results summarized in Table 3.1. Like 
most large-scale LC-MS/MS experiments, a large number of proteins hits 
were identified in our results (around 1000 different proteins). Among them, 
many were inevitably highly abundant, nonspecific proteins that were labelled 
indiscriminately in live cells due to their “sticky” nature. As a result, they 
were labelled by all the compounds. These proteins were automatically 
eliminated as false positives. Of the remaining proteins, we focused on those 
that met the following criteria: 1) proteins labelled by both probes and showed 
high SILAC ratio (> 2), which may be the most potent/real cellular targets; 2) 
proteins have interesting cellular functions deserving further study; or 3) 
methyltransferases. At the end, although the target protein DOT1L was not 
detected, some other interesting hits were identified. In these large scale 
SILAC PD samples, 515 proteins labelled by both probes were identified; 
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however, only 17 proteins of which showed high SILAC ratio (> 2) (Table 3.1). 
Figure 3.9a, b gave the SILAC ratio curves of probe P1 and P2. The protein 
showing highest SILAC ratio was Isoform 1 of Eukaryotic translation 
initiation factor 5A-1 (highlighted in aqua in Table 3.1).Further analysis of the 
MS results indicated that most of the identified proteins were located in 
cytosol and related to “RNA splicing/processing” as well as some metabolic 
functions, which is quite interesting and deserves further investigation. This 
result also explained the ineffective of FED1 and our probes (long incubation 
time and weak fluorescence signal in proteome profiling, cell imaging as well 
as PD/WB analysis), possibly due to the mis-location of the drug. Because of 
the off-targets in cytosol, most drugs would stay in cytosol after entering the 
cells, leaving very little amount to further penetrate nucleus for effective 
inhibition and imaging. The molecular weight of the interesting proteins were 
also checked, most of them are around 40-70 kDa; this explained our 
proteome profiling results in which the fluorescent bands were in the range of 
40-70 kDa. 
By comparing the identified protein targets, it was found that there were 
some differences between P1 and P2, which may be caused by the diverse 
structural designs. From the molecular docking results, it was clear that the 
binding model of P1 and P2 are different. It gave us a clue that different 
tagging approaches may result in different potential cellular hits; hence to 
improve target identification accuracy, labelling the same drug with different 
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tags may be a good choice. Those proteins labelled by both probes may be the 
real targets of the original drug.  




Score Heavy/Light Score Heavy/Light 
Methyltransferases 
Isoform 2 of Putative 
ribosomal RNA 
methyltransferase NOP2 
















160.15 2.507 157.76 2.113 cytoplasm; secreted 
splicing factor 3A subunit 1 
isoform 2 
49.19 2.893 31.41 2.084 nucleus 
Thymosin beta-4-like 
protein 3 
36.32 2.497 27.27 2.209 cytoplasm 
Isoform 4 of Plasminogen 
activator inhibitor 1 
RNA-binding protein 
32.53 2.836 39.17 2.076 
cytoplasm; nucleus; 
perinuclear region  
28 kDa heat- and acid-stable 
phosphoprotein 




receptor-associated protein 3 
36.32 2.497 27.27 2.209 nucleus 
Serpin H1 20.57 2.906 15.51 2.192 
Endoplasmic 
reticulum lumen 
Isoform 1 of Brain acid 
soluble protein 1 
17.68 2.726 9.8 3.467 











cell projection  
GUCA1B protein 
(Fragment) 
14.21 3.386 23.03 2.169 cytoplasm 
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complex   
Finally, considering our potential target DOT1L is one of the PKMTs, we 
focused on looking for methyltransferases in current MS data. These 
methyltransferases showed reasonable protein scores and SILAC ratio. Among 
these methyltransferases, Isoform 2 of Putative ribosomal RNA 
methyltransferase NOP2 (Table 3.1, highlighted in purple, NOP2 for short) 
which was detected in P1-labeled sample showed the highest SILAC ratio and 
was further validated by PD/WB (Figure 3.9c). As expected, NOP2 was 
enriched and detedcted only in P1 treated cells (A431) both in vitro and in situ. 
With the presence of competitor C1, there was nearly no NOP2 protein can be 
enriched. The PD result confirmed that NOP2 was likely to be a genuine 
off-target of FED1. This was further supported by the CETSA results, which 
showed a direct binding between P1 and endogenous NOP2 in A431 cells. 
Similar stabilizing effect was also observed for FED1, which was better than 




Figure 3.9 SILAC ratio curve of a) P1 and b) P2; c) In vitro (Top) and in situ 
(Bottom) PD-WB validation of putative ribosomal RNA methyltransferase NOP2; d) 
In situ Cellular Thermal Shift Assay (CETSA) of probes against Putative ribosomal 
RNA methyltransferase NOP2 in A431 cells, probe concentration: 5 M, cells were 
incubated for 4 days. 
3.4 Conclusion 
DOT1L is the only PKMT to methylate H3K79; abnormal DOT1L 
activity is related to many diseases, especially cancers. For example, DOT1L 
is a contributing factor in mixed lineage leukemia, which cause DOT1L to be 
a promising drug target. In recent years, there are many studies on DOT1L 
inhibitors. Some of the inhibitors have undergone clinical trials. In this study, 
we have successfully designed and synthesized novel small-molecule AfBP P1 
and P2 for the study of DOT1L. During the studies, P2 consistently produced 
better signal in imaging and in situ labelling experiments. Despite these 
unexpected results, P1 was superior at in vitro experiments. Judging from the 
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nucleus. Hence their cellular compartmentalization was similar. A feasible 
reason for low signal intensities when doing imaging might be drug 
mis-location based on the SILAC LC-MS/MS profile results. Besides, our 
PD/WB assay proved the specificity of our probes against the target protein, 
DOT1L, and SILAC LC-MS/MS helped us quantify the on- and off-targets of 
our probes. The MS results also demonstrated and explained our previous 
protein profiling and imaging outcomes. In addition, the MS results provided 
us a clue that making derivations of a wide type drug with different tags and 
quantifying the proteomes with SILAC LC-MS/MS approach may improve 
the protein target identification accuracy. On our current stage, the experiment 
results explained why FED1 and its derivatives show high potency against 
DOT1L but relatively low activity in cell-based experiments, which may be 
due to the mis-location after the inhibitors/probes enter the cells. Most of the 
drugs ended up in the cytosol and only a small amount of drug could finally 
enter the nucleus where the target protein DOT1L is. One interesting potential 
protein targets identified by SILAC LC-MS/MS analysis called putative 
ribosomal RNA methyltransferase NOP2 was further validated and proved our 
SILAC results. Further study will focus on solving the probe efficiency 
problems as well as making such profiling and target validation approaches a 
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A hydrogel-functionalized small molecule microarray has been 
developed, on which PC-3 cancer cells were selectively grown. 
Subsequent controlled release of immobilized bioactive compounds 
enabled cell-based screening to be directly carried out on this platform. 
Our newly developed SMM possesses two key features, which are selective 
growth of cancer cells, and controlled release/cellular uptake of bioactive 
compounds. 
4.2. Introduction 
In the past two decades, high-throughput screening methods using 
microarray technologies have enabled thousands of biochemical 
interactions to be analyzed simultaneously in a single step, resulting in a 
paradigm shift in biology, medicine and drug discovery. Early 
microarrays consisting of regularly repeating arrays of DNA were used 
to measure changes in gene expression.
[1]
 More recently, microarrays 
have been extended to the high-throughput analysis of proteins, peptides, 
carbohydrates, small molecules, even live cells and tissues, with each 
technology possessing distinctive characteristics while providing unique 
opportunities.
[2-3]
 One such technology, small molecule microarray 
(SMM), consisting of miniaturized assemblies of many small molecules 
immobilized across a planar glass slide, has been extensively used for 





 For example, a recently developed 
SMM was used to rapidly and quantitatively screen hundreds of 
small-molecule protein-protein-interaction inhibitors, and a potent 
inhibitor of the protein BRCA1 (a breast cancer-related protein) was 
successfully identified which showed good cellular activity in disrupting 
the association between BRCA1 and its binding proteins.
4a
 Other SMMs 
have in recent years been used to study other protein-protein interactions 
and screen different biological events.
[4b-e]
 Notwithstanding, most 
reported SMMs are only suitable for screening with proteins or cellular 
lysates, not live cells.
[5]
 Previously, Stockwell and co-workers developed 
a microarray for compound screening in mammalian cells by making use 
of polymer-embedded small molecules.
[6]
 This strategy has major 
technical limitations due to issues related to passive diffusion during 
compound immobilization and release processes. Dordick and 
co-workers reported a miniaturized 3D cell-culture array for 
high-throughput (HT) toxicity screening of drug candidates.
[7]
 By using 
a “stamping” method to control the transfer of small molecules from one 
surface to another surface on which cells were grown, the authors 
effectively converted an SMM platform into an HT cell-based assay with 
minimal cross contamination between compounds. Major drawbacks of 
this strategy lie in the SMM preparation, in which droplets of small 
molecules were robotically placed on top of a glass slide without any 
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form of immobilization, rendering the approach impractical in other labs 
for most real applications.  
Herein, we report, in a proof-of-concept study, an SMM platform 
that is compatible with direct mammalian cell-based screening. By 
immobilizing bioactive compounds on a glass slide functionalized with 
hydrogels, we achieved selective growth of PC-3 cancer cells on the 
SMM. Subsequent controlled release of functionally active compounds 
enabled their cellular uptake and direct screening of their biological 
activities in an HT cell-based assay.  
Our newly developed SMM possesses two key features: 1) selective 
growth of cancer cells, and 2) controlled release/cellular uptake of bioactive 
compounds. As shown in Figure 4.1, we constructed the 
hydrogel-functionalized SMM followed by subsequent cell-based screening in 
several steps. First, an alkene-containing, photo-labile 
6-nitroveratroyloxycarbonyl group (NVOC) was used to modify the 
anti-cancer drug, Camptothecin (CPT), at its tertiary OH position, giving 
NVOC-CPT (Scheme 4.1). CPT was chosen as our model compound due to 
its known anti-cancer activities. A Caged-RGD peptide which contains a 
well-known cell growth/adhesion motif (i.e. CGRGDSP) and an N-terminal 
cysteine (used as a handle for peptide immobilization) was synthesized 
(Scheme 4.2). In this RGD peptide, the key aspartic acid residue responsible 
for the cell adhesion was conjugated through a self-immolative linker to a 
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peptide substrate for the prostate-specific antigen (PSA) protease.
[8]
 PSA, a 
serine protease highly secreted by prostate cancer cells but not normal cells, 
has been widely used in caged drugs and imaging reagents in cell culture and 
animal models. The use of PSA for selective control of cell growth in a 
microarray, to our knowledge, had however not been reported. A fluorescently 
labeled hexapeptide, TER-HSSKLY, was used, because it previously showed 
high substrate specificity toward PSA over other ubiquitous serine proteases.
[8a]
 
Upon cleavage of the peptide, the p-aminobenzyl alcohol (PABA) linker 
underwent spontaneous release, thus providing an “uncaged”, functionally 
active RGD peptide.
 
In our study, NVOC-CPT and Caged-RGD peptide 
were co-spotted on a glass slide to generate the corresponding SMM (Figure 
4.1). The TER fluorophore served as a convenient fluorescent marker to 
monitor proper SMM fabrication and subsequent peptide uncaging. Based on a 
previously reported protocol,
[9] 
a hydrogel was next prepared on the SMM 
surface, by first transferring the spotted compound mixtures onto the 
hydrogel’s pre-polymer surface in a spatially controlled manner, followed by 
subsequent curing/polymerization with the well-established thiol-ene 
chemistry (Step I). This process effectively immobilized both NVOC-CPT 
and Caged-RGD peptide in the hydrogel matrix formed on the SMM surface. 
Hydrogels are ideal polymer matrices to grow mammalian cells (including 
stem cells) on glass surfaces.
[9,10]
 In our case, the introduction of Caged-RGD 
peptide enabled us to control the types of mammalian cells that could be 
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grown on the hydrogel-functionalized SMM surface (i.e. PC-3 prostate cancer 
cells; Step II). Normal or other cells that do not secrete PSA protease would 
not grow on this surface as no release of “uncaged” RGD peptide was possible. 
Upon successful growth of PC-3 cells on the SMM, controlled release of free 
CPT into the hydrogel matrix could be initiated by UV irradiation (Step III). 
The hydrogel served to prevent any unnecessary diffusion of the released 
compound, thus ensuring its uptake only by nearby cells. Finally, 
high-throughput cell-based assays or simple visualization of cell 
morphological changes microscopically were used to delineate the cellular 




Figure 4.1 Overall workflow of hydrogel-functionalized small molecule microarray 
(SMM) for selective growth of cancer cells and controlled release of bioactive 
compounds for subsequent on-chip cell-based screening assays. 
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4.3 Results and Discussion 
4.3.1 Chemical synthesis of NVOC-CPT and Caged-RGD 
peptide 
NVOC-CPT was synthesized, as shown in Scheme 4.1, from the 
commercially available vanillin through intermediate 4. Briefly, introduction 
of an allyl group in 4, which served as an immobilization handle for 
NVOC-CPT in the SMM construction/thiol-ene reaction, gave 5 (90% yield). 
Subsequently, NaBH4 reduction gave 6 (95%). The OH group in 6 was next 
converted to NH2 in 3 steps to give 9 (44% overall), which was coupled to the 
tertiary OH of CPT via a carbamate linkage to deliver the final compound (47% 
in 2 steps). Another caged small molecule, NVOC-AQ was similarly 
synthesized by coupling a highly fluorescent dye, 6-aminoquinoline (AQ), to 
the NVOC-containing intermediate 11. The carbamate linkage in NVOC-AQ 
effectively quenched the fluorescence of the compound, but upon UV 
irradiation and “uncaging”, its fluorescence would increase significantly due 
to the release of free AQ. The Caged-RGD peptide was synthesized by using 
solid-phase peptide synthesis (Scheme 4.2); starting from a resin-bound RGD 
peptide, (CGRGDSP), the self-immolative Linker was coupled to the Asp 
side-chain of the RGD peptide via an ester linkage. Subsequent introduction of 
the PSA peptide substrate, followed by TER coupling and finally TFA 
cleavage of the final peptide, gave the desired product. A positive RGD control 











Scheme 4.2 Solid-phase synthesis of CGRGDSP peptide and Caged-RGD peptide. 
4.3.2 Biological Evaluation 
4.3.2.1 SMM and Hydrogel-Functionalized SMM Preparations 
A small molecule microarray was next generated, on which 10 x 10 grids 
of compounds were spotted on a standard glass slide by using a mixture of 
NVOC-CPT (10 M) and Caged-RGD peptide (5 mM) in DMSO/H2O (1:1). 
Positive control spots were created on alternating rows on the SMM by 
co-spotting a mixture of NVOC-CPT, CGRGDSP peptide and 
NVOC-TER/NVOCL-TER (20M) (see grids in Figure 4.2a). Next, 
hydrogel functionalization of the SMM was performed as previously 
described.
[9] 
Briefly, a mixture of Caged-RGD peptide (5 mM) and 
NVOC-CPT (10 M) were dissolved in a DMSO/H2O cosolvent (1:1) and 
directly printed on standard glass slides (10 x 10 grids), with a spotting 
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diameter and spot-to-spot spacing of 500 ± 5 m and 1500 ± 10 m, 
respectively. The spotting pattern was shown in Figure 4.2b, and positive 
control spots where the Positive RGD control (CGRGDSP peptide) was used 
in place of Caged-RGD peptide, were spotted on alternating rows, where 
applicable, NVOC-TER and NVOCL-TER were also spotted (final 
concentration: 20 M) directly as positive control dye spots, or co-spotted 
with the the non-fluorescent peptide (i.e. CGRGDSP). The resulting SMM 
prior to hydrogel functionalization was imaged on a Typhoon 9410 
fluorescence scanner (GE Amersham) to ensure the quality of the resulting 
SMM. Representative microarray images of these SMMs are shown in both 
Figure 4.2 and Figure 4.5a (left). 
Next, the above SMM was hydrogel-functionalized based on a previously 
published protocol by Hawker et al.
[11]
 First, a pre-polymer solution containing 
10% (m/v) 4-arm-PEG-SH (dissolved in deionized water at a concentration of 
0.1 g/mL), PEGDA700, deionized water, 10% ammonium persulfate solution 
(APS, aq.) and N,N,N,N,-Tetramethyl-ethylenediamine (TEMED) at a ratio of 
125:62.5:62.5:12.5:1, was prepared (Scheme 4.3). The pre-polymer solution 
was then slowly poured on top of the SMM covered with a gel mold. The 
hydrogel formed within 2 min at room temperature. Successful formation of 
the corresponding SMM-functionalized hydrogel was confirmed by 
fluorescence scanning using Typhoon 9410 fluorescence scanner (Figure 4.2b); 
uniform fluorescent spots (from the fluorescently labeled Caged-RGD 
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peptide and/or co-spotted NVOC-TER) in the hydrogel SMM image indicate 
minimal spot diffusion/enlargement when compared to the original spotted 
SMM image (Figure 4.2a); no obvious spot diffusion or enlargement was 
observed, indicating successful transfer/immobilization of spotted small 
molecules/peptides of the hydrogel-functionalized SMM. After transfer the 
compound mixture from glass slides to hydrogels, the fluorescence intensity 
nearly no decrease (RFU of compound spots’ on glass slides: 35.5 ± 4.0; RFU 
of compound spots’ after washing: 35.4 ± 6.3). To grow mammalian cells on 
these hydrogel-functionalized SMMs, they were first immersed in a 10% P/S 
(100 units/mL penicillin/streptomycin) solution in PBS overnight, and then 
immersed in 1x PBS (sterilized) overnight before being using for cell culture. 
After washing, the fluorescence intensity didn’t decrease much (RFU: 31.7 ± 
5.1). During the hrdrogel preparation processes, the spot size didn’t change 
much as well (500 ± 10 m after washing) Figure 4.2c shows a representative 
image of the same hydrogel-functionalized SMM (from Figure 4.2a, b) upon 
extensive washes with water and PBS overnight. No significant changes in 
fluorescent spots and intensities were detected, indicating again complete 
immobilization of small molecules/peptides on the hydrogel-functionalized 
SMM. 
Scheme 4.3. Sketch of hydrogel preparation by using thiol-ene reaction. The terminal 
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cysteine of Caged-RGD peptide and the terminal alkene handle of NVOC-CPT 
were used as parts of the handles needed in the thiol-ene reaction, and to attach these 
compounds covalently to hydrogel polymer matrix. 
 
Figure 4.2. Fluorescence images of a representative SMM a) prior to hydrogel 
functionalization, b) after hydrogel-functionalization, and c) after overnight washes 
with H2O and PBS. For spotting pattern, see Figure 2a in the maintext. 
 
The physical properties especially the surface properties of the hydrogel 
were characterized by Fourier-transformed infrared (FT-IR) spectroscopy, 
X-ray photoelectron spectroscopy (XPS), scanning electron microscope (SEM) 
as well as energy dispersive spectroscopy (EDX) as shown in Figure 4.3. In 
detail, the main molecular structures of hydrogel are O-H, C-H, S-H, C-C, 
C-O and C-S bonds. Based on the FT-IR spectrum, all characteristic peaks that 
belong to caged-RGD peptide were observed: C-O (C-S) bond was observed 
at 1730 cm 
−1
, O-H was at 3500 cm 
−1
 and C-H vibration peaks was at 2931 
and 2864 cm 
−1
. The specific bands belonging to the functionalized hydrogel 
including C-N (1100cm
-1




) were also found. In 
addition, the peak of the specific amide bond of the peptide at 1640 cm
 −1
 was 
observed only in the functionalized hydrogels, indicating the successful 
incorporation of the peptides in the hydrogels.
[12]
 XPS analyzed the binding 
energy of the specific chemical bonds of functionalized hydrogel structures, 




interesting bonds showed high intensity at corresponding binding energy, 
which also indicated the sucessesful surface functionalization of the hydrogels. 
SEM shows the surface smoothness information of the hydrogel and EDX 
gives the surface element contents of the hydrogels. According to Figure 4.3c, 
d, the hydrogel surface smoothness is good enough for further cell culture 
processes, and the elements analysis via EDX also proved that the hydrogel 
surface was modified with the drug/peptide containing SMM sucessesfully. All 
these data proved the successful formation of the small molecule-peptide 
contained hydrogels. Here I want to give my thanks to Jiangbo who provided 
the physical property test results and the following enzymatic assay of PSA 
cleavage experiments. 
 
Figure 4.3. Physical parameter determination of the functionalized hydrogels. a) 
FT-IR; b) XPS; c) SEM; d) EDX. 
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4.3.2.2 Enzymatic assay of PSA cleavage 
The cleavage efficiency of the Caged-RGD peptide by PSA protease 
was determined in vitro as shown below, and summarized in Figure 4.6a. The 
peptide (1 mg/ml) was incubated with PSA protease (0.1 mg/mL) in 1×PBS 
(pH 7.4) for 4 h at 37 °C and the cleavage processes was monitored by using 
LC-MS at different time points (0, 0.5, 1, 2, 4 h; see Scheme 4.4 and Figure 
4.4). 
Scheme 4.4 Schematic showing PSA-catalyzed enzymatic cleavage of Caged-RGD 
peptide (20 M in PBS), and subsequent spontaneous fragmentation of Linker 
followed by release of the fully functional RGD peptide. 
 
Figure 4.4. Time-dependent HPLC profiles to monitor PSA cleavage of Caged-RGD 
peptide. Recombinant PSA protease (Sigma) was used and the reaction was done in 
PBS buffer (pH 7.4) over a course of 4 h. The cleaved, fully functional RGD peptide 





4.3.2.3 RGD-dependent cell growth and adhesion efficiency test 
To test the efficiency of RGD-dependent cell growth and adhesion, 
several cell lines, including PC-3 (human prostate cancer cells, known to 
secrete high levels of PSA), HeLa (cervical cancer cells), CHO-9 (Chinese 
hamster ovary cells), NIH 3T3 (fibroblast cells), were seeded on the 
hydrogel-functionalized SMM. Successful growth of cells were visualized by 
staining the corresponding microarray with Hochest nuclear stain, followed 
image acquisition with a standard fluorescence microscope under different 
settings (BF: bright-field; PEP: fluorescent peptides/dye control; NU: nuclear 
stain) at 2x, 10x and 40x magnifications, respectively (part of this experiment 
was done by Jiangbo) (Table 4.1 and Figure 4.5). 
 
Table 4.1 Summary of cell growth/adhesion on the hydrogel-functionalized 
SMMs with different types of mammalian cells 
 
                
Peptide 
Cell lines  







PC-3 (prostate cancer 
cell line) 
++++ 
(300 ± 50 cells) 
++++ 
(310 ± 50 cells) 
HeLa (cancer cell line) 
++++ 
(260 ± 50 cells) 
+ 
(0) 
NIH 3T3 (normal cell 
line) 
++++ 
(330 ± 50 cells) 
+ 
(0) 
CHO-9 (normal cell line) 
++++ 







Figure 4.5 a) Control images of cell growth on functionalized hydrogels. Panel 1: 
Hydrogel surface only, without cell seeding; panel 2: cell grew on hydrogels which 
were only modified with CGRGDSP peptide. Here PC-3 was used as model cell line. 
b) Time-dependent cell growth/adhesion on hydrogel-functionalized SMMs spotted 
with the Positive RGD control (CGRGDSP peptide). Panels (1~4): PC-3 cells; 
panels (5~8): CHO-9 cells; panels (9~12): NIH 3T3 cells; panels (13~16): HeLa cells. 
In the first 3 h, the cells were cultured in 10% FBS-free DMEM medium. After that, 
the medium was changed to normal DMEM growth medium. All cells were 
visualized under DIC (bright-field). Scale Bar = 50 µm. 
As shown in Figure 4.6, on the hydrogel-functionalized SMM at locations 
where Caged-RGD peptide was spotted, only PSA-secreting PC-3 cells grew 
and proliferated successfully (top panels in Figure 4.5b). On the contrary, at 
locations where the positive RGD control (CGRGDSP peptide) was spotted, 
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all four types of mammalian cells grew and proliferated well. In vitro 
PSA-dependent uncaging of Cage-RGD peptide was also performed by 
incubating the peptide with recombinant PSA protease for different periods of 
time and monitoring the release of the “uncaged” RGD peptide by LC-MS 
(Figure 4.4); complete uncaging was observed within 4 h of protease treatment. 
These results thus unambiguously confirm the successful implementation of 
the first key feature in this newly developed SMM platform; by making use of 
cell type-specific “growth factors”, different types of cells may be grown on 
our SMM, in a spatially controlled manner, making it possible to carry out 
future HT cell-specific drug screening. 
 
Figure 4.6 Fluorescence microarray images of different cell lines (PC-3. CHO-9, 
NIH 3T3 and HeLa) grown on a 10 x 10 grid SMM spotted with 
NVOC-CPT/Caged-RGD peptide and NVOC-CPT/CGRGDSP peptide on 
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alternating rows. The fluorescence was either from TER of the fluorescently labelled 
peptide, or co-spotting with NVOC-TER/NVOCL-TER. Upon one day growth of 
different mammalian cells on the hydrogel-functionalized SMM, the arrays were 
imaged using fluorescence microscopy (at 2x & 10x magnifications). The red boxes 
highlighted the cells grown in Caged-RGD peptide modified regions, while the 
green boxes highlighted the cells grown in CGRGDSP peptide (positive control 
peptide) modified regions, the magnifications of cell images were shown also (the 
three columns of 10x magnification images at right, titled in red and green color 
respectively) The images were acquired under BF (bright-field), PEP (fluorescent 
peptide; in red) and NU (Hochest nuclear stain; in blue) channels, and merged where 
indicated. Scale bar: 500 m. 
Prior to subsequent on-chip controlled release studies of NVOC-CPT 
and cell-based screening, we first investigated the UV-dependent compound 
release in vitro. A solution of NVOC-CPT (20 M) was irradiated and the 
fluorescence intensity of the solution was acquired at different time points 
(Figure 4.7a); complete release of CPT was observed in 40 min of UV 
irradiation. To study on-chip compound release, a hydrogel-functionalized 
SMM spotted with different concentrations of NVOC-AQ was used instead, 
as its fluorescence properties were more compatible with our fluorescence 
microscope, and its fluorescence Turn-on property could directly reveal 
compound release in real-time. As shown in Figure 4.7b, at all tested 
concentrations, complete AQ release was observed within 30-60 min of UV 
irradiation, which was similar to what was obtained in the solution study with 
NVOC-CPT. In consideration that prolonged UV exposure might cause cell 
death, in all subsequent cell-based SMM experiments, we chose the irradiation 
condition of up to 20 min, to ensure a balance between maximum compound 




Figure 4.6 UV-induced controlled release and cell screening. a) Solution-phase 
UV-induced release of NVOC-CPT (20 M in PBS); b) On-chip release of different 
spotted NVOC-AQ (0 to 100 M; NC = no compound); c) Images of 
Hochest-stained PC-3 cells after drug release and overnight growth. Scale bar = 10 
M; d) Relative fluorescence intensity of lysates of PC-3 cells obtained from c); e) 
WB analysis of cleaved Caspase 3 from cells collected in c) & d). STS = 
staurosporine (positive apoptosis control). UV irradiation was done at 1000 J/cm2; f) 
Apoptosis effect caused by released CPT on HeLa cells grown on positive control 
peptide (CGRGDSP peptide) after overnight incubation in 37 
oC, Panels (1~5): cells’ 
morphology change at different concentrations of immobilized CPT. NC: Negative 
Control (no CPT): cells’ morphology before UV irradiation. Scale bar: 10 M. g) 
Relative fluorescence intensity of lysates of HeLa cells obtained from f); h) Western 
Blot determination of cleaved Caspase-3 expression level of HeLa cells after 
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UV-induced CPT release and subsequent overnight incubation in 37 
o
C incubator 
before cell harvest and lysis. 
Following cell growth and UV-initiated compound release on the 
hydrogel-functionalized SMM, a series of experiments were conducted on 
affected cells to confirm successful cellular uptake of free CPT and subsequent 
cellular drug effect (Figure 4.7c~e). First, despite resistance of PC-3 cells 
toward low (1~5 M) dosages of CPT,[13] we observed obvious morphological 
changes of cells following concentration-dependent (0 to 100 M), on-chip 
NVOC-CPT release and overnight incubation after 1 days culturing on 
hydrogels (Figure 4.7c); cells became rounded and clustered on the SMM 
where 50-100 M of the compound were spotted (panels 4 & 5). To further 
confirm cellular uptake/internalization of UV-released CPT, above PC-3 cells 
were detached from the SMM, lysed, and the fluorescence intensity of the total 
cell lysates were measured (Figure 4.7d); a concomitant fluorescence increase 
of free CPT (as a result of its binding to cellular DNA) was observed with 
increasing amounts of immobilized NVOC-CPT. Finally, to confirm the 
released CPT caused cell apoptosis, we carried out Western blotting analysis 
(Figure 4.7e); successful detection of cleaved caspases-3 band (at ~17 kDa) 
exclusively on the hydrogel-functionalized SMM where NVOC-CPT was 
spotted and UV-irradiated, unequivocally confirms the second key feature of 
our SMM design in controlled release of bioactive compounds and effects of 
subsequent cellular changes. Morphological changes of cells as a result of 
drug uptakes were not only apparent for PC-3 at this stage, but also much 
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more with the HeLa cells (Figure 4.7f) by comparing panels 1 and 5. One 
could easily detect significant changes in HeLa cell morphology-cells became 
round and some were even dead. Cellular effects due to drug uptakes were 
further confirmed by collection of affected cells, lysis followed by 
fluorescence analysis of the resulting cell lysates (Figure 4.7g) and Western 
blotting analysis (Figure 4.7h). The fluorescence intensity of the total cell 
lysates were recorded using the Tecan microplate reader (ex = 350 nm, em = 
442 nm). To confirm cell apoptosis caused by released CPT, the cleaved 
Caspases-3 expression levels of affected cells were determined. WB 
experiments were carried out by referring to the general procedure using 
anti-cleaved Caspase 3 (1: 1000). The molecular weight of target protein 
cleaved-Caspase 3 is around 17 kDa. The band intensity was determined by 
Image J. Before UV irradiation, there was nearly no caspase-3 activity, 
however, after UV irradiation, with the increase of immobilized NVOC-CPT 
concentration, the expression level of cleaved Caspase-3 increased as well, 
and reached balance at the concentration of 50 M. These results further 
indicate that the UV-induced release of CPT was successful; the free CPT 
went into the cells and cause cell apoptosis. 
4.4 Conclusion 
We have successfully developed a hydrogel-functionalized small 
molecule microarray on which PC-3 cancer cells were selectively grown. 
Subsequent controlled release of immobilized drugs enabled cell-based 
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screening to be directly carried out on this platform. With the prospect of 
spatially and temporally controlling both the types of cells and compounds on 
an SMM, we envisage this platform might find applications in future 
high-throughput cell-based screening and stem cell chemical biology. 
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In chemical biology research, drug discovery including corresponding 
cellular targets interrogation is one of the study hot points. To investigate the 
potent cellular drugs as well as their functions against specific targets at 
molecular and cellular levels, many chemical biology tools have been 
developed. During the exploration processes, developing novel chemical 
biology tools is still in progress. This thesis mainly discussed about several 
chemical biology tools developed and widely used in recent years, and 
introduced several newly developed chemical biology tools used for 
addressing some real chemical biology issues. 
Chapter 2 introduced a newly developed activity-based probe of DNMT1, 
named T1, using which we conducted the detection and inhibition of abnormal 
DNMT1 simultaneously. T1 is a clickable analog of tryptophan and was able 
to covalently label endogenous DNMT1 and inhibit its enzymatic activity. 
Besides, we also designed 12 tetrazole-based novel DNMT1 inhibitors, some 
of which showed good inhibition activities against DNMT1 based on the 
enzymatic assays and cell proliferation assays. Based on our current results, 
more extensive studies are underway to understand the functions of those 
probes/inhibitors in the study of DNMT biology. 
As an extension of chapter 2, in chapter 3, two affinity-based novel 
DOT1L (a sole histone H3 lysine 79 (H3K79) methyltransferase) probes were 
designed and synthesized, named P1 and P2 respectively. They can efficiently 
profile endogenous DOT1L expressed in mammalian cells, the methylation 
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assays also proved the inhibition potency of the two probes. However, both of 
the probes faced the cell permeability problems, which limit their application 
and accuracy in live cell-based studies. Hence further study is clearly needed 
and will focus on solving the current issues and developing more efficiency 
chemical biology tools for the study of DOT1L protein. 
Differently, in chapter 4, a hydrogel-functionalized small molecule 
microarray was discovered, on which, PC-3 cancer cells can selectively grow. 
Followed by the cell growth, a controlled release of CPT, an anti-cancer drug 
was conducted to affect cell proliferation properties. With this platform, both 
the cell-type specific growth and drug release can be spatially and temporally 
controlled. As a novel SMM-based chemical biology tool, hope this platform 
can find applications in future high-throughput cell-based screening and stem 


















6.1 General Information 
All chemicals were purchased from commercial vendors and used 
without further purification, unless otherwise noted. N,N-Dimethylformamide 
(DMF) and Dichloromethane (CH2Cl2, DCM) were distilled over CaH2. All 
non-aqueous reactions were carried out under nitrogen atmosphere in 
oven-dried glassware. Reaction progress was monitored by TLC on pre-coated 
silica plates (Merck 60 F254, 250 μm thicknesses) and spots were visualized by 
ceric ammonium molybdate, ninhydrin, basic KMnO4, UV light or iodine. 
Flash column chromatography was carried out using Merck silica gel 
(0.040-0.063). 
1
H NMR and 
13
C NMR spectra were recorded on a Bruker 
model Advance 300 MHz or DPX-500 MHz NMR spectrometer. Chemical 
shifts are reported in parts per million relative to internal standard 
tetramethylsilane (Si(CH3)4 = 0.00 ppm) or residual solvent peaks (CDCl3 = 
7.26 ppm, MeOD = 3.31 ppm). 
1
H NMR coupling constants (J) are reported in 
Hertz (Hz) and multiplicity is indicated as follows: s (singlet), d (doublet), t 
(triplet), m (multiplet), dd (doublet of doublet), dt (doublet of triplet). MS 
spectra were recorded on a Finnigan LCQ mass spectrometer, a Shimadzu 
LC-IT-TOF spectrometer or a Shimadzu LC-ESI spectrometer. Analytical 
HPLC was carried out on Shimadzu LC-IT-TOF or LC-ESI systems equipped 
with an autosampler, using reverse-phase Phenomenex Luna 5 μm C18 100 Å 
50 × 3.0 mm columns. Preparative HPLC was carried out on Gilson 
preparative HPLC system using Trilution software and reverse-phase 
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Phenomenex Luna 5 μm C18 (2) 100 Å 50 × 30.00 mm column. 0.1% 
TFA/H2O and 0.1% TFA/acetonitrile were used as eluents for all HPLC 
experiments. The flow rate was 0.6 mL/min for analytical HPLC and 8 
mL/min for preparative HPLC. UV-vis absorption and fluorescence spectra 
were measured by using a Shimadzu UV-vis spectrophotometer and a Perkin 
Elmer LS50 spectrofluorometer, respectively. All the measurements were 
performed at room temperature. 
6.2 Chapter 2 
6.2.1 Chemical Synthesis 
6.2.1.1 Synthesis of activity-based probe T1 
(S)-methyl 2-((tert-butoxycarbonyl)amino)-3-(5-hydroxy-1H-indol-3-yl) 
Propanoate (1a) 
Thionyl Chloride (2.25 mL) was added dropwise to 
L-5-Hydroxytryptophan (1 g, 4.54 mmol) in a methanol (22.5 mL) solution at 
0 
o
C. The brown solution was refluxed for 4 h. When the reaction was 
completed, the solution was evaporated to remove the solvent and excessive 
SOCl2 under reduced pressure. The dark green residue was dissolved in a 
minimal amount of hot methanol. Et2O was added to obtain the dark green 
product precipitation as a solid. The crude product was then re-dissolved in 
dioxane-H2O cosolvent (110 mL, dioxane:H2O = 1:1). To the solution, a 
NaHCO3 solution (sat.) was added at 0 
o
C to adjust the pH of the solution to 8. 
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Then Boc2O (0.99 g, 4.53 mmol) was added to the above solution at 0 
o
C, 
followed by stirring overnight at room temperature. The reaction mixture was 
extracted with EtOAc for three times, the organic layer was combined, washed 
with brine and dried over Na2SO4. Flash column chromatography 
(Hexane:EtOAc = 3:1) was used to afford the protected unnatural amino acid 
1a as a pale white solid (1.25 g, 83% in two steps); 
1
H NMR (300 MHz, 
MeOD) δ 7.15 (d, J = 8.6 Hz, 1H), 7.00 (s, 1H), 6.90 (d, J = 2.2 Hz, 1H), 6.67 
(dd, J = 8.6, 2.1 Hz, 1H), 4.39 (d, J = 6.7 Hz, 1H), 3.65 (s, 3H), 3.22-2.92 (m, 
2H), 1.31 (d, J = 48.1 Hz, 9H); 
13C NMR (75 MHz, MeOD) δ 174.76, 157.51, 
151.34, 132.95, 129.40, 125.19, 112.73, 112.51, 109.97, 103.41, 80.67, 55.98, 
52.58, 28.65. MS (ESI): [M+H
+
] calcd for C17H22N2O5 335.15, found 335.20. 
(S)-methyl 2-((tert-butoxycarbonyl)amino)-3-(5-(prop-2-yn-1-yloxy)-1H- 
indol-3-yl)propanoate (1b) 
Compound 1a (200 mg, 0.598 mmol) was dissolved in anhydrous DMF 
(2 mL). Then anhydrous potassium carbonate (124 mg, 0.897 mmol) was 
added to the solution. The obtained mixture was stirred at room temperature 
for 30 min. Propargyl bromide (80% in toluene, 0.1 mL, 0.897 mmol) was 
added to the reaction mixture, which was subsequently stirred at room 
temperature overnight. After the completion of the reaction, water was added 
to dilute the reaction solution. The crude product was extracted with EtOAc 
for three times, the organic layer was combined, washed with water and brine, 
dried over Na2SO4 and concentrated. Flash column chromatography 
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(Hexane:EtOAc = 2:1) was used to generate the titled product 1b as a yellow 
oil (220.35 mg, 99%); 
1
H NMR (300 MHz, CDCl3) δ 8.28 (s, 1H), 7.23 (d, J = 
8.8 Hz, 1H), 7.10 (d, J = 1.5 Hz, 1H), 6.99-6.87 (m, 2H), 5.28 (s, 1H), 4.72 (d, 
J = 2.2 Hz, 2H), 3.67 (s, 3H), 3.24 (s, 1H), 3.22 (s, 1H), 2.53 (s, 1H), 1.42 (s, 
9H); 
13
C NMR (75 MHz, CDCl3) δ 172.78, 155.12, 152.05, 131.90, 127.86, 
123.81, 112.93, 111.93, 109.81, 102.93, 79.94, 79.18, 75.19, 57.05, 54.17, 
52.22, 28.25. MS (ESI): [M+H
+
] calcd for C20H24N2O5 373.17, found 373.14. 
(S)-methyl 2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-3-(5-(prop-2-yn-1 
-yloxy)-1H-indol-3-yl) propanoate (T1) 
Compound 1b (200 mg, 0.54 mmol) was dissolved in HPLC-grade DCM 
(2 mL). To the solution, TFA (2 mL) was added dropwise. The reaction 
mixture was stirred at room temperature for 1 h. After the reaction was 
completed, the volatile was removed under reduced pressure. The residue was 
diluted with water. After adjusting the pH value of the solution to 7~8 with 
saturated NaHCO3 solution, then the product was extracted with EtOAc. The 
organic phase was combined, washed with brine, dried over Na2SO4 and 
concentrated. The product 1b-amine can be directly used in the next step 
without further purification.  
Maleic anhydride (19.8 mg, 0.202 mmol) was dissolved in glacial acetic 
acid (0.5 mL) at room temperature. To the solution, a solution of compound 
1b-amine (50 mg, 0.184 mmol) in glacial acetic acid (0.5 mL) was added 
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dropwise. The reaction mixture was refluxed for 4 h. After the reaction 
completion, the reaction was cooled to room temperature and water was added 
to quench the reaction. Saturated sodium bicarbonate solution was employed 
to neutralize the reaction solution. The crude product was extracted with 
EtOAc for three times, the organic layer was combined, washed with water 
and brine, dried over Na2SO4 and concentrated. Flash column chromatography 
(DCM:MeOH = 95:5) was used to afford the titled product T1 as a yellowish 
solid (20 mg, 31% in two steps): 
1
H NMR (300 MHz, CDCl3) δ 7.22 (d, J = 
8.8 Hz, 1H), 7.08 (d, J = 2.3 Hz, 1H), 6.98 (d, J = 2.3 Hz, 1H), 6.89 (dd, J = 
8.8, 2.4 Hz, 1H), 6.57 (s, 2H), 5.04 (dd, J = 9.2, 7.0 Hz, 1H), 4.73 (d, J = 2.4 
Hz, 2H), 3.80 (s, 3H), 3.64-3.54 (m, 2H), 2.54 (t, J = 2.4 Hz, 1H); 
13
C NMR 
(125 MHz, CDCl3) δ 170.04, 169.65, 152.26, 134.18, 131.89, 127.63, 123.64, 
113.39, 112.06, 111.01, 102.63, 79.34, 75.35, 57.14, 53.00, 52.63, 24.79. 
HRMS: [M+Na
+
] calcd for C19H16N2O5 375.0951, found 375.0965. 
6.2.1.2 Synthesis of activity-based probe Gn 
(S)-methyl 2-amino-3-(4-nitrophenyl)propanoate (2a) 
Thionyl chloride (12 mL) was added dropwise to a solution of 
4-nitro-3-phenyl-L-alanine (10 g, 47.58 mmol) in HPLC-grade methanol (150 
mL) at 0
 o
C. The mixture was refluxed for 2 h. When the reaction was 
completed, the reaction mixture was cooled to room temperature and removed 
the solvent under reduced pressure. The residue was re-dissolved in water and 
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NaHCO3 was added to adjust the pH of the solution to 7~8. The mixture was 
extracted with DCM for three times. The organic phase was combined, 
washed with water and brine. Finally the organic phase was dried with Na2SO4 
and concentrated in vacuo to afford the methylated amino acid as yellow oil 
(10.46 g, 98%). The product was used in the next step without further 
purification. 
The methylated amino acid (1.933 g, 8.62 mmol) was dissolved in a 
dioxane/H2O co-solvent (50 mL, dioxane:H2O = 1:1). To the solution, a 
NaHCO3 solution (sat.) was added at 0 
o
C to adjust the pH of the solution to 
around 8. To this solution, a solution of benzyl chloroformate (1.765 g, 10.34 
mmol) in dioxane was added dropwise at 0 
o
C. After addition, the reaction 
mixture was allowed to warm to room temperature, followed by stirring 
overnight. After the reaction was completed, EtOAc was used to extract the 
crude product for three times, the organic layer was collected and combined, 
washed with diluted HCl solution, saturated NaHCO3 solution, water and brine, 
dried over Na2SO4 and concentrated. The crude product was purified by flash 
column chromatography (Hexane:EtOAc = 3.5:1) to yield the protected 
unnatural amino acid 2a as a white solid (3.06 g, 99%): 
1
H NMR (500 MHz, 
CDCl3) δ 8.07 (d, J = 8.3 Hz, 2H), 7.37-7.27 (m, 5H), 7.24 (s, 2H), 5.51 (s, 
1H), 5.06 (dd, J = 30.8, 12.2 Hz, 2H), 4.68 (dd, J = 13.3, 6.6 Hz, 1H), 3.72 (s, 
3H), 3.27 (dd, J = 13.8, 5.4 Hz, 1H), 3.10 (dd, J = 13.8, 6.8 Hz, 1H); 
13
C NMR 
(125 MHz, CDCl3) δ 171.38, 155.58, 147.08, 143.85, 136.09, 130.19, 128.51, 
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128.30, 128.09, 123.62, 67.06, 54.52, 52.60, 38.06. MS (ESI): [M+H
+
] calcd 
for C18H18N2O6 359.12, found 359.10. 
(S)-methyl 3-(4-aminophenyl)-2 (((benzyloxy)carbonyl) amino)propanoate 
(2b) 
Compound 2a (3.06 g, 8.54 mmol) was dissolved in a mixed solution of 
ethanol/H2O (125 mL, EtOH:H2O = 3:2). After that, 7.9 mL concentrated 
hydrochloric acid (37%) was added to the solution. Anhydrous tin (II) chloride 
(14.34 g, 75.62 mmol) was added and the resulting solution was refluxed at 70 
~ 80 
o
C for 50 min. When the reaction was completed, the reaction mixture 
was basified with NaHCO3 to adjust the pH around 8 immediately. The 
precipitated Sn(OH)2 was removed by filtration through a short pad of celite 
and washed with EtOAc for three times. The filtrate was collected and 
extracted with EtOAc. The organic phase was washed with water and brine, 
dried over Na2SO4 and concentrated. The crude product was further purified 
by flash column chromatography (Hexane:EtOAc = 3:1) to obtain the titled 
product 2b as a golden yellow oil (2.28 g, 81%): 
1
H NMR (500 MHz, CDCl3) 
δ 7.40-7.28 (m, 5H), 6.88 (d, J = 8.3 Hz, 2H), 6.62 (d, J = 8.2 Hz, 2H), 5.22 (d, 
J = 7.3 Hz, 1H), 5.09 (d, J = 2.1 Hz, 2H), 4.59 (dd, J = 13.9, 5.8 Hz, 1H), 3.71 
(s, 3H), 3.06-2.94 (m, 2H); 
13
C NMR (75 MHz, CDCl3) δ 172.30, 155.76, 
145.46, 136.28, 130.17, 128.57, 128.14, 128.07, 125.36, 115.42, 66.97, 55.06, 
52.31, 37.40. MS (ESI): [M+H
+
] calcd for C18H20N2O4 329.14, found 329.12; 
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General procedure  
Synthesis of tetrazole compound (2dn)  
Aldehyde N and PhSO2NHNH2 (1:1.2 equiv.) were dissolved in ethanol 
(6.8 mL/mmol) and the resulting solution was stirred at room temperature for 
3 h. After the completion of the reaction, EtOH was removed under reduced 
pressure to give compound 2cn. The crude product was used in the next step 
directly without further purification.
[1]
 
Compound 2cn (0.85 equiv.) was re-dissolved in pyridine (10.4 mL/mmol) 
and cooled to -10 ~ -20 
o
C in an ice/NaCl bath to derive solution A. Separately, 
to a solution of compound 2b (1 equiv.) in mixed EtOH-H2O (10.4 mL/mmol, 
EtOH:H2O = 1:1) was added concentrated hydrochloric acid (0.48 mL/mmol), 
and the mixture was cooled to -5
 o
C with an ice/NaCl bath. Subsequently, a 
cold solution of NaNO2 (1.5 equiv.) in water (1.74 mL/mmol) was added 
dropwise into to derive solution B (it is very important to keep the 
temperature below 0 
o
C during the entire addition process!). 
Solution B was added to solution A slowly and kept the temperature 
below -5 
o
C at all the time. Upon the completion of addition, the reaction 
mixture was allowed to warm to room temperature. The solution was extracted 
with EtOAc/H2O, washed with diluted HCl solution and brine, then dried with 
Na2SO4 and concentrated. The crude product was further purified via column 
chromatography (1% EtOAc in DCM) to afford the titled compound 2dn. 
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Synthesis of the target probe Gn (avoiding light during all the process) 
To a solution of tetrazole amino acid derivatives 2dn (100 mg) in HPLC 
MeOH was added 10% Pd/C (20 mg). The reaction was sealed and air was 
removed by inletting nitrogen gas into the system. While air was totally 
removed, the reaction mixture was hydrogenated at room temperature (1 atm) 
overnight. And the catalyst was removed by filtration through a short pad of 
celite and washing with EtOAc. The solvent was removed under reduced 
pressure and the obtained product 2en can be directly used in the next step. 
To a solution of maleic anhydride in HPLC-grade CHCl3 (0.8 mL/mmol), 
a solution of compound 2en (1 equiv.) in HPLC CHCl3 (0.2 mL/mmol) was 
added dropwise. The resulting mixture was stirred at room temperature for 2 h. 
After starting materials were completely reacted, the solvent was removed 
under reduced pressure. The residue was re-dissolved in acetic anhydride (1 
mL/mmol) and sodium acetate (20 mg/mmol) was added. The mixture was 
refluxed for 2 h, cooled and quenched with water. The aqueous solution was 
extracted with EtOAc, washed with saturated NaHCO3 solution, water and 
brine, dried over Na2SO4 and concentrated. The crude product Gn was 
purified by flash column chromatography. 
(S)-methyl 2-(((benzyloxy)carbonyl)amino)-3-(4-(5-(4-isopropylphenyl) 
-2H-tetrazol-2-yl) phenyl) propanoate (2d1) 
139 
 
A yellowish solid (130 mg, 86%): 
1
H NMR (500 MHz, CDCl3) δ 8.17 (d, 
J = 8.2 Hz, 2H), 8.09 (d, J = 8.3 Hz, 2H), 7.41-7.27 (m, 9H), 5.31 (d, J = 7.7 
Hz, 1H), 5.09 (t, J = 12.7 Hz, 2H), 4.75-4.69 (m, 1H), 3.75 (s, 3H), 3.27 (dd, J 
= 13.9, 5.6 Hz, 1H), 3.15 (dd, J = 13.9, 6.1 Hz, 1H), 3.03-2.95 (m, 1H), 1.31 
(d, J = 6.9 Hz, 6H); 
13
C NMR (125 MHz, CDCl3) δ 171.61, 165.29, 155.56, 
151.72, 137.64, 136.13, 135.98, 130.53, 128.56, 128.30, 128.17, 127.11, 
127.08, 124.68, 119.98, 67.13, 54.71, 52.55, 38.02, 34.18, 23.84. MS 
(IT-TOF): [M+H
+
] calcd for C28H29N5O4 500.22, found 500.20. 
(S)-methyl 2-(((benzyloxy)carbonyl)amino)-3-(4-(5-(4-fluorophenyl)-2H 
-tetrazol-2-yl)phenyl) propanoate (2d2) 
A yellowish solid (128 mg, 88%): 
1
H NMR (500 MHz, CDCl3) δ 
8.27-8.19 (m, 2H), 8.09 (d, J = 8.2 Hz, 2H), 7.36-7.27 (m, 6H), 7.25-7.18 (m, 
3H), 5.29 (s, 1H), 5.09 (t, J = 11.8 Hz, 2H), 4.72 (s, 1H), 3.75 (s, 3H), 3.25 (s, 
1H), 3.15 (d, J = 7.4 Hz, 1H); 
13
C NMR (125 MHz, CDCl3) δ 171.57, 165.23, 
163.83 (d, J = 148.6 Hz), 155.53, 137.85, 136.11, 135.86, 130.58, 129.10 (d, J 
= 8.6 Hz), 128.55, 128.29, 128.16, 123.39, 119.95, 116.13 (d, J = 22.0 Hz). 
MS (IT-TOF): [M+H
+
] calcd for C25H22FN5O4 476.17, found 476.16. 
(S)-methyl 2-(((benzyloxy)carbonyl)amino)-3-(4-(5-(naphthalen-1-yl)-2H 
-tetrazol-2-yl)phenyl) propanoate (2d3) 
A yellowish solid (208.1 mg, 84%): 
1
H NMR (500 MHz, CDCl3) δ 9.02 
(d, J = 8.5 Hz, 1H), 8.38 (d, J = 7.2 Hz, 1H), 8.18 (d, J = 8.0 Hz, 2H), 8.03 (d, 
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J = 8.1 Hz, 1H), 7.96 (d, J = 8.0 Hz, 1H), 7.68-7.56 (m, 3H), 7.34 (d, J = 9.5 
Hz, 7H), 5.33 (d, J = 7.8 Hz, 1H), 5.10 (t, J = 13.2 Hz, 2H), 4.74 (d, J = 6.9 
Hz, 1H), 3.77 (s, 3H), 3.30 (dd, J = 13.6, 5.6 Hz, 1H), 3.18 (dd, J = 14.1, 6.0 
Hz, 1H); 
13
C NMR (125 MHz, CDCl3) δ 171.61, 165.35, 155.56, 137.84, 
136.13, 135.97, 134.01, 131.28, 130.64, 128.69, 128.67, 128.57, 128.32, 
128.19, 127.44, 126.33, 125.78, 125.25, 123.92, 120.06, 67.14, 54.72, 52.58, 
38.04. MS (IT-TOF): [M+H
+
] calcd for C29H25N5O4 508.19, found 508.18. 
(S)-methyl 2-(((benzyloxy)carbonyl)amino)-3-(4-(5-(4-methoxyphenyl)-2H 
-tetrazol-2-yl) phenyl) propanoate (2d4) 
A yellowish solid (55.4 mg, 37%): 
1
H NMR (500 MHz, CDCl3) δ 8.18 (d, 
J = 8.8 Hz, 2H), 8.08 (d, J = 8.4 Hz, 2H), 7.40-7.26 (m, 7H), 7.04 (d, J = 8.8 
Hz, 2H), 5.30 (d, J = 8.2 Hz, 1H), 5.10 (q, J = 12.2 Hz, 2H), 4.72 (d, J = 7.6 
Hz, 1H), 3.89 (s, 3H), 3.75 (s, 3H), 3.26 (dd, J = 13.7, 5.7 Hz, 1H), 3.15 (dd, J 
= 14.0, 6.1 Hz, 1H); 
13
C NMR (125 MHz, CDCl3) δ 171.60, 165.10, 161.51, 
155.55, 137.58, 136.14, 135.99, 130.53, 128.60, 128.56, 128.30, 128.17, 
119.93, 119.72, 114.39, 67.13, 55.41, 54.71, 52.54, 38.02. MS (IT-TOF): 
[M+H
+
] calcd for C26H25N5O5 488.19, found 488.18. 
(S)-methyl 2-(((benzyloxy)carbonyl)amino)-3-(4-(5-(4-(dimethylamino) 
phenyl)-2H-tetrazol-2-yl)phenyl) propanoate (2d5) 
A yellowish solid (35.8 mg, 24%): 
1
H NMR (500 MHz, CDCl3) δ 
8.13-8.07 (m, 2H), 7.35-7.26 (m, 9H), 6.85 (s, 2H), 5.29 (d, J = 7.6 Hz, 1H), 
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5.11 (q, J = 12.2 Hz, 2H), 4.72 (d, J = 7.7 Hz, 1H), 3.75 (s, 3H), 3.28-3.23 (m, 
1H), 3.18-3.13 (m, 1H), 3.07 (s, 6H). MS (IT-TOF): [M+H
+
] calcd for 
C27H28N6O4 501.22, found 501.19. 
(S)-methyl 2-(((benzyloxy)carbonyl)amino)-3-(4-(5-phenyl-2H-tetrazol-2 
-yl)phenyl)propanoate (2d6) 
A yellowish solid (79.2 mg, 57%): 
1
H NMR (500 MHz, CDCl3) δ 8.25 
(dd, J = 7.8, 1.7 Hz, 2H), 8.10 (d, J = 8.4 Hz, 2H), 7.52 (dd, J = 5.7, 3.8 Hz, 
3H), 7.38-7.27 (m, 7H), 5.31 (d, J = 7.7 Hz, 1H), 5.09 (t, J = 12.4 Hz, 2H), 
4.73 (dd, J = 13.8, 6.0 Hz, 1H), 3.76 (s, 3H), 3.27 (dd, J = 13.9, 5.7 Hz, 1H), 
3.16 (dd, J = 13.9, 6.2 Hz, 1H); 
13
C NMR (125 MHz, CDCl3) δ 171.60, 165.22, 
155.58, 137.77, 135.94, 130.60, 130.57, 128.98, 128.56, 128.31, 128.17, 
127.14, 127.07, 120.00, 67.14, 54.71, 52.56, 38.03. MS (IT-TOF): [M+H
+
] 
calcd for C25H23N5O4 458.18, found 458.17. 
(S)-methyl 2-(((benzyloxy)carbonyl)amino)-3-(4-(5-(3,5-difluorophenyl) 
-2H-tetrazol-2-yl) phenyl) propanoate (2d7) 
A yellowish solid (111.6 mg, 74%): 
1
H NMR (500 MHz, CDCl3) δ 8.08 
(d, J = 8.3 Hz, 2H), 7.84-7.73 (m, 2H), 7.33 (dd, J = 16.8, 7.3 Hz, 7H), 6.95 (tt, 
J = 8.8, 2.3 Hz, 1H), 5.32 (d, J = 6.4 Hz, 1H), 5.09 (t, J = 11.8 Hz, 2H), 4.73 
(dd, J = 13.5, 6.1 Hz, 1H), 3.76 (s, 3H), 3.28 (dd, J = 13.9, 5.6 Hz, 1H), 3.16 
(dd, J = 13.9, 6.2 Hz, 1H); 
13
C NMR (125 MHz, CDCl3) δ 171.56, 164.37 (d, J 
= 12.8 Hz), 163.45, 162.44, 155.54, 138.24, 135.69, 130.67, 128.57, 128.32, 
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128.18, 120.02, 110.20 (d, J = 7.0 Hz), 110.03 (d, J = 6.8 Hz), 105.95, 67.15, 
54.69, 52.58, 38.04. MS (IT-TOF): [M+H
+
] calcd for C25H21F2N5O4 494.16, 
found 494.14. 
(S)-methyl 2-(((benzyloxy)carbonyl)amino)-3-(4-(5-(4-(hexyloxy)phenyl) 
-2H-tetrazol-2-yl) phenyl) propanoate (2d8) 
A yellowish solid (88.3 mg, 69%): 
1
H NMR (500 MHz, CDCl3) δ 8.17 (d, 
J = 8.8 Hz, 2H), 8.08 (d, J = 8.4 Hz, 2H), 7.38-7.26 (m, 7H), 7.03 (d, J = 8.9 
Hz, 2H), 5.29 (d, J = 7.9 Hz, 1H), 5.11 (q, J = 12.2 Hz, 2H), 4.72 (d, J = 7.7 
Hz, 1H), 4.04 (t, J = 6.6 Hz, 2H), 3.75 (s, 3H), 3.26 (dd, J = 14.0, 5.7 Hz, 1H), 
3.15 (dd, J = 13.9, 6.0 Hz, 1H), 1.86-1.78 (m, 2H), 1.53-1.25 (m, 6H), 0.92 (t, 
J = 7.1 Hz, 3H); 
13
C NMR (125 MHz, CDCl3) δ 171.58, 165.16, 161.12, 
155.34, 136.00, 130.50, 128.55, 128.28, 128.15, 119.92, 119.43, 114.90, 68.19, 
67.11, 54.70, 52.52, 37.88, 31.57, 29.17, 25.70, 22.59, 14.01. MS (IT-TOF): 
[M+H
+
] calcd for C31H35N5O5 558.26, found 558.23. 
(S)-methyl 2-(((benzyloxy)carbonyl)amino)-3-(4-(5-(pyridin-4-yl)-2H 
-tetrazol-2-yl)phenyl)propanoate (2d9) 
A yellowish solid (39 mg, 33%): 
1
H NMR (500 MHz, CDCl3) δ 8.83 (s, 
2H), 8.12 (dd, J = 21.4, 6.5 Hz, 4H), 7.34 (dd, J = 7.5, 4.9 Hz, 7H), 5.33 (d, J 
= 7.8 Hz, 1H), 5.17-5.03 (m, 2H), 4.73 (dd, J = 13.7, 6.1 Hz, 1H), 3.76 (s, 3H), 
3.29 (dd, J = 13.9, 5.6 Hz, 1H), 3.16 (dd, J = 13.9, 6.1 Hz, 1H); 
13
C NMR (125 
MHz, CDCl3) δ 171.55, 163.12, 155.57, 150.41, 138.44, 136.13, 135.65, 
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130.72, 128.57, 128.33, 128.19, 121.10, 120.09, 67.16, 54.69, 52.60, 38.06. 
MS (IT-TOF): [M+H
+
] calcd for C24H22N6O4 459.17, found 459.14. 
(S)-methyl 2-(((benzyloxy)carbonyl)amino)-3-(4-(5-(4-(difluoromethoxy) 
phenyl)-2H-tetrazol-2yl)phenyl)propanoate (2d10) 
A yellowish solid (34 mg, 27%): 
1
H NMR (500 MHz, CDCl3) δ 8.26 (d, J 
= 8.7 Hz, 2H), 8.09 (d, J = 8.3 Hz, 2H), 7.38-7.26 (m, 9H), 6.60 (t, J = 73.4 
Hz, 1H), 5.31 (d, J = 8.0 Hz, 1H), 5.14-5.07 (m, 2H), 4.72 (d, J = 7.5 Hz, 1H), 
3.76 (s, 3H), 3.27 (dd, J = 13.9, 5.6 Hz, 1H), 3.15 (dd, J = 13.9, 6.2 Hz, 1H); 
13
C NMR (125 MHz, CDCl3) δ 171.58, 164.34, 155.55, 152.87, 137.92, 
136.12, 135.86, 130.60, 128.76, 128.56, 128.31, 128.17, 124.37, 119.99, 
119.80, 115.64, 67.14, 54.70, 52.55, 38.04. MS (IT-TOF): [M+H
+
] calcd for 
C26H23F2N5O5 524.17, found 524.15. 
(S)-methyl 2-(((benzyloxy)carbonyl)amino)-3-(4-(5-(4-(trifluoromethyl) 
phenyl)-2H-tetrazol-2-yl)phenyl)propanoate (2d11) 
A yellowish solid (48 mg, 35%): 
1
H NMR (500 MHz, CDCl3) δ 8.38 (d, J 
= 8.2 Hz, 2H), 8.10 (d, J = 8.3 Hz, 2H), 7.80 (d, J = 8.3 Hz, 2H), 7.31 (dd, J = 
24.4, 16.4 Hz, 7H), 5.31 (d, J = 7.6 Hz, 1H), 5.09 (dd, J = 15.8, 7.2 Hz, 2H), 
4.73 (d, J = 6.0 Hz, 1H), 3.76 (s, 3H), 3.31-3.22 (m, 1H), 3.16 (dd, J = 13.8, 
6.1 Hz, 1H); 
13
C NMR (125 MHz, CDCl3) δ 171.54, 164.02, 155.55, 138.12, 
136.11, 135.77, 132.50, 132.24, 130.66, 128.57, 128.32, 128.18, 127.35, 
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126.01 (d, J = 3.9 Hz), 120.05, 67.15, 54.70, 52.58, 38.05. MS (IT-TOF): 
[M+H
+
] calcd for C26H22F3N5O4 526.16, found 526.16. 
(S)-methyl 2-(((benzyloxy)carbonyl)amino)-3-(4-(5-(3,5-dimethylphenyl) 
-2H-tetrazol-2-yl) phenyl) propanoate (2d12) 
A yellowish solid (97 mg, 77%): 
1
H NMR (500 MHz, CDCl3) δ 8.10 (d, J 
= 8.3 Hz, 2H), 7.87 (s, 2H), 7.40-7.26 (m, 7H), 7.14 (s, 1H), 5.30 (d, J = 7.9 
Hz, 1H), 5.11 (q, J = 12.2 Hz, 2H), 4.72 (dd, J = 13.5, 6.0 Hz, 1H), 3.75 (s, 
3H), 3.27 (dd, J = 13.9, 5.6 Hz, 1H), 3.15 (dd, J = 13.9, 6.1 Hz, 1H), 2.42 (s, 
6H); 
13
C NMR (125 MHz, CDCl3) δ 171.60, 165.44, 155.31, 138.66, 137.68, 
136.12, 135.98, 132.29, 130.54, 128.56, 128.30, 128.16, 126.86, 124.81, 
119.99, 67.13, 54.71, 52.53, 38.03, 21.30 (d, J = 1.7 Hz). MS (IT-TOF): 
[M+H
+
] calcd for C27H27N5O4 486.21, found 486.19. 
(S)-methyl 2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-3-(4-(5-(4-isopropyl 
phenyl)-2H-tetrazol-2-yl)phenyl)propanoate (G1) 
A yellowish solid (21 mg, 35%): 
1
H NMR (300 MHz, CDCl3) δ 8.11 (dd, 
J = 19.3, 8.5 Hz, 4H), 7.36 (dd, J = 11.7, 8.4 Hz, 4H), 6.64 (s, 2H), 5.01 (dd, J 
= 11.1, 5.7 Hz, 1H), 3.80 (s, 3H), 3.57 (t, J = 8.3 Hz, 2H), 2.98 (dt, J = 13.8, 
6.8 Hz, 1H), 1.30 (d, J = 6.9 Hz, 6H); 
13
C NMR (125 MHz, CDCl3) δ 169.75, 
168.86, 165.27, 151.71, 138.36, 135.87, 134.18, 130.10, 127.09, 127.07, 
124.63, 120.08, 77.29, 77.04, 76.78, 53.08, 52.84, 34.25, 34.18, 29.66, 23.84. 
HRMS: [M+Na
+




phenyl)-2H-tetrazol-2-yl)phenyl) propanoate (G2) 
A yellowish solid (18.6mg, 43%): 
1
H NMR (300 MHz, CDCl3) δ 8.23 
(dd, J = 8.8, 5.4 Hz, 2H), 8.07 (d, J = 8.5 Hz, 2H), 7.35 (d, J = 8.5 Hz, 2H), 
7.22 (dd, J = 16.4, 7.7 Hz, 3H), 6.64 (s, 2H), 5.01 (dd, J = 11.1, 5.7 Hz, 1H), 
3.81 (s, 3H), 3.65-3.52 (m, 2H). 
13
C NMR (125 MHz, CDCl3) δ 169.88, 
168.97, 165.36, 163.96 (d, J = 146.3 Hz), 138.71, 135.88, 134.31, 130.29, 
129.26, 123.49, 120.20, 116.28 (d, J = 22.5 Hz), 53.23, 52.96, 34.39. HRMS: 
[M+Na
+
] calcd for C21H16FN5O4 444.1079, found 444.1090. 
(S)-methyl 2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-3-(4-(5-(naphthalen-1 
-yl)-2H-tetrazol-2-yl)phenyl) propanoate (G3) 
A yellowish solid (29.2mg, 48%): 
1
H NMR (500 MHz, CDCl3) δ 8.99 (d, 
J = 8.5 Hz, 1H), 8.36 (d, J = 7.2 Hz, 1H), 8.17 (d, J = 8.4 Hz, 2H), 8.02 (d, J = 
8.2 Hz, 1H), 7.95 (d, J = 8.0 Hz, 1H), 7.67-7.56 (m, 3H), 7.38 (d, J = 8.4 Hz, 
2H), 6.65 (s, 2H), 5.03 (dd, J = 11.5, 5.3 Hz, 1H), 3.81 (s, 3H), 3.67-3.51 (m, 
2H).
13
C NMR (125 MHz, CDCl3) δ 169.90, 168.99, 165.46, 138.69, 135.98, 
134.33, 134.11, 131.41, 130.72, 130.33, 128.82, 128.79, 127.58, 126.46, 
125.87, 125.37, 124.00, 120.29, 53.23, 52.98, 34.42. HRMS: [M+Na
+
] calcd 
for C25H19N5O4 476.1329, found 476.1335. 
(S)-methyl 2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-3-(4-(5-(4-methoxy 
phenyl)-2H-tetrazol-2-yl)phenyl) propanoate (G4) 
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A yellowish solid (21.5mg, 35%): 
1
H NMR (500 MHz, CDCl3) δ 
8.19-8.14 (m, 2H), 8.07 (d, J = 8.6 Hz, 2H), 7.33 (d, J = 8.5 Hz, 2H), 
7.06-7.01 (m, 2H), 6.64 (s, 2H), 5.01 (dd, J = 11.5, 5.3 Hz, 1H), 3.89 (s, 3H), 
3.81 (s, 3H), 3.61-3.53 (m, 2H); 
13
C NMR (125 MHz, CDCl3) δ 169.73, 
168.85, 165.07, 161.49, 130.08, 128.57, 120.03, 119.66, 114.37, 55.40, 53.06, 
52.83, 34.23. HRMS: [M+Na
+
] calcd for C22H19N5O5 456.1278, found 
456.1284. 
(S)-methyl 3-(4-(5-(4-(dimethylamino)phenyl)-2H-tetrazol-2-yl)phenyl) 
-2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl) propanoate (G5) 
A yellowish solid (1 mg, 9%): 
1
H NMR (500 MHz, CDCl3) δ 8.15-8.02 
(m, 4H), 7.32 (d, J = 8.5 Hz, 2H), 6.80 (d, J = 8.9 Hz, 2H), 6.63 (s, 2H), 5.01 
(dd, J = 11.5, 5.4 Hz, 1H), 3.80 (s, 3H), 3.57 (dd, J = 16.5, 8.4 Hz, 2H), 3.05 
(s, 6H); 
13
C NMR (125 MHz, CDCl3) δ 169.74, 168.74, 165.65, 151.59, 
137.98, 134.16, 130.01, 128.17, 119.98, 111.94, 53.05, 52.86, 40.24, 34.23. 
HRMS: [M+Na
+
] calcd for C23H22N6O4 469.1595, found 469.1611. 
(S)-methyl 2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-3-(4-(5-phenyl-2H 
-tetrazol-2-yl)phenyl)propanoate (G6) 
A yellowish solid (27.5 mg, 51%): 
1
H NMR (500 MHz, CDCl3) δ 8.23 
(dd, J = 7.7, 1.8 Hz, 1H), 8.09 (d, J = 8.5 Hz, 1H), 7.56-7.45 (m, 2H), 7.35 (d, 
J = 8.5 Hz, 1H), 6.64 (s, 1H), 5.01 (dd, J = 11.5, 5.3 Hz, 1H), 3.81 (s, 2H), 
3.58 (ddd, J = 25.9, 14.4, 8.5 Hz, 1H), 
13
C NMR (125 MHz, CDCl3) δ 169.88, 
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168.98, 165.33, 138.62, 135.96, 134.31, 130.73, 130.26, 129.10, 127.23, 
127.18, 53.21, 52.97, 34.39. HRMS: [M+Na
+
] calcd for C21H17N5O4 426.1173, 
found 426.1181. 
(S)-methyl 3-(4-(5-(3,5-difluorophenyl)-2H-tetrazol-2-yl)phenyl)-2-(2,5 
-dioxo-2,5-dihydro-1H-pyrrol-1-yl) propanoate (G7) 
A white solid (16.1 mg, 44%): 
1
H NMR (500 MHz, CDCl3) δ 8.07 (d, J = 
8.4 Hz, 2H), 7.76 (d, J = 6.0 Hz, 2H), 7.36 (d, J = 8.4 Hz, 2H), 6.99-6.90 (m, 
1H), 6.64 (s, 2H), 5.01 (dd, J = 11.5, 5.3 Hz, 1H), 3.80 (s, 3H), 3.58 (ddd, J = 
25.9, 14.4, 8.5 Hz, 2H); 
13
C NMR (125 MHz, CDCl3) δ 169.86, 168.93, 
164.49 (d, J = 12.6 Hz), 163.57, 162.56, 139.08, 135.72, 134.32, 130.37, 
120.27, 110.23 (dd, J = 20.8, 6.9 Hz), 106.07 (t, J = 25.4 Hz), 53.23, 52.94, 
34.42. HRMS: [M+Na
+
] calcd for C21H15F2N5O4 462.0984, found 462.0975. 
(S)-methyl 2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-3-(4-(5-(4-(hexyloxy) 
phenyl)-2H-tetrazol-2-yl)phenyl) propanoate (G8) 
A white solid (13.2 mg, 17%): 
1
H NMR (500 MHz, CDCl3) δ 8.14 (d, J = 
8.8 Hz, 2H), 8.07 (d, J = 8.5 Hz, 2H), 7.33 (d, J = 8.5 Hz, 2H), 7.02 (d, J = 8.8 
Hz, 2H), 6.63 (s, 2H), 5.01 (dd, J = 11.5, 5.3 Hz, 1H), 4.03 (t, J = 6.6 Hz, 2H), 
3.80 (s, 3H), 3.57 (ddd, J = 25.9, 14.4, 8.5 Hz, 2H), 1.86-1.76 (m, 2H), 
1.53-1.45 (m, 2H), 1.36 (d, J = 3.7 Hz, 4H), 0.92 (t, J = 7.0 Hz, 3H); 
13
C NMR 
(125 MHz, CDCl3) δ 169.71, 168.83, 165.13, 161.10, 138.24, 135.86, 134.14, 
130.06, 128.51, 120.00, 119.37, 114.87, 68.16, 53.03, 52.82, 34.22, 31.56, 
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29.15, 25.69, 22.58, 14.01. HRMS: [M+Na
+
] calcd for C27H29N5O5 526.2061, 
found 526.2080. 
(S)-methyl 2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-3-(4-(5-(pyridin-4-yl) 
-2H-tetrazol-2-yl)phenyl) propanoate (G9) 
A yellow solid (4.8 mg, 22%): 
1
H NMR (500 MHz, CDCl3) δ 8.82 (s, 
2H), 8.16 (d, J = 4.7 Hz, 2H), 8.10 (d, J = 8.4 Hz, 2H), 7.38 (d, J = 8.4 Hz, 
2H), 6.65 (s, 2H), 5.01 (dd, J = 11.4, 5.3 Hz, 1H), 3.81 (s, 3H), 3.59 (dt, J = 
14.2, 5.9 Hz, 2H); 
13
C NMR (125 MHz, CDCl3) δ 169.71, 168.74, 162.93, 
149.89, 139.21, 135.52, 135.30, 134.18, 130.29, 121.21, 120.21, 53.08, 52.78, 
34.29. HRMS: [M+Na
+
] calcd for C20H16N6O4 427.1125, found 427.1130. 
(S)-methyl 2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-3-(4-(5-(4-(trifluoro 
methyl)phenyl)-2H-tetrazol-2-yl)phenyl) propanoate (G10) 
A yellowish solid (2.6 mg, 17%): 
1
H NMR (500 MHz, CDCl3) δ 8.24 (d, 
J = 8.8 Hz, 2H), 8.08 (d, J = 8.5 Hz, 2H), 7.35 (d, J = 8.5 Hz, 2H), 7.27 (d, J = 
6.9 Hz, 2H), 6.78-6.40 (m, 3H), 5.01 (dd, J = 11.5, 5.3 Hz, 1H), 3.81 (s, 3H), 
3.63-3.53 (m, 2H); 
13
C NMR (125 MHz, CDCl3) δ 169.72, 168.80, 164.31, 
152.85, 138.62, 135.73, 134.16, 130.15, 128.73, 124.32, 120.08, 119.76, 
115.62. HRMS: [M+Na
+
] calcd for C22H17F2N5O5 492.1090, found 492.1084. 
(S)-methyl 3-(4-(5-(4-(difluoromethoxy)phenyl)-2H-tetrazol-2-yl)phenyl) 
-2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl) propanoate (G11) 
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A yellowish solid (7.9 mg, 29%): 
1
H NMR (500 MHz, CDCl3) δ 8.36 (d, 
J = 8.1 Hz, 2H), 8.10 (d, J = 8.6 Hz, 2H), 7.79 (d, J = 8.2 Hz, 2H), 7.36 (d, J = 
8.5 Hz, 2H), 6.64 (s, 2H), 5.01 (dd, J = 11.5, 5.3 Hz, 1H), 3.81 (s, 3H), 
3.62-3.54 (m, 2H); 
13
C NMR (125 MHz, CDCl3) δ 169.72, 168.78, 164.00, 
138.87, 135.66, 134.17, 130.21, 127.32, 126.00, 125.97, 120.15, 53.07, 52.81, 
34.28. HRMS: [M+Na
+
] calcd for C22H16F3N5O4 494.1047, found 494.1033. 
(S)-methyl 3-(4-(5-(3,5-dimethylphenyl)-2H-tetrazol-2-yl)phenyl)-2-(2,5 
-dioxo-2,5-dihydro-1H-pyrrol-1-yl) propanoate (G12) 
A white solid (11 mg, 18%): 
1
H NMR (500 MHz, CDCl3) δ 8.08 (d, J = 
8.0 Hz, 2H), 7.85 (s, 2H), 7.34 (d, J = 8.1 Hz, 2H), 7.13 (s, 1H), 6.64 (s, 2H), 
5.01 (dd, J = 11.4, 5.2 Hz, 1H), 3.80 (s, 3H), 3.65-3.48 (m, 2H), 2.41 (s, 6H); 
13
C NMR (125 MHz, CDCl3) δ 169.71, 168.83, 165.41, 138.63, 138.38, 
135.84, 134.15, 132.26, 130.08, 126.80, 124.77, 120.08, 53.03, 52.82, 34.23, 
21.26. HRMS: [M+Na
+




6.2.2 Biological evaluations 
6.2.2.1 General information 
Antibodies were purchased from the following vendors: anti-DNMT1 
(ab19905, Abcam) Rabbit, HRP-conjugated secondary antibodies: Goat 
anti-Rabbit IgG (#31210, Pierce), Zymax
TM
 Goat anti-rabbit IgG (H + L) 
Cy
TM
 5 Conjugate antibody. Nuclear staining reagent Hochest 33342, 
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trihydrochloride, trihydrate (10 mg/mL solution in water) were purchased 
from Invitrogen. Western blot was done by using the SuperSignal
®
 West Dura 
Extended Duration Substrate Kit (200 mL Kit, Thermal Scientific). FACS 
experiments were carried out on a BD Accuri™ C6 cell analyzer. Cell imaging 
was done by In Cell Analyzer 2200 (GE). 
Cell lines were obtained from the National Cancer Institute 
Developmental Therapeutics Program (NCI-60). MCF-7 cell line were 
cultured in Dulbeccoʼs modified Eagle medum (DMEM; Invitrogen, Carlsbad, 
CA) containing 10% heat-inactivated fetal bovine serum (FBS; Invitrogen), 
100 units/mL penicillin, and 100 μg/mL streptomycin (Thermo Scientific) and 
maintained in a humidified 37 °C incubator with 5% CO2. Protein 
concentration was determined by Bradford protein assay. 
6.2.2.2 Enzymatic activity/inhibition assay 
The enzymatic activity/inhibition assay of probe T1 and inhibitors Gn 
against DNMT1 was determined by using the DNMT Activity/Inhibition 
Assay Ultra Kit (Fluorometric, EpiQuik
TM
). The sample wells provided in the 
kit was modified with a universal DNMT substrate, which was incubated with 
pure DNMT1 together with the probes or inhibitors, as well as positive control 
enzyme provided in the kit and negative control (no enzyme applied) for 90 min. 
After incubation, the excess enzyme contained solutions were removed and the 
sample wells were washed with buffers supplied in the kit for several times, 
followed by applying capture and detection antibodies. Finally, the sample 
151 
 
wells were washed again and the fluorescence signal was developed by develop 
solution. The fluorescence was red by Tecan microplate reader (Multimode 
Reader, Infinite
®
200). The results and detailed explanation were also presented 
in Chapter 2 Figure 2.2a. 




Concentration-dependent experiments were performed to determine the 
inhibition potency. Dose-dependent inhibition assays were performed by 
varying the concentration of the probe and inhibitors in live MCF-7 cells. The 
GI50 values of the probe and inhibitors were calculated from the percentage 
activity vs. log [concentration of probe] curves generated using GraphPad 
Prism software. 
6.2.2.4 Fluorescence-Activated Cell Sorting (FACS) of live 
MCF-7 cells 
The cells were seeded in 6-well cell culture plates and grown untill ~90% 
confluence. Next, cells were first treated with 10 μM probe T1 and inhibitors 
Gn, as well as the two control inhibitors RG108 and 1149 at 37 
o
C for 6 h. 
Then the cells were washed with 1 x PBS once to remove excess probes. 
Subsequently, the cells was detached with trypsin from dishes and washed 
with cold PBS twice, then analyzed by BD Accuri 6 In Cell Flowcytometer 
(BD Pharmingen 
TM
 FITC Annexin V Apoptosis Detection Kit I) 
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6.2.2.5 In vitro Proteome Profiling 
These experiments were carried out largely based on previously 
published protocols with necessary modifications as shown below.
 [2, 3]
 Briefly, 
MCF-7 cells were grown to > 90% confluence in 15 cm cell culture dishes. 
After washing with 1 x PBS twice, cells were scraped and lysed in 2 mL lysis 
buffer (50 mM Tris, 150 mM NaCl, 5 mM EDTA, 0.1 mM PMSF, 0.1% Triton 
X-100, pH 8.0). The cell lysates (100 g) were pre-incubated with competitors 
(G6, 1149 and RG108, gradual concentrations) for 1 h at room temperature 
respectively. Subsequently, the lysates were further incubated with probe T1 
(10 M) for 1 h at room temperature. After incubation, copper (I) catalyzed 
azide-alkyne [3+2] cycloaddition (CuAAC) was applied. Four microliters of a 
freshly premixed click chemistry reaction cocktail (final concentrations of 
reagents: 40 μM TER-Biotin-azide, 40 μM TBTA, 400 μM TCEP and 400 μM 
CuSO4) was added to the labelled lysates. The whole reaction mixture was 
further incubated at room temperature for additional 2 h with gentle shaking 
before termination by addition of five-fold volume prechilled acetone 
(incubated for overnight at -20 °C). Precipitated proteins were subsequently 
collected by centrifugation (13, 000 rpm, 10 min at 4 °C). The supernatant was 
discarded and the residue pellet was washed with prechilled methanol for 2~3 
times (incubated for 2 h at -80 °C each time before centrifugation), air-dried 
the protein samples until the pellet started to shrink. Then the residue was 
resuspended in 1 x standard SDS-loading buffer, sonicated for 10 min and 
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heated for 10 min at 95 °C with gentle mixing. Finally, the protein samples 
were loaded onto an 8% SDS-PAGE gel and separated, followed by in-gel 
fluorescence scanning with a Typhoon 9410 variable mode imaging scanner 
and CBB staining.  
6.2.2.6 Pull-down and target validation 
To identify potential cellular targets of the probes and their parental 
compounds, pull-down (PD) experiments were carried out, and followed by 
Western Blotting (WB). Here, MCF-7 cell line was used as the tested cancer 
cell line. The general pull-down procedure was based on previously reported 
procedures 
[2b, 3d]
. Before pull-down, fresh MCF-7 cell lysates were prepared 
and their protein concentrations determined, as previously described. Cellular 
lysates (6 mg) were lysed with 500 µL 1× Tris buffer (50 mM Tris, 150 mM 
NaCl, 5 mM EDTA, 0.1 mM PMSF, 0.1% Triton X-100, pH 8.0) and 
pre-incubated with competitors (G6, 1149 and RG108, gradual concentrations) 
for 1 h at room temperature respectively. Subsequently, probe T1 (final 
concentration was 10 µΜ) was added, and labeling was carried out for 
additional 1 h at room temperature. The CuAAC click chemistry was then 
performed with TER-Biotin-azide trifunctional reporter under the conditions 
described in the labeling procedure. Subsequently, the proteins were acetone 
precipitated, washed with methanol for 2~3 times and re-solubilized in 1% 
SDS in PBS with brief sonication. These re-suspended samples were then 
incubated with avidin-agarose beads (100 µL/mg protein) for 6 h at room 
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temperature. After centrifugation, the supernatants were removed and the 
beads were washed with 1% SDS three times, 5% SDS twice, 1% SDS three 
times and 1 x PBS once. After washing, the beads were boiled in 1× SDS 
loading buffer (200 mM Tris pH 6.8, 400 mM DTT, 8% SDS) for 15 min. 
DMSO was used as control PD and carried out concurrently. WB experiments 
were carried out by referring to the general procedure using anti-DNMT1.  
6.2.2.7 Bio-imaging 
In order to demonstrate the utility of the cell-permeable probes or 
inhibitors for imaging of potential cellular targets, we performed fluorescence 
microscopy to visualize probe-treated cells (Figure 6.5). The general 
procedures are similar to what was previously reported 
[4b, e]
. Briefly, MCF-7 
cells were seeded in a 24-well plate (Cellstar) and grown until 50-60% 
confluence. Cells were then treated with 0.5 mL DMEM medium contained 
DMSO or competitors G6, RG108 and 1149 at different concentrations. After 
30 min incubation 37 
o
C, the medium was gently removed, and cells were 
gently washed once with PBS, 0.5 mL DMEM medium contained probe T1 (5 
µΜ) or DMSO was then added. After additional 30 min incubation at 37 oC, 
the medium was gently removed, and cells were gently washed twice with 
PBS again. Then the cells were subsequently fixed for 30 min at 37
 o
C with 
3.7% formaldehyde in PBS, washed twice with cold PBS again, and 
permeabilized with 0.1% Triton X-100 in PBS for 15 min at 37
 o
C. Cells were 
then treated with a freshly premixed click chemistry reaction solution in a 300 
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μL volume (final concentrations of reagents: 200 µΜ CuSO4, 200 µΜ TCEP, 
20 µΜ TBTA, and 5 µΜ TER-PEG-N3 in PBS) for 2 h at room temperature 
with vigorous shaking. Then cells were first washed with PBS twice, and then 
washed with EDTA (50 mM)-0.1% Tween-20 in PBS until no more copper left. 
Cells were washed with PBS twice again and blocked with 1% BSA in PBST 
(0.05% Tween-20) for 1 h and washed three times with PBS for 
immunofluorescence experiments. After blocking, cells were further incubated 
with anti-DNMT1 antibody (1:200) for 1 h at room temperature, after washing 
three times with PBS, the secondary antibody Zymax
TM
 Goat anti-rabbit IgG 
(H + L) Cy
TM
 5 Conjugate antibody (1:200) was added and cells were 
incubated for additional 1 h, following by washing with PBS for three times 
again. Finally, the cells were stained with Hochest 33342 to localize the nuclei. 
Imaging was done with the In Cell Analyzer 2200 (GE), a total of channels 
were employed including Bright-field (BF), Probe-treated channel (upon 
clicked with TER-PEG-N3), immunofluorescence (IF) and Hochest-stained 




6.3 Chapter 3 
6.3.1 Chemical Synthesis 






FED1 (wild type inhibitor) 
 
C1 (control 1) 
 





To a solution of dry THF (100 mL) at -78°C was added 4-Fluoro phenyl 
magnesium bromide (20 g, 100.3 mmol) under a closed system flushed with 
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N2. The reaction was stirred for 15 minutes at -78°C before addition of 
CF3COOEt (28.4 g, 200.62 mmol) drop by drop. The solution was stirred at 
-78°C for 2 h before adjusting the pH to 2 with 1 M HCl. The organic layers 
were extracted with EtOAc twice after which they were combined, washed 
with brine and dried over Na2SO4. The solvents were evaporated in vacuo.The 
residue was purified by silica gel column chromatography (Hexane, Rf = 0.45) 
to afford 2 (9.5 g, 50%) as a colourless liquid. 
1
H NMR (300 MHz, CDCl3) δ 
8.13-8.17 (m, 2H), 7.22-7.30 (m, 2H); 
13
C NMR (75 MHz, CDCl3) δ 178.86 
(2JC-F = 35.25 Hz) (s), 167.01 (s), 132.96 (s), 118.14 (1JC-F = 292.5Hz)(s), 




To a solution of 2 (9.2 g, 47.91 mmol) in dry DMF (80 mL) was added 
NaN3 (15.5 g, 239.5 mmol), and the reaction was left to stir at room 
temperature for 12 h. The reaction mixture quenched with water and the 
resulting mixture was extracted with EtOAc twice. The combined organic 
layers was washed with brine, dried over Na2SO4, filtered and concentrated in 
vacuo. The residue was purified by silica gel column chromatography (Hexane, 
Rf = 0.6) to afford 3 (8.1 g, 79%) as a yellow liquid. 
1
H NMR (300 MHz, 
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CDCl3) δ 8.13 (dd, J= 0.9, 8.7 Hz, 2H), 7.19-7.32 (m, 2H); 
13
C NMR (75 MHz, 
CDCl3) δ 179.08 (2JC-F = 34.86 Hz) (s), 147.77 (s), 132.29 (s), 126.48 (s), 
116.83 (s), 116.84 (1JC-F = 289.26 Hz) (s). 
 
 
1-(4-azidophenyl)-2,2,2-trifluoroethanone oxime (4) 
The trifluoromethyl ketone 3 (4.3 g, 20.0 mmol) was dissolved in 60 mL 
of EtOH containing 10 mL of pyridine. Hydroxylamine hydrochloride (1.68 g, 
1.2 eq) was then added, and the mixture was refluxed for 12 h before the 
solvent was removed under vacuum and the residue was purified by 
chromatography (Hexane:EtOAc = 20:1). The oxime products are thus 
obtained as a mixture of isomers (3.5 g, 75%). 
1
H NMR (300 MHz, CDCl3) δ 
9.52 (s, 1H), 7.60 (d, J = 8.5 Hz, 2H), 7.05-7.17 (m, 2H); 
13
C NMR (75 MHz, 
CDCl3) δ 146.5 (d, J = 31.5 Hz), 142.6, 130.5, 122.0, 120.5 (q, J = 819.7 Hz), 
119.1.  
The oximes prepared above (3.45 g, 15.0 mmol) were treated with 
4-toluenesulfonyl chloride (1.1 eq) in acetone (50 mL) and triethylamine (10 
mL). After 1 h the solutions were filtered, evaporated to dryness, and purified 
by flash chromatography (Hexane:EtOAc = 40:1). The product 4 is obtained 
as a mixture of isomers (5.2 g, 90%). 
1
H NMR (500 MHz, CDCl3) δ 7.82-7.98 





NMR (126 MHz, CDCl3) δ 153.0 (q, J = 107.5 Hz), 146.2, 143.8, 131.2, 130.4, 




The tosyloxime 4 (3.2 g, 8.3 mmol) was dissolved in diethyl ether (20 mL) 
and added to 20-25 mL of liquid NH3 at -78 °C. The mixture was stirred at 
-78°C for 4 h and brought to room temperature overnight. The mixture was 
then evaporated to dryness and purified by flash chromatography 
(Hexane:EtOAc = 70:30), to obtain the diaziridine 5
 
(1.5 g, 77%). 
1
H NMR 
(300 MHz, CDCl3) δ 7.60 (d, J = 8.5 Hz, 2H), 6.95-7.16 (m, 2H), 2.27 (br, 
2H); 
13
C NMR (75 MHz, CDCl3) δ 142.0, 129.7, 128.3 (d, J = 189.7 Hz), 




The azide 5 (1.5 g, 6.5 mmol) was dissolved in dry THF (100 mL), the 
solution was cooled to 0°C and LiAlH4 (240 mg, 1.0 eq) was added 
portion-wise over 10 min. After the starting material was completely 
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consumed as monitored by TLC, the reaction was quenched with sat. NaHCO3 
(10 mL), and then extracted with EtOAc (3 × 30 ml). The combined organic 
extracts were dried (Na2SO4) and concentrated. Purification by flash column 
chromatography (Hexane:EA = 2:1) afforded 0.93 g (70%) of diazirinyl 
hydrazine. 
1
H NMR (300 MHz, CDCl3) δ 7.37 (d, J = 8.3 Hz, 2H), 6.66 (d, J = 
8.7 Hz, 2H), 3.79 (s, 2H), 2.70 (s, 1H), 2.15 (d, J = 7.6 Hz, 1H); 
13
C NMR (75 
MHz, CDCl3) δ 147.9, 129.2, 125.4, 121.8, 121.0, 114.6. MS (ESI): [M+H]
+ 
calcd for C8H8F3N3 204.07, found 204.07.  
The diazirinyl hydrazine (0.41 g, 2 mmol) was dissolved in DCM at 0°C, 
then followed by TEA and I2 until the purple color of I2 persists. The solution 
was then stirred at 0°C for 1 h, quenched with Na2S2O3, extracted with EtOAc 
and purified by column chromatography (Hexane:EtOAc = 85:15) to afford 
compound 6b (0.30 g, 75%). 
1
H NMR (300 MHz, CDCl3) δ 7.00 (d, J = 8.6 Hz, 
2H), 6.56-6.73 (m, 2H), 3.79 (s, 2H); 
13
C NMR (75 MHz, CDCl3) δ 147.7, 







To a solution of triphosgene (100 mg, 0.34 mmol) in 5mL dry DCM was 
slowly added to a mixture of amine 6b (1 mmol, 201 mg) and TEA(1.1 eq) in 2 
mL DCM over a period of 10 mins at room temperature under nitrogen 
atmosphere. After a further 30 min of stirring, a solution of amine 11 (1 mmol) 
and TEA (2.2 mmol) in 2 mL dry DCM was added. The reaction mixture was 
stirred for 1 h at room temperature, then evaporated to dryness, which was 
purified by column chromatography (Hexane:EtOAc = 2:1) to afford 
compound 7b (173 mg, 50%). 
1
H NMR (500 MHz, CDCl3) δ 7.33 (d, J = 8.7 
Hz, 2H), 7.08 (d, J = 8.5 Hz, 2H), 4.92 (t, J = 4.3 Hz, 1H), 3.89-4.00 (m, 2H), 
3.74-3.89 (m, 2H), 3.30-3.49 (m, 2H), 1.81-1.97 (m, 2H); 
13
C NMR (125 MHz, 
CDCl3) δ 155.5, 140.3, 127.3, 123.1, 119.6, 103.3, 64.8, 35.4, 33.1. MS (ESI): 
[M+H]
+ 





To a solution of 7b (100 mg, 0.29 mmol) in THF (2 mL) was added 1M 
HCl (1 mL). The reaction mixture was left to stir at room temperature for 12 h. 
The reaction was quenched by sat. NaHCO3 (aq.) where the solution was 
neutralized and extracted with EtOAc twice. The combined organic extracts 
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were dried (Na2SO4) and concentrated. Purification by flash column 
chromatography (Hexane:EtOAc = 1:2) afforded 52 mg (60%) of product 8b. 
1H NMR (300 MHz, MeOD) δ 7.32-7.42 (m, 2H), 7.19 (d, J = 8.3 Hz, 2H), 
5.19 (t, J = 2.7 Hz, 1H), 3.56 (td, J = 12.5, 4.2 Hz, 1H), 3.10-3.32 (m, 2H), 
1.81-2.12 (m, 2H);
 13C NMR (75 MHz, MeOD) δ 157.1, 145.5, 129.6, 128.4, 
127.9, 125.7, 81.4, 36.3, 30.6. MS (ESI): [M+H]
+ 
calcd for C12H11F3N4O2 















NMR (300 MHz, CDCl3) δ 7.82 (s, 1H), 7.20-7.32 (m, 4H), 6.15 (s, 1H), 4.92 
(t, J = 4.5 Hz, 1H), 3.90 (dt, J = 13.0, 8.4 Hz, 2H), 3.81 (dt, J = 9.0, 8.4 Hz, 
2H), 3.40 (dd, J = 12.2, 6.3 Hz, 2H), 1.90 (dd, J = 11.1, 6.5 Hz, 2H), 1.31 (s, 
9H);
 13
C NMR (75 MHz, CDCl3) δ 156.80 (s), 145.63 (s), 136.46 (s), 125.65 






Synthesis of 8a was followed according to the procedure from Nat 
Commun 2012, 3, 1288. 
1
H NMR (300 MHz, CDCl3) δ 7.42-7.44 (m, 2H), 
7.23-7.26 (m, 2H), 5.23 (d, J = 2.7, Hz), 3.61-3.70 (m, 1H), 1.97-2.18 (m, 2H), 
1.45 (s, 9H); 
13
C NMR (75 MHz, CDCl3) δ 155.91 (s), 149.32 (s), 139.19 (s), 
127.20 (s), 125.29 (s), 79.87 (s), 34.54 (s), 33.84 (s), 30.25 (s), 28.85 (s). MS 
(IT-TOF): [M+H
+





To a solution of 12 (500 mg, 1.87 mmol) in dry acetone at 0°C was added 
HClO4 drop by drop till 12 completely dissolved. The reaction was stirred at 
0°C for 1 h, then the ice bath was removed and the reaction was left to stir at 
room temperature for 20 h. Next, the reaction mixture was placed in an ice 
bath and the pH of the reaction mixture was adjusted to pH 7 with NaHCO3. 
The resulting mixture is then filtered and concentrated in vacuo. The residue 
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was purified by silica gel column chromatography (DCM:MeOH = 96:4) to 
afford 13 (448 mg, 78%) as a white powder. 
1H NMR (300 MHz, DMSO) δ 
8.34 (s, 1H), 8.15 (s, 1H), 7.35 (s, 2H), 6.12 (d, J = 3.1 Hz, 1H), 5.34 (dd, J = 
6.1, 3.1 Hz, 1H), 5.24 (t, J = 5.5 Hz, 1H), 4.96 (dd, J = 6.2, 2.4 Hz, 1H), 4.21 
(dd, J = 7.2, 4.7 Hz, 1H), 3.54 (dd, J = 11.1, 5.8 Hz, 2H), 2.08 (s, 1H), 1.54 (s, 
3H), 1.32 (s, 3H);
 13C NMR (75 MHz, DMSO) δ 156.52 (s), 153.01 (s), 149.18 
(s), 140.08 (s), 119.48 (s), 113.41 (s), 90.01 (s), 86.72 (s), 83.59 (s), 81.73 (s), 




[3,4-d][1,3]dioxol-4-yl)methyl methanesulfonate (14) 
To a solution of 13 (200 mg, 0.651 mmol) in dry DCM (4 mL) and TEA 
(0.23 mL, 1.63 mmol) at 0°C was added MsCl (0.06 mL, 0.716 mmol) slowly. 
The ice bath was removed and the reaction was left to stir at room temperature 
for 1 h, before quenching with H2O. The resulting mixture was extracted with 
DCM twice and the combined organic layers was washed with brine, dried 
over Na2SO4, filtered and concentrated in vacuo. The residue was purified by 
silica gel column chromatography (EtOAc) to afford 14 (181 mg, 72%) as a 
white powder. 
1H NMR (300 MHz, DMSO) δ 9.44 (d, J = 30.6 Hz, 2H), 8.67 
(s, 1H), 8.51 (s, 1H), 6.70 (s, 1H), 5.01 (d, J = 10.0 Hz, 3H), 4.40-4.64 (m, 
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2H), 2.31 (s, 3H), 1.48 (s, 3H), 1.23 (s, 3H); 
13C NMR (75 MHz, DMSO) δ 
157.10 (s), 149.64 (s), 140.48 (s), 139.63 (s), 120.00 (s), 112.83 (s), 91.22 (s), 





Isopropylamine (5 mL) and DMAP (2 mg, 0.016mmol) was added to 14 
(50 mg, 0.13 mmol) and left to stir at 60°C for 22 h. The reaction mixture was 
quenched with H2O and the resulting mixture was extracted with DCM twice. 
The combined organic layers was washed with brine, dried over Na2SO4, 
filtered and concentrated in vacuo. The residue was purified by silica gel 
column chromatography (CHCl3:MeOH = 97:3) to attain 15c (19 mg, 42%) as 
a white powder. 
1
H NMR (300 MHz, CDCl3) δ 8.25 (d, J = 2.8 Hz, 1H), 7.89 
(d, J = 1.0 Hz, 1H), 6.56 (s, 2H), 5.97 (d, J = 2.8 Hz, 1H), 5.42 (dd, J = 4.0, 
2.4 Hz, 1H), 4.97 (dd, J = 6.2, 3.4 Hz, 1H), 4.24-4.38 (m, 1H), 2.82 (s, 2H), 
2.68 (d, J = 2.1 Hz, 1H), 2.09 (s, 1H), 1.54 (s, 3H), 1.31 (s, 3H), 0.95 (s, 6H);
 
13
C NMR (75 MHz, CDCl3) δ 155.87 (s), 152.92 (s), 149.14 (s), 139.70 (s), 
120.03 (s), 114.39 (s), 90.61 (s), 85.64 (s), 83.38 (s), 82.21 (s), 48.71 (d, J = 






,3-dioxol- 4-yl)-9Hpurin-6-ylamine (16) 
To 2’,3’-O-isopropylideneadenosine (1.00 g, 3.25 mmol) suspended in 
1,4 dioxane (15 mL) was added DPPA (1.7 g, 6.51 mmol) and DBU (1.40 g, 
9.77 mmol) at room temperature under N2. The solution was stirred for 16 
hours after NaN3 (846 mg, 13.02 mmol) were added and the reaction mixture 
was heated. After 4 hours the solid was removed by filtration. The solvent was 
evaporated and the crude product was purified by column chromatography 
(EtOAc : Et2O = 1:1  MeOH : EtOAc = 1:5, Rf = 0.4). After drying under 
high vacuum, a colourless solid 16 (610 mg, 57%) was obtained. 
1
H NMR(300 
MHz, CDCl3) δ 8.31 (s, 1H), 7.96(s, 1H), 7.10 (s, 2H), 6.14 (d, J = 1.8 Hz, 
1H), 5.48 (dd, J = 1.8, 6.3 Hz, 1H), 5.06 (dd, J = 3.3, 6.3 Hz, 1H), 4.36 (dd, J 
= 5.4, 8.7 Hz, 1H), 3.53-4.05 (m, 2H), 1.58 (s, 3H), 1.36 (s, 3H); 
13
C NMR (75 
MHz, CDCl3) δ 155.97 (s), 152.70 (s), 148.61 (s), 140.19 (s), 129.46 (s), 
125.33 (s), 119.56 (s), 114.18 (s), 90.07 (s), 85.11 (s), 83.75 (s), 81.77 (s), 
51.91 (s), 26.13 (s), 24.28 (s). MS (IT-TOF): [M+H
+
] calcd for C13H16N8O3 







To a 100 mL round-bottomed flask was added diazide 16 (610 mg, 1.8 
mmol), palladium (300 mg, 10% w/w on activated carbon) and EtOH (15 mL). 
The flask was sealed with a septum and while stirring H2 gas was bubbled 
through the reaction mixture from a balloon, while venting with needle. After 
5 min the venting needle was removed and the reaction stirred under a positive 
pressure (1 atm) of H2 gas for 12 h. The mixture was filtered through a pad (2 
x 2 cm) of Celite under vacuum. The filter cake was washed with MeOH (2 x 
25 mL) and the filtrate concentrated under vacuum. Purification by silica 
column chromatography, eluting with (CHCl3:MeOH:conc. NH4OH(aq) = 
91:8:1, Rf = 0.3) yielded 17 (380 mg, 68%) as a white solid. 
1
H NMR(300 
MHz, DMSO-d6) δ 8.35 (s, 
1
H), 8.14 (s, 1H), 8.08 (br, s, 2H), 7.37 (s, 2H), 
6.23 (d, J = 2.4 Hz, 1H), 5.39 (dd, J = 2.7, 6.3 Hz, 1H), 5.09-5.12 (m, 1H), 
4.32-4.38 (m, 1H), 3.15-3.18 (m, 2H), 1.53 (s, 3H), 1.30 (s, 3H); 
13
C NMR (75 
MHz, CDCl3) δ 156.01 (s), 152.47 (s), 148.35 (s), 140.83 (s), 129.37 (s), 
119.39 (s), 114.54 (s), 90.80 (s), 83.83 (s), 83.02 (s), 81.87 (s), 41.13 (s), 
25.92 (s), 23.99 (s). MS (IT-TOF): [M+H
+
















An oven-dried 10 mL round-bottomed flask was charged with amine 15d 
(12 mg, 34.7 μmol), oxazinanol 8b (11 mg, 36.6 μmol), 4 Å molecular sieves 
(ca. 80 mg; finely powdered with a mortar and pestle) and EtOH (1.0 mL). 
After stirring the mixture at room temperature for 5 min, NaBH3CN (0.15 mL, 
0.50 M solution in EtOH, 0.075 mmol) and HOAc (0.08 mL, 1.0 M solution in 
EtOH, 0.08 mmol) were added sequentially via syringe. The reaction mixture 
was heated at 45 °C for 12 h. On cooling to room temperature the mixture was 
filtered through a pad of Celite and the filter cake washed with CHCl3. The 
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filtrate was diluted with half saturated NaHCO3 and extracted with CHCl3. 
The organic extracts were pooled, dried with Na2SO4 and concentrated. This 
crude product was added to a solution of 9:1 TFA: H2O (1 mL) and stirred for 
2 h, then concentrated to dryness from toluene (3 x 2 mL) to leave a colourless 
residue. Purification by silica column chromatography, (CHCl3:MeOH:conc. 
NH4OH = 89:10:1) yielded P1 (8.1 mg, 40%) as a yellow solid. 
1
H NMR (300 
MHz, MeOD) δ 8.26 (s, 1H), 8.19 (s, 1H), 7.37-7.48 (m, 2H), 7.09 (d, J = 8.5 
Hz, 2H), 5.99 (d, J = 4.4 Hz, 1H), 4.68-4.75 (m, 1H), 4.28 (t, J = 5.3 Hz, 1H), 
4.17-4.24 (m, 1H), 3.52 (d, J = 2.3 Hz, 2H), 3.24 (t, J = 6.6 Hz, 2H), 2.94 (dd, 
J = 5.6, 3.2 Hz, 2H), 2.70 (t, J = 6.9 Hz, 2H), 2.59 (t, J = 2.3 Hz, 1H), 1.70 (p, 
J = 6.7 Hz, 2H); 
13C NMR (75 MHz, MeOD) δ 157.99 (s), 157.59 (s), 154.16 
(s), 150.79 (s), 143.35 (s), 141.58 (s), 130.16 (s), 128.50 (s), 125.84 (s), 
122.97 (s), 120.91 (s), 119.99 (s), 90.84 (s), 84.25 (s), 79.37 (s), 75.13 (d, J = 
3.0 Hz), 73.84 (s), 57.19 (s), 53.39 (s), 43.80 (s), 39.65 (s), 28.61 (s). HRMS: 
[M+Na]
+ 








An oven-dried 10 mL round-bottomed flask was charged with amine 15d 
(20 mg, 57.5 μmol), oxazinanol 8a (15 mg, 60.0 μmol), 4 Å molecular sieves 
(ca. 120 mg; finely powdered with a mortar and pestle) and EtOH (1.0 mL). 
After stirring the mixture at room temperature for 5 min, NaBH3CN (0.24 mL, 
0.50 M solution in EtOH, 0.12 mmol) and HOAc (0.13 mL, 1.0 M solution in 
EtOH, 0.13 mmol) were added via sequentially via syringe. The reaction 
mixture was heated at 45 °C for 12 h. On cooling to room temperature the 
mixture was filtered through a pad of Celite and the filter cake washed with 
CHCl3. The filtrate was diluted with half saturated NaHCO3 and extracted 
with CHCl3. The organic extracts were pooled, dried (Na2SO4) and 
concentrated. This crude product was added to a TFA/H2O co-solvent (9:1, 1 
mL) and stirred for 2 h, then concentrated to dryness from toluene (3 x 2 mL) 
to leave a colorless residue. Purification by silica column chromatography 
(CHCl3:MeOH:conc. NH4OH = 89:10:1) yielded C1 (10 mg, 33%) as a white 
solid. 
1H NMR (300 MHz, MeOD) δ 8.28 (s, 1H), 8.21 (s, 1H), 7.18-7.36 (m, 
4H), 6.00 (d, J = 4.4 Hz, 1H), 4.69-4.79 (m, 1H), 4.29 (t, J = 5.4 Hz, 1H), 4.21 
(dt, J = 9.8, 5.0 Hz, 1H), 3.51 (d, J = 2.1 Hz, 2H), 3.24 (t, J = 6.6 Hz, 2H), 
2.86-3.04 (m, 2H), 2.70 (t, J = 6.9 Hz, 2H), 2.59 (t, J = 2.2 Hz, 1H), 1.64-1.79 
(m, 2H), 1.29 (s, 9H);
 13
C NMR (126 MHz, MeOD) δ 158.8, 157.6, 154.2, 
150.8, 146.8, 141.6, 138.4, 126.8, 120.7, 90.8, 84.3, 79.4, 75.0, 75.1, 73.8, 
57.2, 53.3, 43.8, 39.6, 35.3, 32.1, 28.8. HRMS: [M+Na]
+ 
calcd for C27H36N8O4 







An oven-dried 10 mL round-bottomed flask was charged with amine 15c 
(20 mg, 57.5 μmol), oxazinanol 8b (18 mg, 60.0 μmol), 4 Å molecular sieves 
(ca. 150 mg; finely powdered with a mortar and pestle) and EtOH (1.0 mL). 
After stirring the mixture at room temperature for 5 min, NaBH3CN (0.24 mL, 
0.50 M solution in EtOH, 0.12 mmol) and HOAc (0.13 mL, 1.0 M solution in 
EtOH, 0.13 mmol) were added via sequentially via syringe. The reaction 
mixture was heated at 45 °C for 12 h. On cooling to room temperature the 
mixture was filtered through a pad of Celite and the filter cake washed with 
CHCl3. The filtrate was diluted with half saturated NaHCO3 and extracted 
with CHCl3. The organic extracts were pooled, dried (Na2SO4) and 
concentrated. This crude product was added to a solution of 9:1 TFA:H2O (1 
mL), stirred for 2 h, then concentrated to dryness from toluene (3 x 2 mL) to 
leave a colourless residue. Purification by silica column chromatography, 
(CHCl3:MeOH:conc. NH4OH = 89:10:1) yielded C2 (16 mg, 47%) as a yellow 
solid. 
1H NMR (500 MHz, MeOD) δ 8.27 (s, 1H), 8.19 (s, 1H), 7.43 (d, J = 
8.7 Hz, 2H), 7.09 (d, J = 8.5 Hz, 2H), 5.99 (d, J = 4.5 Hz, 1H), 4.75 (t, J = 4.9 
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Hz, 1H), 4.30 (t, J = 5.3 Hz, 1H), 4.17 (dd, J = 11.8, 5.1 Hz, 1H), 3.17-3.32 (m, 
2H), 3.06 (dt, J = 12.7, 6.3 Hz, 1H), 2.92 (dd, J = 13.9, 4.5 Hz, 1H), 2.75 (dd, 
J = 13.9, 7.2 Hz, 1H), 2.60 (t, J = 6.6 Hz, 2H), 1.64-1.78 (m, 2H), 1.06 (d, J = 
6.5 Hz, 3H), 1.01 (d, J = 6.5 Hz, 3H); 
13C NMR (75 MHz, MeOD) δ 157.9, 
157.6, 154.1, 150.8, 143.3, 141.6, 128.4, 125.9, 122.9, 122.2, 120.9, 119.9, 
90.7, 85.0, 75.0, 73.8, 53.9, 52.2, 49.6, 39.8, 29.4, 18.7, 18.0. HRMS: 
[M+Na]
+ 






An oven-dried 10 mL round-bottomed flask was charged with amine 15c 
(25 mg, 73.5 μmol), oxazinanol 8a (20 mg, 80.0 μmol), 4 Å molecular sieves 
(ca. 150 mg; finely powdered with a mortar and pestle) and EtOH (1.0 mL). 
After stirring the mixture at room temperature for 5 min, NaBH3CN (0.30 mL, 
0.50 M solution in EtOH, 0.15 mmol) and HOAc (0.16 mL, 1.0 M solution in 
EtOH, 0.16 mmol) were added via sequentially via syringe. The reaction 
mixture was heated at 45 °C for 24 h. On cooling to room temperature the 
mixture was filtered through a pad of Celite and the filter cake washed with 
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CHCl3. The filtrate was diluted with half saturated NaHCO3 and extracted 
with CHCl3. The organic extracts were pooled, dried (Na2SO4) and 
concentrated. This crude product was added to a solution of 9:1 TFA:H2O (1 
mL), stirred for 2 h, then concentrated to dryness from toluene (3 x 2 mL) to 
leave a colourless residue. Purification by silica column chromatography 
(CHCl3:MeOH:conc. NH4OH = 89:10:1) yielded FED1 (16 mg, 39%) as a 
white solid. 
1H NMR (500 MHz, MeOD) δ 8.25 (s, 1H), 8.18 (s, 1H), 
7.22-7.30 (m, 2H), 7.16-7.22 (m, 2H), 5.98 (d, J = 4.6 Hz, 1H), 4.75 (t, J = 5.0 
Hz, 1H), 4.54-4.72 (m, 1H), 4.31 (t, J = 5.3 Hz, 1H), 4.16 (dd, J = 11.9, 5.0 Hz, 
1H), 3.16-3.26 (m, 2H), 3.01-3.10 (m, 1H), 2.92 (dd, J = 13.8, 4.1 Hz, 1H), 
2.77 (s, 1H), 2.59 (d, J = 6.2 Hz, 2H), 1.63-1.72 (m, 2H), 1.27 (s, 9H), 1.05 (d, 
J = 6.6 Hz, 3H), 0.99 (d, J = 6.5 Hz, 3H);
 13C NMR (75 MHz, MeOD) δ 158.8, 
157.6, 154.1, 150.8, 146.7, 141.8, 138.4, 126.8, 120.9, 120.6, 90.8, 85.0, 74.9, 
73.8, 53.9, 52.5, 49.7, 39.7, 35.3, 32.1, 29.5, 18.8, 17.9. HRMS: [M+Na]
+ 
calcd for C27H40N8O4 540.3173, found 50.3178. 
 
Synthesis of the minimalist linker (L1 – L7) was referred to Ref.4 and 
described as followed. 
 
 




H NMR (300 MHz, CDCl3) δ 4.20 (q, J = 7.1 Hz, 1H), 3.46 (s, 1H), 2.86 (t, J 
= 7.2 Hz, 1H), 2.48 (td, J = 7.3, 2.6 Hz, 1H), 1.97-1.94 (m, 1H), 1.28 (t, J = 
7.1 Hz, 2H). 
 
 
Ethyl 2-(2-(but-3-yn-1-yl)-1,3-dioxolan-2-yl)acetate (L3) 
1
H NMR (300 MHz, CDCl3) δ 4.10-4.22 (m, 1H), 3.92-4.04 (m, 2H), 2.65 (s, 






H NMR (300 MHz, CDCl3) δ 4.01 (4 H, s), 3.76 (2 H, q, J = 5.4 Hz), 2.60 (1 
H, t, J = 5.4 Hz), 2.5-1.8 (7 H, m).  
 
 
1-hydroxylhept-6-yn-3-one (L5)  
1H NMR (500 MHz, CDCl3) δ3.87 (t, J = 5.0 Hz, 2H), 2.70 (m, 4H), 2.47 (t, J 











1H NMR (500 MHz, CDCl3) δ 2.89 (t, J = 7.5, 2H), 2.12 (t, J = 7.5, 2H), 1.98 






To compound 16 (332 mg, 1.0 mmol) in anhydrous DMF (5 ml) NaH (95%) 
(50 mg, 2.0 mmol) was slowly added at room temperature under nitrogen 
atmosphere. After stirring for 2 h, L7 (248 mg, 1.0 mmol) in DMF (2 ml) was 
slowly added to the mixture. The mixture was stirred for 1 h at room 
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temperature followed by an additional 2 h at 60°C. The mixture was poured 
into cold water (20 ml) and extracted with EtOAc (2×20 ml). The extracts 
were washed with cold water (3×10 ml) and the solvent removed. PPh3 (262 
mg, 1.0 mg) was added to the residue in 5 ml THF and 0.5 ml H2O. After the 
reaction was stirred for 12 h, the solvent was removed and the mixture purified 
by column chromatography (DCM:MeOH = 1:1), leaving a residue, 18 (65 mg, 
15.3%). 
1H NMR (300 MHz, MeOD) δ 8.27 (s, 1H), 8.23 (s, 1H), 6.15 (d, J = 
3.1 Hz, 1H), 5.48 (dd, J = 6.4, 3.1 Hz, 1H), 5.02 (dd, J = 6.4, 3.4 Hz, 1H), 4.24 
(td, J = 5.7, 3.5 Hz, 1H), 3.38-3.64 (m, 2H), 2.91 (d, J = 5.9 Hz, 2H), 2.27 (t, J 
= 2.7 Hz, 1H), 2.05 (td, J = 7.3, 2.5 Hz, 2H), 1.83 (t, J = 7.2 Hz, 2H), 1.68 (t, J 
= 7.4 Hz, 2H), 1.61 (s, 3H), 1.39 (s, 3H);
 13C NMR (75 MHz, MeOD) δ 156.0, 
154.0, 141.4, 121.1, 115.6, 91.5, 88.4, 84.9, 83.6, 83.2, 70.3, 44.5, 36.5, 33.6, 






A flask was charged with amine 18 (21.3 mg, 0.05 mmol), MeOH (0.5 mL) 
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and acetone (75 µL, 10% v/v solution in MeOH, 0.10 mmol). After the 
solution had been stirred 5 min, NaBH3CN (0.19 mL, 0.50 M solution in 
MeOH, 0.10 mmol) and HOAc (0.10 mL, 1.0 M solution in MeOH, 0.10 
mmol) were added sequentially. The reaction was stirred for 2 h, then 
oxazinanol 8a (15 mg, 0.6 mmol) was added in one portion followed by 4 Å 
molecular sieves (ca. 70 mg; finely powdered with a mortar and pestle). After 
5 min, NaBH3CN (0.19 mL, 0.50 M solution in MeOH, 0.10 mmol) and 
HOAc (0.10 mL, 1.0 M solution in MeOH, 0.10 mmol) were added 
sequentially and the reaction mixture stirred rapidly at 55 °C for 24 h. The 
mixture was allowed to cool to room temperature and filtered through a pad (2 
x 4 cm) of Celite and the filter cake washed with CHCl3 (2 x 10 mL). The 
filtrate was diluted with half saturated NaHCO3 solution (25 mL) and 
extracted with CHCl3 (3 x 25 mL). The organic extracts were pooled, dried 
(Na2SO4) and filtered, concentration under vacuum. This crude product was 
added to a solution of TFA: CHCl3 = 1:9 (1 mL) and stirred for 12 h, then 
concentrated to dryness from toluene (3 x 2 mL) to leave a colourless residue. 
Purification by silica column chromatography (CHCl3:MeOH:conc. NH4OH  
= 89:10:1) yielded P2 (12 mg, 36 %) as a yellow solid. 
1
H NMR (300 MHz, 
MeOD) δ 8.25 (s, 1H), 8.22 (s, 1H), 7.23 (td, J = 9.0, 2.4 Hz, 4H), 5.99 (d, J = 
4.5 Hz, 1H), 4.73-4.79 (m, 1H), 4.31 (t, J = 5.3 Hz, 1H), 4.17 (dd, J = 11.9, 
5.0 Hz, 1H), 3.50 (s, 2H), 3.22 (td, J = 6.5, 3.0 Hz, 2H), 3.01-3.15 (m, 1H), 
2.93 (dd, J = 14.0, 4.6 Hz, 1H), 2.72-2.84 (m, 1H), 2.63 (dd, J = 14.9, 8.4 Hz, 
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2H), 2.26 (t, J = 2.6 Hz, 1H), 2.05 (td, J = 7.4, 2.6 Hz, 2H), 1.82 (t, J = 7.2 Hz, 
2H), 1.60-1.74 (m, 4H), 1.29 (s, 10H), 1.07 (d, J = 6.6 Hz, 3H), 1.01 (d, J = 
6.5 Hz, 3H);
 13C NMR (75 MHz, MeOD) δ 158.5, 155.9, 153.8, 146.4, 140.9, 
138.0, 132.3, 126.5, 121.1, 120.3, 90.4, 84.7, 83.6, 74.6, 73.5, 70.3, 53.6, 52.1, 
49.4, 39.4, 35.0, 33.7, 33.4, 31.8, 29.2, 27.8, 18.4, 17.6, 13.8. HRMS: 
[M+Na]
+ 
calcd for C34H48N10O4 683.3936, found 683.3933. 
6.3.2 Biological evaluations 
6.3.2.1 General information 
Antibodies were purchased from the following vendors: Rabbit 
anti-H3K79me2 (ab3594, Abcam), Rabbit anti-Histone H3 (ab1791, Abcam), 
Rabbit Anti-KMT4/DOT1L (ab157199, Abchem), Rabbit anti-DOT1L 
(NB100-40845, Novus Biologicals), NOP2 Polyclonal Antibody (PA5-34712, 
Thermal Fisher Scientific), Rabbit anti-Beta-tubulin (ab6046,Abcam) 
HRP-conjugated secondary antibodies: Goat anti-Rabbit IgG (#31210, Pierce). 
Nuclear staining reagent Hochest 33342, trihydrochloride, trihydrate (10 
mg/mL solution in water) were purchased from Invitrogen. Western blot was 
done by using the SuperSignal
®
 West Dura Extended Duration Substrate Kit 
(200 mL Kit, Thermal Scientific). Imaging was done by a Leica TCS SP5X 
Confocal microscope equipped with a 40 × water immersion objective. A431 
cell lines were obtained from Tang Bor Luen from the National University of 
Singapore, which were cultured in Dulbeccoʼs modified Eagle medum 
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(DMEM; Invitrogen) containing 10% heat-inactivated fetal bovine serum 
(FBS; Invitrogen), 100 units/mL penicillin, and 100 μg/mL streptomycin 
(Thermo Scientific) and maintained in a humidified 37 °C incubator with 5% 
CO2. Protein concentration was determined by Bradford protein assay. DOT1L 
(1-351 and 1-420) plasmids were obtained from Cheryl H. Arrowsmith at the 
University of Toronto. For SILAC experiments, the cells were culture in 
SILAC DMEM (89985/88420, Life Technologies
TM
) containing 10% dialyzed 
FBS (89986/88440/88212, Life Technologies
TM
), 100 units/mL penicillin, and 
100 μg/mL streptomycin (Thermo Scientific) and maintained in a humidified 









N2) (CNML-539)) were 
purchased from Cambradge Isotope laboratoires Inc., Andover MA. 
6.3.2.2 Probe labeling of bacteria lysates 
Recombinant Protein Expression and Purification 
Recombinant DOT1L (1-420) tagged with a His6 tag at its N-terminal 
was expressed by use of a pET28-MHL vector in BL21 (DE3) pRARE2 E. 
coli strain. The plasmids containing DOT1L were transformed into BL21 
(DE3) pRARE2 E. coli cells and plated on Luria-Bertani (LB) agar with 
kanamycin (50 µg/mL) and chloramphenicol (34 µg/mL) and grown overnight 
at 37°C. The following day, a single colony was picked and resuspended in LB 
medium supplemented with kanamycin (50 µg/mL) and chloramphenicol (34 
µg/mL). Starter cultures were grown to an OD600 of 0.4 at 37°C and stored 
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overnight at 4°C. The starter culture was diluted 1:100 in LB media 
supplemented with kanamycin (50 µg/mL) and chloramphenicol (34 µg/mL) 
and grown to an OD600 of 1.2 at 37°C. The culture was cooled for 1 h with 
shaking at 15°C prior to induction for 16 h at 15°C with 
isopropylβ-D-thiogalactoside (IPTG, final concentration 1 mM). Cells were 
harvested by centrifugation (4,000 rpm, 15 mins, 4°C) and stored in -80°C, or 
resuspended in chiled lysis buffer (20 mM Tris, 500 mM NaCl, 10 mM 
imidazole, 5 mM β-mercaptoethanol, 10% glycerol) with 1 mM phenylmethyl 
sulfonyl fluoride (PMSF) for immediate purification by Ni-NTA affinity 
chromatography. The re-suspended pellet was lysed by sonication (6x pulses of 
15s each at half maximal power) on ice. The solution was clarified by 
centrifugation at 10000 g (30 min, 4 °C) and loaded onto a column containing 
200 μL of His-tagged resin (Amersham) pre-equilibrated with lysis buffer. 
Following incubation for 1 h at 4 °C, the resin was washed 6 times with wash 
buffer (20 mM Tris, 500 mM NaCl, 20 mM imidazole) and the protein was 
finally eluted with elution buffer (20 mM Tris, 500 mM NaCl, 200 mM 
imidazole). The protein was dialyzed with Microcon® centrifugal filter device 
(MW cut off: 48 KDa), and stored at -20 °C with 50% glycerol. The induction 




Figure 6.1. Time-dependent induction of DOT1L 1-420. 
Labelling of bacterial lysates (containing overexpressed DOT1L 1-420) 
was done by referring to the published procedure.
[4]
 To 50 µg of fresh bacterial 
lysates prepared above, the probes were added to fresh cell lysates (50 µg) in 
50 µL Tris buffer at various concentrations in the presence or absence of 10 
times concentrated competitor FED1 (the wild type DOT1L inhibitor). 
Samples were incubated for 2 h and UV irradiated (350 nm) for 30 mins. 4 µL 
of a freshly premixed click chemistry reaction cocktail in PBS containing 0.1 
mM CuSO4 (from a 100 mM freshly prepared stock solution in deionized 
water) 0.01 mM TBTA (from a 10 mM freshly prepared stock solution in 
deionized water), 1 mM TCEP (from a 100 mM freshly prepared stock 
solution in deionized water), and 10 µM TER-N3 (from a 50 mM stock 
solution in DMSO) were added. The reaction was incubated at room 
temperature for 2 h with gentle mixing. After 2 h of click reaction, 5×SDS 
loading dye was added and the mixture was heated to 95 ºC for 10 min. The 
resulting proteins were resolved by 12% sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) gel and the fluorescence 













mode image scanner. The coomassie staining (CBB) were also carried out on 
the gels to determine the total protein amount of each lane. 
6.3.2.3 Isothermal titration calorimetry (ITC) 
DOT1L (1-420) Protein Expression and Purification (specific for ITC) 
To produce recombinant DOT1L fragments containing N-terminal 420 
amino acids in E. coli, the corresponding cDNA fragments were amplified by 
PCR and cloned into a modified pET28-MHL vector with an N-terminal 6-His 
tag. The proteins were over-expressed in E.coli BL21 (DE3) V2R-pRARE in 
Terrific Broth medium in the presence of 50 μg/mL kanamycin and 34μg/mL 
chloramphenicol. Cells were grown at 37°C to an OD600 of 1.2 and induced 
by isopropyl-1-thio-D-galactopyranoside (IPTG, final concentration 1 mM) 
and incubated at 0, 1,3,5 7 hours and overnight at 15°C. The cell pellets were 
collected by centrifuged at 4,000rpm for 15mins and was frozen and stored at 
-20°C. For purification, Cell pellets were suspended in buffer A (50 mM 
Tris-Buffer pH7.4, 150m M NaCl, 5% glycerol, 1mM phenylmethyl sulfonyl 
fluoride (PMSF)) and sonicated for 15 minutes on ice, and the resulting lysate 
was centrifuged at 13,200 rpm for 20 minutes at 4 degrees. Ni-NTA beads 
(Qiagen) were mixed with lysate supernatant for 60 minutes and washed with 
buffer A (50 mM Tris-Buffer pH7.4, 150m M NaCl and 20mM Imidazole) for 
5 times and elution with the Buffer B (50 mM Tris-Buffer pH7.4, 150m M 
NaCl and 20mM Imidazole). The Fraction was collected and incubated with 
1.0 mM 5-iodotubercidin for one hour at room temperature. The sample was 
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then concentrated to 0.5 mL and then diluted with 50 mM K2HPO4/ KH2PO4 
pH 7. The diluted sample was loaded onto a HiTrap SP FF column (GE 
Healthcare) and then washed with 400 milliliters of Buffer C(50 mM 
K2HPO4/ KH2PO4, pH 7.0) with a flow rate of 5 mL/min to remove SAM 
before elution with Buffer D (50 mM K2HPO4/ KH2PO4, 1M NaCl). Finally, 
the purified protein was profiled using SDS-PAGE and stained with CBB. 
Isothermal titration calorimetry (ITC) 
SAM-free DOT1L (1-420), purified by the method mentioned above, was 
used in the ITC experiment with an ITC200 calorimeter (GE, Amersham). The 
enthalpy of binding of DOT1L (200 µM in syringe) and the inhibitors (20 µM 
in cell) was measured at 25°C in 50 mM HEPES pH 7.4, 150 mM NaCl, 1.5% 
DMSO. The KD was calculated by fitting the binding isotherms. 
6.3.2.4 Cellular Thermal Shift Assay (CETSA) 
Cellular thermal shift assay was also employed to determine the 
efficiency of probe P1 and P2 stabilizing the target protein DOT1L by 
referring to a published procedure.
[5]
 Briefly, the drugs (DMSO, NP, FED1, 
P1 and P2, 5 µM) was directly added to live A431 cells, followed by 
incubation at 37 ºC/5% CO2 for 4 days. DMSO should never exceed 1% in the 
final solution. The medium was aspirated, and cells were washed once gently 
with PBS to remove the excessive probe, followed by UV irradiation (~350 
nm) for 20 min on ice. Then the cells were harvested and washed with PBS 
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once. The cells were then re-suspended in PBS supplemented with complete 
protease inhibitor cocktail (PMSF, 0.1 mM). The cell suspensions were 
distributed to 12 Eppendorf tubes (100 L/tube) and heated with 12 
temperature endpoints (40 ~ 73 
o
C) for 3 min individually. After heating, 
immediately incubated the tubes at room temperature for 3 min and froze the 
samples in -80 
o
C overnight. The following day, freeze-thawed the cells three 
times using liquid nitrogen. The soluble fraction (lysate) was separated from 
the cell debris by centrifugation at 132000 x g for 1 h at 4°C. The top layer 
supernatants were transferred to new Eppendorf tubes and analyzed by 
SDS-PAGE followed by western blot (WB) analysis. 
6.3.2.5 Methylation assay 
Western Blot detection 
Cells were seeded in 6-well plates with a cell density of 2x10
5
 cells per 
well in a final volume of 2mL. P1, P2, FED1 or DMSO were added at desired 
concentrations and incubated at 37
o
C, 5% CO2, for 4 days. The cells were 
harvested by centrifugation (1,200 rpm, 2 min) and washed twice with PBS. 
Histone extraction protocol was carried out by referring to a protocol from 
Cancer Cell with some minor modifications. The cells are lysed by a 15mins 
incubation on ice in 250uL histone extraction buffer (10 mM Tris-HCl, 10 mM 
MgCl2, 25 mM KCl, 1% Triton X-100, 8.6% Sucrose, 0.1 mM PMSF) with 
gentle stirring. The histones were collected by centrifugation (2,000rpm, 
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10mins) and the supernatant removed. The samples were washed once with 150 
µL of TEB buffer (0.5% Triton X-100, 0.02% NaN3, 0.1% PMSF in PBS) 
before addition of 100 µL of 0.4N sulphuric acid. The histones were acid 
extracted at 4
o
C overnight with gentle stirring. The following day, the samples 
are pelleted (10,000 rpm, 10 min, 4
o
C) and the supernatant was extracted and 
added to 10 x the volume of acetone. The samples were left to precipitate in 
-80
o
C for 2 hours and pelleted by centrifugation (10,000 rpm, 10 min). 50 µL of 
water was added to the samples and their concentration determined with 
Bradford assay. The histones were separated on 15% SDS-PAGE gels and 
transferred overnight onto 0.2 µM PVDF membranes. The membrane was 
blocked for 1 h in blocking solution (3% BSA in TBST) before probing with 
primary antibody against Histone H3 (ab1791) or H3K79Me2 (ab3594) 
antibodies at 1:1000 dilution. After which, the membranes are probed with 
secondary anti-rabbit HRP antibody (1:5000) before being developed with 
SuperSignal West Dura Kit (Thermo Scientific). 
Cellular H3K79 methylation assay (IF) 
In order to demonstrate the methylation inhibition efficiency of the 
probes against H3K79Me2 protein, we performed fluorescence microscopy to 
visualize probe-treated cell. The general procedures are similar to what was 
previously reported.
[3b, e]
 Briefly, A431 cells were seeded in Cellview cell 
culture dishes (Greiner Bio-One, Ref. 627870) and grown until 20-30% 
confluence. Cells were then treated with 0.5 mL drug-containing DMEM 
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medium (drug concentration: 0.5 and 5 M) and incubated at 37 oC for 4 days. 
The medium was gently removed, and cells were gently washed twice with 
PBS again. Then the cells were subsequently fixed for 30 min at 37
 o
C with 
3.7% formaldehyde in PBS, washed twice with cold PBS again, and 
permeabilized with 0.1% Triton X-100 in PBS for 15 min at 37
 o
C. Cells were 
washed with PBS twice again and blocked with 1% BSA in PBST (0.05% 
Tween-20) for 1 h and washed three times with PBS for immunofluorescence 
experiments. After blocking, cells were further incubated with 
anti-H3K79Me2 antibody (1:200) for 1 h at room temperature, after washing 
three times with PBS, the secondary antibody Zymax
TM
 Goat anti-rabbit IgG 
(H + L) Cy
TM
 5 Conjugate antibody (1:200) was added and cells were 
incubated for additional 1 h, following by washing with PBS for three times 
again. Finally, the cells were stained with Hochest 33342 to localize the nuclei. 
Imaging was done with the the Leica TCS SP5X confocal microscope system 
equipped with Leica HCX PL APO 63×/1.20 W CORR CS, 405 nm diode 
laser, white laser (470-670 nm, with 1 nm increments, with eight channels 
AOTF for simultaneous control of eight laser lines, each excitation 
wavelength provides 1.5 mV), and a photomultipliertube (PMT) detector 
ranging from 410 to 700 nm for steady state fluorescence, a total of channels 
were employed including DIC channel, immunofluorescence (IF) and 




6.3.2.6 Cellular imaging 
To demonstrate the utility of the cell-permeable probes or inhibitors for 
imaging of potential cellular targets, we performed fluorescence microscopy to 
visualize probe-treated cells. The general procedures are similar to what was 
reported earlier. Briefly, A431 cells were seeded in Cellview cell culture 
dishes (Greiner Bio-One, Ref. 627870) and grown until 30% confluence. Cells 
were then treated with 0.5 mL DMEM medium containing DMSO or 2 µΜ 
probes/C1. After 4h, 1 day or 4 days incubation in 37 
o
C incubator, the 
medium was gently removed, and cells were gently washed twice with PBS. 
Then the cells were subsequently fixed for 30 min at 37
 o
C with 3.7% 
formaldehyde in PBS, washed twice with cold PBS again, and permeabilized 
with 0.1% Triton X-100 in PBS for 15 min at 37
 o
C. Cells were then treated 
with a freshly premixed click chemistry reaction solution in a 300 μL volume 
(final concentrations of reagents: 400 µΜ CuSO4, 400 µΜ TCEP, 40 µΜ 
THPTA, and 10 µΜ TER-PEG-N3 in PBS) for 2 h at room temperature with 
vigorous shaking. Then cells were first washed with PBS twice, and then 
washed with EDTA (50 mM)-0.1% Tween-20 in PBS until no more copper left. 
The following Immunofluorescence (IF) and nuclear staining was carried out 
as previously described. Imaging was done with the Leica TCS SP5X confocal 
microscope system equipped with Leica HCX PL APO 63×/1.20 W CORR CS, 
405 nm diode laser, white laser (470-670 nm, with 1 nm increments, with 
eight channels AOTF for simultaneous control of eight laser lines, each 
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excitation wavelength provides 1.5 mV), and a photomultipliertube (PMT) 
detector ranging from 410 to 700 nm for steady state fluorescence, a total of 
channels were employed including DIC channel, Probe-treated channel (upon 
clicked with TER-PEG-N3, Probe), immunofluorescence (IF) and 
Hochest-stained channel (NU). Images were processed with Photoshop CS6. 
6.3.2.7 In Vitro and In Situ Proteome Labeling 
The procedure is similar to our previously reported methods but with 
further optimizations as described below.
[2b, 3d]
 For in vitro proteome labeling, 
the probe with or without excessive competitor was added to 50 μg fresh A431 
cell lysates (prepared as previously described
[3b, 3e, 6]) in 50 μL of Tis buffer 
(50 mM Tris, 150 mM NaCl, 5 mM EDTA 0.1 mM PMSF, 0.1% Triton X-100, 
pH 8.0) at various concentrations. Unless indicated otherwise, samples were 
incubated for 30 min at room temperature and then UV-irradiated (350 nm) for 
20 min. Four microliters of a freshly premixed click chemistry reaction 
cocktail in PBS containing0.1 mM CuSO4 (from a 100 mM freshly prepared 
stock solution in deionized water) 0.01 mM TBTA (from a 10 mM freshly 
prepared stock solution in deionized water), 1 mM TCEP (from a 100 mM 
freshly prepared stock solution in deionized water), and 10 µM TER-N3 (from 
a 50 mM stock solution in DMSO) were added. The reaction was further 
incubated for 2 h with gentle mixing, before being terminated by addition of 
prechilled acetone (0.5 mL; 30 min incubation at -20 °C). Precipitated proteins 
were subsequently collected by centrifugation (13000 rpm × 10 min at 4 °C). 
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The supernatant was discarded and the pellet was washed with 200 μL of 
prechilled methanol. After thoroughly drying the protein samples, 1× SDS 
loading buffer was added to dissolve the proteins, the samples were then 
heated for 10 min at 95 °C. Around 20 μg (per gel lane) of proteins were 
separated by SDS−PAGE (12% gel) and then visualized by in-gel fluorescence 
scanning using Typhoon 9410 variable mode image scanner.  
For in situ labeling, cells were grown to 80−90% confluency in 6-well 
plates under conditions described above. The medium was removed, and cells 
were washed twice with cold PBS and then treated with 0.5 mL of the 
DMEM-containing probe in the presence or absence of excess competitor 
(diluted from DMSO stocks whereby DMSO never exceeded 1% in the final 
solution). After 4 h or 4 days of incubation at 37 °C/5% CO2, the medium was 
aspirated, and cells were washed gently with PBS (2×) to remove excessive 
probe, followed by UV irradiation for 20 min on ice. The cells were 
trypsinized and pelleted by centrifugation. Eventually, the cell pellets were 
re-suspended in PBS (50 μL), homogenized by sonication, and diluted to 1 
mg/mL with PBS. All subsequent procedures were similar to those from in 
vitro experiments. The protein pellets were then re-suspended in 20 μL of 1× 
SDS loading buffer and heated for 10 min at 95 °C. Around 20 μg (per gel lane) 
of proteins were separated by SDS−PAGE (12% gel) and then visualized by 




6.3.2.8 Pull-down and target validation 
To identify potential cellular targets of the probes and their parental 
compounds, pull-down (PD) experiments were carried out, and followed by 
Western Blotting (WB). Here, A431 cell line was used as the tested cancer cell 
line. The general pull-down procedure was based on previously reported 
procedures.
[2b, 3d]
 Before pull-down, fresh A431 cell lysates were prepared and 
their protein concentrations determined, as previously described. For in vitro 
pull-down, Cellular lysates (6 mg) were supplemented with 500 µL 1× Tris 
buffer (50 mM Tris, 150 mM NaCl, 5 mM EDTA, 0.1 mM PMSF, 0.1% Triton 
X-100, pH 8.0) and pre-incubated with C1 (50 µΜ) for 2 h at room 
temperature. Subsequently, probe P1 and P2 (final concentration was 1 and 5 
µΜ) was added, and labeling was carried out for additional 2 h at room 
temperature. The CuAAC click chemistry was then performed with 
Biotin-azide reporter under the conditions described in the labeling procedure. 
Subsequently, the proteins were acetone precipitated, washed with methanol 
for 2~3 times and re-solubilized in 1% SDS in PBS with brief sonication. 
These re-suspended samples were then incubated with avidin-agarose beads 
(100 µL/mg protein) for 6 h at room temperature. After centrifugation, the 
supernatants were removed and the beads were washed with 1% SDS three 
times and 1 x PBS once. After washing, the beads were boiled in 1× SDS 
loading buffer (200 mM Tris pH 6.8, 400 mM DTT, 8% SDS) for 15 min to 
release the captured proteins. WB experiments were carried out by referring to 
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the general procedure using anti-DOT1L (ab157199, 1:1000) to detect the 
target protein DOT1L (~185 kDa). For in situ PD, briefly, the probe P1 and P2 
(5, 10 µM) was directly added to live cells, followed by incubation at 37 ºC/5% 
CO2 for 4 days. DMSO should never exceed 1% in the final solution. The 
medium was aspirated, and cells were washed twice gently with PBS to 
remove the excessive probe, followed by UV irradiation (~350 nm) for 20 min 
on ice. The cells were then trypsinized and pelleted by centrifugation. 
Eventually, the cell pellets were resuspended in Tris buffer (50 µL), 
homogenized by sonication, and diluted to 1 mg/mL with Tris buffer. The 
labeled lysates were then subjected to click reaction with biotin azide, and all 
subsequent experiments were carried out as above described. Control PD 
using the negative probe (C1; 10 M final concentration) was carried out 
concurrently with live cells. WB experiments were carried out as previously 
described using the corresponding antibodies. 
SILAC pull-down and LC-MS/MS validation 
The SILAC experiments were done by referring to the reported 
procedures.
[11]
 Briefly, the cells were seeded into two wells of a 6-well plate 
with a 15% to 20 % confluence. Label them light and heavy respectively (use 
specific SILAC medium). Upon cell attachment, light and heavy wells are 
replaced with 2 mL light and 2 mL heavy SILAC medium immediately. 
Change medium every 2-3 days if cells are not ready for subculture. After 2-3 
days cultivation, upon cells reach confluent culture, subdivide the light and 
192 
 
heavy cells into 3 wells of a 6-well plate respectively. In order to reduce 
medium consumption, during detachment, upon cells rounding, carefully 
aspirate off trypsin, use either light or heavy medium directly suspend the cells 
and then subdivide. After 2-3 days cultivation, upon cell reaches 90% 
confluence, detach and combine the 3 wells light and the 3 wells heavy cells 
into one 10 cm culture dish each. Furnish with 10mL light or heavy medium 
and leave them grow to confluent culture. Either light or heavy amino acids 
should be reasonably incorporated at this stage. If it is the first time for this 
cell line to incorporate heavy amino acids, subdivide one portion of either 
light or heavy cells into 1 well of a 6-well plate respectively. Upon reaching 
confluent culture, these cells are used for checking of full incorporation of 
SILAC amino acids. For the rest of the cells, continue subdividing and 
culturing the light and heavy cells until enough numbers are reached. Cell 
stocks can be frozen meanwhile following standard routine procedure.  
To check the full cooperation of amino acids, lyse an aliquot of cells (1 
well light or heavy cells of a 6-well plate is sufficient) at the end of the 
adaptation phase by adding 300 μl of a mix of 6 M urea and 2 M thiourea to 
one well of a 6-well plate. N.B. This analysis does not have to be performed 
each time a SILAC experiment is carried out, but should be performed when 
working with a new cell type or cell stock. The parameters for successful 
labelling can be recorded and applied to subsequent SILAC experiments. 
Scrape the dish with a cell scraper and pipette the lysate into a microcentrifuge 
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tube, then vortex the lysate intermittently for 5 min, followed by pelleting the 
debris by centrifuging for 10 min at 16,000-20,000 g in a benchtop centrifuge 
at 18 
o
C. The supernatant was collected in a new microcentrifuge tube, taking 
care to avoid DNA or the cell pellet. DNA may not pellet completely and 
appears as a colorless gel-like clump, which can be easily removed when 
aspirating with the pipette. Estimate protein concentration using a standard 
assay (Bradford or BCA) and use about 100 μg of protein for the following 
general in-solution digest procedures. 
The rest of cells were used for the real SILAC PD, LC-MS/MS analysis. 
The probe/inhibitor concentration is 2 M while the concentration of 
competitor (C1) is 20 M; cell amount is that three 10 cm cell culture dishes 
cells were used for one compound labeling. All the other processes are the 
same with the PD procedure as described above. One thing should pay 
attention to here is that, the light and heavy cells should be lysed separately 
and the cell lysate should be mixed equally. Then the mixture was used in the 
following protein enrichment/separation steps. Finally, the proteins were 
separated with SDS-PAGE and trypsin digested to obtain the peptide fragment 
(in-gel digestion) for further MS analysis. 
In situ pull-down and validation of potential off-target putative ribosomal 
RNA methyltransferase NOP2 
The in situ pull-down and Western Blot was processed as described above. 
According to the SILAC LC-MS/MS results, putative ribosomal RNA 
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methyltransferase NOP2 (88.9 kDa as detected) could be one of the interesting 
off-targets of probe P1. Therefore further PD/WB as well as CETSA 
validation was done and the CETSA result is shown below (Figure 6.2). 
 
Figure 6.2 WB plots of in situ CETSA assay against putative ribosomal RNA 
methyltransferase NOP2. 
6.4 Chapter 4 
6.4.1 Chemical Synthesis 
6.4.1.1 Synthesis of protected bioactive compounds 
 
4-(benzyloxy)-3-methoxybenzaldehyde (2).  












































mol), potassium carbonate (5 g, 0.036 mol) and acetone (165 mL) was 
refluxed for 12 h. After the completion of the reaction, water (165 mL) was 
added. The precipitated product was recrystallized from ethanol to yield 
compound 2 as a white solid (16.8 g, 97%). 
1H NMR (300 MHz, Acetone) δ 
9.83 (s, 1H), 7.51-7.45 (m, 3H), 7.37 (ddd, J = 19.7, 8.2, 4.4 Hz, 4H), 7.20 (d, 
J = 8.2 Hz, 1H), 5.21 (s, 2H), 3.86 (s, 3H); 
13C NMR (75 MHz, Acetone) δ 
191.28, 154.61, 151.07, 137.64, 131.44, 129.35, 128.87, 128.60, 126.59, 
113.50, 110.58, 71.24, 56.16. MS (IT-TOF): [M+H
+
] calcd for C15H14O3 
243.09, found 243.10 
 
 
4-(benzyloxy)-5-methoxy-2-nitrobenzaldehyde (3).  
Compound 2 (13.5 g, 0.056 mol) was added to nitric acid (65 mL) and 
the reaction was stirred at 0 
o
C for 1 h. The solid product was collected by 
filtration and recrystallized from ethyl acetate to provide compound 3 as 
yellow needles (12.8 g, 80%). 
1
H NMR (500 MHz, CDCl3) δ 10.43 (d, J = 1.1 
Hz, 1H), 7.67 (s, 1H), 7.4-7.40 (m, 6H), 5.27 (s, 2H), 4.02 (s, 3H); 
13
C NMR 
(126 MHz, CDCl3) δ 187.74, 153.70, 151.39, 143.59, 134.81, 128.88, 128.69, 
127.56, 127.18, 125.70, 110.00, 108.88, 71.54, 56.70. MS (IT-TOF): [M+H
+
] 





4-hydroxy-5-methoxy-2-nitrobenzaldehyde (4).  
A mixture of 3 (5.2 g, 0.018 mol) and acetic acid (36.2 mL) was kept at 
85 
o
C while 48% hydrobromic acid (11 mL) was added dropwise. The reaction 
mixture was kept at 85 
o
C for 1 h. The solid product was collected by filtration 
and recrystallized from hot ethanol to obtain compound 4 as yellow needles 
(2.74 g, 76%). 
1
H NMR (300 MHz, MeOD) δ 10.24 (s, 1H), 7.51 (s, 1H), 7.44 
(s, 1H), 4.01 (s, 3H); MS (IT-TOF): [M+H
+




4-(allyloxy)-5-methoxy-2-nitrobenzaldehyde (5).  
Compound 4 (1.6 g, 8.1 mmol), potassium carbonate (1.7 g, 12.3 mmol) 
and allyl bromide (1.17 g, 9.7 mmol) were mixed in dry ethanol (16.2 mL), 
and the reaction was refluxed overnight. Subsequently, the mixture was poured 
into water, extracted into ethyl acetate, washed with water and brine, dried 
over anhydrous sodium sulfate and concentrated. The crude product was 
further purified by column chromatography (10% ethyl acetate/90% hexane) 
to obtain compound 5 as a yellow solid (1.74 g, 90%). 
1
H NMR (500 MHz, 
CDCl3) δ 10.45 (s, 1H), 7.62 (s, 1H), 7.42 (s, 1H), 6.07 (ddd, J = 16.0, 10.6, 
5.3 Hz, 1H), 5.49 (d, J = 17.2 Hz, 1H), 5.41 (d, J = 10.6 Hz, 1H), 4.76 (d, J = 
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5.4 Hz, 2H), 4.02 (s, 3H); 
13
C NMR (126 MHz, CDCl3) δ 187.72, 153.52, 
151.31, 131.19, 125.60, 119.74, 109.98, 108.59, 70.44, 56.72. MS (IT-TOF): 
[M+H
+
] calcd for C11H11NO5 238.06, found 238.09 
 
 
(4-(allyloxy)-5-methoxy-2-nitrophenyl)methanol (6).  
To a solution of 5 (1.6 g, 6.7 mmol) in THF-ethanol (1:1, 36.2 mL) at 0 
o
C was added NaBH4 (506 mg, 13.4 mmol) slowly. The mixture was allowed 
to warm to room temperature and stirred overnight. The reaction mixture was 
poured into water and extracted with ethyl acetate. The organic layers were 
combined, washed with water and brine, dried over anhydrous sodium sulfate 
and concentrated to afford the desired product 6 as a pale white solid which 
can be used in the next step without further purification (1.53 g, 95%). 
1
H 
NMR (300 MHz, CDCl3) δ 7.72 (s, 1H), 7.17 (s, 1H), 6.07 (ddd, J = 22.7, 10.7, 
5.4 Hz, 1H), 5.41 (dd, J = 30.2, 13.2 Hz, 2H), 4.96 (s, 2H), 4.68 (d, J = 5.5 Hz, 
2H), 4.00 (s, 3H); 
13
C NMR (75 MHz, CDCl3) δ 163.22, 154.28, 139.65, 
132.33, 131.92, 119.15, 111.27, 109.91, 70.16, 62.88, 56.45. MS (IT-TOF): 
[M+H
+
] calcd for C11H13NO5 240.08, found 240.10 
 
 
4-(allyloxy)-5-methoxy-2-nitrobenzyl methanesulfonate (7). 
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Methanesulfonyl chloride (481.2 mg, 4.2 mmol) was added dropwise to a 
stirred solution of compound 6 (830 mg, 3.5 mmol) and triethylamine (425 mg, 
4.2 mmol) in anhydrous diethyl ether (5.25 mL) at 0
 o
C. After 3 h, water was 
added to the reaction mixture. The organic layer was separated, washed with 
water and brine, dried over anhydrous sodium sulfate and concentrated to 
afford the desired product 7 as a yellow solid which can be used in the next 
step without further purification (1.06 g, 96%). 
1
H NMR (500 MHz, CDCl3) δ 
7.76 (s, 1H), 7.15 (s, 1H), 6.11-6.02 (m, 1H), 5.65 (s, 2H), 5.47 (dd, J = 17.3, 
1.3 Hz, 1H), 5.37 (dd, J = 10.5, 1.0 Hz, 1H), 4.69 (d, J = 5.5 Hz, 2H), 4.01 (s, 
3H), 3.14 (s, 3H); 
13
C NMR (126 MHz, CDCl3) δ 154.27, 147.68, 139.32, 
131.69, 125.08, 119.32, 110.85, 109.93, 70.21, 68.80, 56.61, 37.81. MS 
(IT-TOF): [M+H
+
] calcd for C12H15NO7S 318.06, found 318.09 
 
 
1-(allyloxy)-4-(azidomethyl)-2-methoxy-5-nitrobenzene (8).  
Sodium azide (221 mg, 3.4 mmol) was added to a solution of compound 
7 (430 mg, 1.36 mmol) in dry DMF (1 mL). The reaction mixture was stirred 
at 70 
o
C for 3 h. The resulting mixture was poured into water and the crude 
product was extracted with ethyl acetate. The organic phase was combined, 
washed with brine, dried over anhydrous Na2SO4 and concentrated to afford 
the desired product 8 as a yellow solid (347.36 mg, 50%). 
1
H NMR (300 MHz, 
CDCl3) δ 7.73 (s, 1H), 7.07 (s, 1H), 6.16-5.98 (m, 1H), 5.41 (dd, J = 29.9, 
199 
 
13.9 Hz, 2H), 4.87 (s, 2H), 4.68 (d, J = 5.4 Hz, 2H), 4.00 (s, 3H); 
13
C NMR 
(75 MHz, CDCl3) δ 154.0, 147.15, 139.63, 131.83, 126.74, 119.20, 111.25, 
110.04, 70.19, 56.51, 52.24. MS (IT-TOF): [M+H
+
] calcd for C11H12N4O4 




To a solution of 8 (200 mg, 0.76 mmol) in anhydrous diethyl ether (1 mL) 
at 0
 o
C was added triphenylphosphine (299 mg, 1.14 mmol), and the mixture 
was allowed to stir at room temperature for 5 h. Water was then added and the 
reaction was further stirred for another 20 h. The resulting mixture was poured 
into 10% aq. HCl, and extracted with diethyl ether. The aqueous layer was 
then adjusted to basic form with sodium carbonate prior to extraction with 
ethyl acetate. The organic layer was washed with brine, dried over anhydrous 
sodium sulfate and concentrated. The crude product was further purified by 
column chromatography (3% MeOH/97% DCM) to afford the desired product 
9 as a yellow oil (166.10 mg, 92%). 
1H NMR (500 MHz, DMSO) δ 7.82 (s, 
1H), 7.22 (s, 1H), 6.13-6.02 (m, 1H), 5.45 (dd, J = 17.3, 1.6 Hz, 1H), 5.31 (dd, 
J = 10.6, 1.4 Hz, 1H), 4.70 (d, J = 5.3 Hz, 2H), 4.34 (s, 2H), 4.01 (s, 3H). MS 
(IT-TOF): [M+H
+






 Camptothecin (CPT, 20 mg, 0.06 mmol) and 4-nitrophenyl 
chloroformate (36.3 mg, 0.18 mmol) were dissolved in HPLC-grade DCM (1 
mL) at 0
 o
C, followed by the addition of DMAP (44 mg, 0.36 mmol). The 
resulting solution was stirred at room temperature for 1 h. The resulting 
mixture was diluted with DCM and washed with 0.1 M HCl solution. The 
organic layer was dried over anhydrous sodium sulfate and concentrated under 
reduced pressure to ~ 0.5 mL. The crude product was precipitated by ether, 
filtered and dried to give compound 10 as a yellow powder which was used 
directly in the next step (20 mg, 68%).
[7]
 Compound 10 (20 mg) dissolved in 
DMF (1 mL) was added compound 9, and the resulting mixture was stirred at 
room temperature for 3 h. DMF was subsequently removed under reduced 
pressure, and the resulting residue was purified by column chromatography 
(100% ethyl acetate) followed by preparative TLC to yield the titled 
compound (11.4  mg, 48%). 
1
H NMR (500 MHz, CDCl3) δ 8.33 (d, J = 88.2 
Hz, 2H), 7.95 (d, J = 7.9 Hz, 1H), 7.86 (s, 1H), 7.65 (dd, J = 26.7, 16.7 Hz, 
2H), 7.34 (s, 1H), 6.93 (s, 1H), 6.03-5.92 (m, 1H), 5.69 (d, J = 17.1 Hz, 1H), 
5.35 (dd, J = 41.6, 13.8 Hz, 5H), 4.74-4.37 (m, 4H), 3.87 (s, 3H), 2.17 (d, J = 
65.2 Hz, 2H), 0.96 (d, J = 6.7 Hz, 3H). 
13
C NMR (126 MHz, CDCl3) δ 168.16, 
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157.39, 154.86, 154.20, 152.40, 148.83, 146.98, 146.76, 146.09, 140.06, 
131.89, 131.17, 130.71, 129.59, 128.98, 128.04, 127.70 (d, J = 9.0 Hz), 126.88, 
119.88, 119.25, 119.01, 112.60, 96.29, 76.01, 70.02, 67.06, 56.63, 50.60, 43.12, 
31.98, 7.60. HRMS: [M+Na
+




4-(allyloxy)-5-methoxy-2-nitrobenzyl (4-nitrophenyl) carbonate (11). 
To a stirred solution of compound 6 (50 mg, 0.21 mmol) in dry THF, 
4-nitrophenyl chloroformate (63.5 mg, 0.32 mmol). The resulting mixture was 
stirred at room temperature for 1.5 h. Subsequently, the mixture was 
concentrated in vacuo and the residue was partitioned between ethyl acetate 
and water. The organic fraction was washed with water and brine, dried over 
anhydrous sodium sulfate and concentrated. The crude product was further 
purified by column chromatography (17% ~ 20% ethyl acetate in hexane) to 
afford the desired product 11 as a yellow oil (84.5 mg, 94%). 
1
H NMR (300 
MHz, CDCl3) δ 8.26 (d, J = 9.1 Hz, 2H), 7.76 (s, 1H), 7.40 (d, J = 9.1 Hz, 2H), 
7.11 (s, 2H), 6.05 (ddd, J = 16.0, 10.6, 5.3 Hz, 1H), 5.69 (s, 2H), 5.52-5.29 (m, 
2H), 4.68 (d, J = 5.4 Hz, 2H), 4.00 (s, 3H). 
13
C NMR (75 MHz, CDCl3) δ 
161.90, 154.02, 152.07, 147.56, 145.41, 139.67, 131.59, 126.13, 125.32, 
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121.70, 119.31, 110.86, 110.00, 70.17, 67.67, 56.50. MS (IT-TOF): [M+H
+
] 




To a solution of 6-aminoquinoline (15 mg, 0.04 mmol) and triethylamine 
compound 11 (dissolved in anhydrous THF). The mixture was stirred at room 
temperature overnight. Upon solvent evaporation, the residue was purified by 
column chromatography (8% ethyl acetate in DCM) to afford the desired 
product as a light yellow solid (7.1 mg, 47%). 
1
H NMR (500 MHz, CDCl3) δ 
8.30 (d, J = 9.1 Hz, 2H), 7.78 (s, 1H), 7.42 (d, J = 9.1 Hz, 2H), 7.26 (s, 2H), 
7.11 (s, 1H), 6.08 (ddd, J = 22.6, 10.7, 5.4 Hz, 1H), 5.71 (s, 2H), 5.48 (d, J = 
17.3 Hz, 1H), 5.38 (d, J = 10.5 Hz, 1H), 4.70 (d, J = 5.5 Hz, 2H), 4.02 (s, 3H); 
13
C NMR (126 MHz, CDCl3) δ 155.36, 154.06, 152.08, 147.70, 145.57, 
139.89, 139.86, 131.72, 125.38, 125.17, 121.71, 119.33, 110.88, 110.86, 
110.11, 110.08, 70.23, 67.72, 56.56. HRMS: [M+Na
+
] calcd for C21H19N3O6 






Compound 9 (12 mg, 0.05 mmol) dissolved in dry DMF (1 mL) was 
added EDC•HCl (8.8 mg, 0.046 mmol), HOBt (6.2 mg, 0.046 mmol), DIEA 
(17 mg, 0.132 mmol) and TER acid
[8]
 (20 mg, 0.033 mmol). The reaction 
mixture was allowed to stir at room temperature overnight in the dark. The 
crude product was further purified by prep-HPLC to afford the desired product 
as a dark red solid (13.4 mg, 49%). HRMS: [M
+
] calcd for C47H55N6O8
+
 




To a solution of TER-acid (50 mg, 0.082 mmol) in DMF (25 ml), HBTU 
(37 mg, 0.098 mmol) and HOBt (13.2 mg, 0.098 mmol) was added and stirred 
at room temperature for 10 min. tert-Butyl 3-aminopropylcarbamate
[9]
 (21.4 
mg, 0.12 mmol) and DIEA (21 mg, 0.16 mmol) was added and the pH should 
be kept around 8. The mixture was allowed to stir at room temperature 
overnight. After the reaction was completed, the reaction solution was 
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transferred to the separation funnel and saturated sodium chloride solution was 
added. The crude product was extracted with isopropyl alcohol/DCM =2:1 
co-solvent. The organic layer was collected, dried over Na2SO4 and 
concentrated (keep the temperature below 40℃). The residue was redissolved 
in chloroform until no more salt precipitate out. Then filtered, collected the 
filtrate and concentrate again to obtain  product Boc-protected TER-amine 
as a dark red solid which was used in the next step without further purification 
(62.8 mg, 88%).  
The Boc-protected TER-amine (30 mg, 0.039 mmol) was dissolved in 
HPLC DCM (3 ml), then trifluoroacetic acid (3 ml) was added dropwise and 
the mixture was stirred at room temperature for 30 min. when the reaction was 
completed, solvent was removed under reduced pressure to afford free 
TER-amine. Simultaneously, a solution of N,N'-Carbonyldiimidazole (CDI, 
5.84 mg, 0.036 mmol) in dry DCM (0.5 mL) at 0 
0
C was added compound 6 
(8.6 mg, 0.036 mmol). The resulting mixture was stirred at room temperature 
for 8 h, TER-amine (20 mg, 0.03 mmol) was next added and the solution was 
stirred at room temperature for another 72 h. The resulting crude product was 
further purified by prep-HPLC to provide the desired product as a dark red 
solid (11.3 mg, 41%). HRMS: [M
+
] calcd for C51H62N7O10
+
 932.4553, found 
932.4553. 
6.4.1.2 Synthesis of peptides 
CGRGDSP peptide (positive RGD control). As shown in Scheme 4.2a, 
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Rink amide resin (500 mg, 0.25 mmol) was swelled in DMF for 
approximately 30 min and then filtered. The resin was then treated with 20% 
piperidine in DMF for 1 h at room temperature to remove the Fmoc-protective 
group and washed with DMF for 3 times, DCM for three times, MeOH for 
three times and DMF for three times. After that, Fmoc-Pro-OH (4.0 eq., 
337.37 mg, 1 mmol), and standard coupling reagents, HOBT (4.0 eq., 135.13 
mg, 1 mmol), HBTU (4.0 eq., 379.25 mg, 1 mmol) and DIEA (8.0 eq., 330 
L, 2 mmol) were dissolved in 150 mL of DMF. The mixture was added to 
the resin and the reaction was stirred overnight. The resin was then washed 
with DMF for 3 times, DCM for three times, MeOH for three times and DMF 
for three times. Fmoc-Ser-(tBu)-OH, Fmoc-Asp (OAll)-OH, Fmoc-Gly-OH, 
Fmoc-Arg(pdf)-OH, Fmoc-Gly-OH and Boc-Cys (Trt)-OH were sequentially 
coupled to the resin similarly. The allyl group was removed using the 
following procedure. First, the resin was dried at 40 
o
C under reduced 
pressure in a glass vessel sealed with a rubber septum. Next, the vessel was 
flushed with argon gas before introduction of Pd(PPh3)4 (3 eq.) and a mixture 
of CHCl3/AcOH/N-methylmorpholine (37:2:1) (15 mL/g of resin). The 
reaction was continued under Ar for 2 h with occasional gentle agitation. 
Subsequently, the allyl-deprotected resin was transferred to a sintered glass 
funnel and washed consecutively with 0.5% DIPEA (in DMF) and sodium 
diethyldithiocarbomate (0.5% w/w in DMF) to remove the catalyst thoroughly. 
The resin was further washed with DMF for 3 times, DCM for three times, 
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MeOH for three times and DMF for three times. Finally, the resin was washed 
with DCM for three times and dried thoroughly under reduced pressure, the 
cleavage solution (TFA/Thioanisole/EDT/Anisole = 90:5:3:2) was added to 
the resin and the mixture was stirred at room temperature for 1 h. The resin 
was filtered off. The solvent was removed in vacuo. The synthesized 
CGRGDSP peptide was purified by preparative HPLC (80% yield). MS 
(IT-TOF): [M+H
+
] calcd for C25H43N11O10S 690.29, found 690.10. 
Fmoc-L-tyrosyl-4-(hydroxymethyl)anilide (Linker). 
Fmoc-L-tyrosyl-4-(hydroxymethyl)anilide was synthesized using a 
previously published procedure (Scheme 4.2b).
[10]
 To a solution of 
p-aminobenzyl alcohol (323 mg, 2.62 mmol) in anhydrous THF (54.5 mL) 
cooled to 0 
o
C, HOBt (354 mg, 2.62 mmol), Fmoc-tyrosine (1 g 2.18 mmol), 
and EDC•HCl (503 mg, 2.62 mmol) were added. The mixture was stirred at 0 
o
C for 2 h and at room temperature overnight. Upon solvent removal, the 
residue was taken up in ethyl acetate and washed with saturated NH4Cl, 
NaHCO3 and brine. The organic layer was dried over anhydrous Na2SO4 and 
concentrated. The crude product was purified by flash chromatography 
(EtOAc:Hexane = 1:1) to obtain compound Linker as a brown solid (1.11 g, 
90%). 
1
H NMR (500 MHz, CDCl3) δ 8.02 (s, 1H), 8.02 (s, 1H), 7.65 (d, J = 
7.3 Hz, 2H), 7.43 (t, J = 8.5 Hz, 2H), 7.28 (t, J = 7.1 Hz, 2H), 7.10 (dd, J = 
62.3, 18.9 Hz, 8H), 6.78 (d, J = 8.1 Hz, 2H), 5.81 (s, 1H), 4.55-4.00 (m, 6H), 
3.00 (s, 2H), 1.18 (s, 9H); 
13
C NMR (126 MHz, CDCl3) δ 170.08, 156.52, 
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154.24, 143.54 (d, J = 25.2 Hz), 141.14, 136.96, 136.46, 131.09, 129.72, 
127.66, 127.49, 127.03, 124.96, 124.21, 120.23, 119.88, 78.36, 67.32, 64.49, 
57.16, 46.84, 38.23, 28.66. MS (IT-TOF): [M+H
+
] calcd for C35H36N2O5 
565.26; found, 565.26.  
Caged-RGD peptide.  
Scheme 4.2c illustrates the synthesis of Caged-RGD peptide, from the 
above ally-deprotected resin (100 mg, with loading ~0.6 mmol/g). Upon DMF 
washes of the resin, a mixture of compound Linker (4 eq.), PyBOP (4 eq.) and 
DIEA (8 eq.) dissolved in DMF (10 mL) and pre-activated for 20 min, was 
added. The reaction was shaken at room temperature overnight. The resin was 
washed with DMF for 3 times, DCM for three times, MeOH for three times 
and DMF for three times. Next, the resin was treated with 20% piperidine in 
DMF for 1 h at room temperature to remove the Fmoc-protective group. The 
resin was then washed with DMF for 3 times, DCM for three times, MeOH for 
three times and DMF for three times. After that, Fmoc-Leu-OH (4 eq.) 
pre-activated with HOBT (4 equiv.), HBTU (4 equiv.) and DIEA (8 equiv.) in 
DMF for 10 min, was added. The coupling was continued at room temperature 
overnight. The cycle of Fmoc deprotection/coupling was repeated with 
Fmoc-Lys(Boc)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Ser(tBu)-OH, 
Fmoc-His(Trt)-OH. Finally, the resin was coupled with TER acid (2 equiv.) 
similarly at room temperature with continuous shaking for 2 days. After 
washing with DMF for 3 times, DCM for three times, MeOH for three times 
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and DCM for three times and dried thoroughly under reduced pressure, the 
resin was cleaved (TFA/Thioanisole/EDT/Anisole = 90:5:3:2) at room 
temperature for 1 h. The resin was filtered off. The solvent was removed in 
vacuo. The synthesized Caged-RGD peptide was purified by preparative 
HPLC. MS (IT-TOF): [M+H
+
] calcd for C101H140N25O23S
+
 2103, 1/2 [M+H]
+
 
1051.5, found, 1052. 
6.4.2 Biological Assays 
6.4.2.1 General information 
Antibodies were purchased from the following vendors: anti-cleaved 
caspase 3 (#9661, Cell Signaling) Rabbit, HRP-conjugated secondary 
antibodies: Goat anti-Rabbit IgG (#31210, Pierce). Nuclear staining reagent 
Hochest 33342, trihydrochloride, trihydrate (10 mg/mL solution in water) 
were purchased from Invitrogen. Western blot was done by using the 
SuperSignal
®
 West Dura Extended Duration Substrate Kit (200 mL Kit, 
Thermal Scientific). FACS experiments were carried out on a BD Accuri™ 
C6 cell analyzer. Imaging was done by In Cell Analyzer 2200 (GE). Cell lines 
were obtained from the National Cancer Institute Developmental Therapeutics 
Program (NCI-60). Prostate cancer (PC-3) cells, Chinese hamster ovary 
(CHO-9) cells, Mouse embryonic fibroblast cell line (NIH 3T3) cells and 
human epithelioid carcinoma (HeLa) cells were cultured in Dulbeccoʼs 
modified Eagle medum (DMEM; Invitrogen) containing 10% heat-inactivated 
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fetal bovine serum (FBS; Invitrogen), 100 units/mL penicillin, and 100 μg/mL 
streptomycin (Thermo Scientific) and maintained in a humidified 37 °C 
incubator with 5% CO2. Protein concentration was determined by Bradford 
protein assay. Recombinant PSA protease was obtained from Sigma-Aldrich 
(USA). 
6.4.2.2 Experiments 
Functionalized hydrogels, as earlier described, were placed in 6-well cell 
culture plates and immersed in phosphate buffered saline (1× PBS) containing 
1% penicillin-streptomycin overnight at room temperature. Different cell lines 
(PC-3, CHO-9, NIH3T3 and HeLa) were seeded at 30K cells cm
-2 
on the 
hydrogels using serum-free DMEM medium with 1% penicillin-streptomycin. 
After 3 h, the medium was removed gently and replaced with normal DMEM 
growth medium. After three days of culturing, the cells grew as a round shape 
cluster. After cell grew full on the peptide containing spots, the total live cell 
count was summarized also in Table 4.1. The fluorescent spots indicate the 
position of peptides, which were shown as an array like SMM array on glass 
slides. The resulting spot diameters were around 0.5 mm (close to that 
expected for hemispherical spots), and the center-to-center distance between 
two spots was around 1.5 mm. After one day culturing on hydrogels, only 
PC-3 cells grew on the spots containing Caged-RGD peptide or CGRGDSP 
peptide, other types of cells grew on spots containing CGRGDSP peptide, but 
grew only sparingly on Caged-RGD peptide. Only PC-3 cells were known to 
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overexpress and secrete PSA protease, thus were capable of cleaving 
Caged-RGD peptide to restore its activity. The cell type-specific growth 
results were also summarized in Table 4.1. Subsequently, the SMM was 
visualized upon cell staining with Hochest nuclear stain. Three channels were 
employed including BF: (bright-field), PEP (to detect fluorescence 
peptides/dyes; in red), and NU (to detect nuclear stained mammalian cells; in 
blue). Images were uniformly processed with Photoshop CS6, and merged. 
To ensure the success of the light-induced release of Camptothecin (CPT), 
a solution-phase test was applied. The photo-labile small molecule 
NVOC-CPT was dissolved in PBS buffer (20 M, 20 L) and irradiated with 
1000 J/cm2 UV exposure, then a UV time-dependent experiment was carried 
out (0, 10, 20, 30, 40, 40, 50, 60 min). During the whole irradiation processes, 
the reaction solution was cooled using ice. The recovered fluorescence 
intensity of the reaction solution was detected using Tecan microplate reader 
(Multimode Reader, Infinite®200; ex = 350 nm, em = 442 nm) (Figure 4.7a). 
NVOC-AQ was next used for on-chip UV-induced compound release 
experiments, due to its more favorable fluorescence properties. Upon SMM 
fabrication and hydrogel functionalization as earlier described, with different 
spotting concentrations of NVOC-AQ (0 to 100 M), UV irradiation (1000 
J/cm2, ice cooling) was initiated for indicated periods of time. The on-gel 
fluorescence signals (showing as fluorescent spots on hydrogels) at different 
UV time points and NVOC-AQ concentrations were captured by In-Cell 
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Analyzer 2200, using DAPI channel (excitation filter: 390 ± 18 nm; emission 
filter: 432.5 ± 48 nm) to quantify the fluorescent spots. The data was 
processed by the software ImageJ to measure the exact fluorescence intensity 
and plotted graphically. The fluorescence images were also shown in Figure 
6.3. Based on the image, it can be confirmed that even after UV irradiation, 
the spot size becomes bigger; there are still enough space between two spots, 
which help avoid passive diffusion effect between neighbouring spots. 
 
Figure 6.3 Fluorescence images of on-gel drug release assay after 1 h UV irradiation. 
Most of the fluorescence is released. At gradual drug concentrations, the fluorescence 
intensity increases gradually. 
In order to confirm whether the released CPT was taken up by 
mammalian cells, an in vitro experiment was performed. Cells (PC-3, with 
HeLa as controls) were grown for three days on hydrogel-functionalized 
SMMs containing either the positive control peptide (CGRGDSP) or 
Caged-RGD peptide (5 mM), and co-spotted with NVOC-CPT (0 to 100 M; 
NC = no compound). After photo-release (1000 J/cm2, ice cooling) for 20 
min, the cells were further incubated at 37 
o
C overnight. Subsequently, cells 
100 50 10 5 0Conc. (M)
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were stained with Hochest stain and microscopically visualized at different 
magnifications. 
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NMR spectrum of compounded used in this thesis are listed in this appendix. 










































































































































































































































































































































































































































































































































































































































Proteins showed in SILAC PD samples labelled by both P1 and P2 (SILAC ratio >2) 







Score Heavy/Light Score Heavy/Light 
Peptidyl-prolyl cis-trans 
isomerase A 
18 160.15 2.507 157.76 2.113 cytoplasm; secreted 
Accelerate the folding of proteins. Catalyzes the cis-trans 
isomerization of proline imidic peptide bonds in 
oligopeptides 
splicing factor 3A subunit 1 
isoform 2 
81.6 49.19 2.893 31.41 2.084 nucleus 
In vitro conversion of 15S U2 snRNP into an active 17S 
particle that performs pre-mRNA splicing 
Thymosin beta-4-like protein 
3 
5.1 36.32 2.497 27.27 2.209 cytoplasm 
A major cellular constituent in many tissues, can be used for 
actin binding, "moonlighting"; tissue regenerating; 
anti-inflammatory role for sulfoxide; terminal 
deoxynucleotidyl transferase 
Isoform 4 of Plasminogen 
activator inhibitor 1 
RNA-binding protein 
42.4 32.53 2.836 39.17 2.076 
cytoplasm; nucleus; 
perinuclear region  
May play a role in the regulation of mRNA stability 
28 kDa heat- and acid-stable 
phosphoprotein 
20.6 26.42 2.861 26.46 2.899 
cytoplasm; 
membrane 
Enhances PDGFA-stimulated cell growth in fibroblasts, but 
inhibits the mitogenic effect of PDGFB 
Thyroid hormone 
receptor-associated protein 3 
108.6 36.32 2.497 27.27 2.209 nucleus 
Involved in pre-mRNA splicing. Remains associated with 
spliced mRNA after splicing. Can trigger mRNA decay. May 
be involved in nuclear mRNA decay. Involved in regulation 
of signal-induced alternative splicing. During splicing of 
PTPRC/CD45 is proposed to sequester phosphorylated SFPQ 
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from PTPRC/CD45 pre-mRNA in resting T-cells. Involved in 
cyclin-D1/CCND1 mRNA stability. Involved in response to 
DNA damage. Initially thought to play a role in 
transcriptional coactivation. Cooperatively with HELZ2, 
enhances the transcriptional activation mediated by PPARG. 
May play a role in the terminal stage of adipocyte 
differentiation. Plays a role in the positive regulation of the 
circadian clock. Acts as a coactivator of the 
CLOCK-ARNTL/BMAL1 heterodimer and promotes its 
transcriptional activator activity and binding to circadian 
target genes 
Serpin H1 46.4 20.57 2.906 15.51 2.192 
Endoplasmic 
reticulum lumen 
Binds specifically to collagen. Could be involved as a 
chaperone in the biosynthetic pathway of collagen 
Isoform 1 of Brain acid 
soluble protein 1 
22.7 17.68 2.726 9.8 3.467 
cell membrane; cell 
projection 
Diaphragm development; Glomerular visceral epithelial cell 
differentiation; Gonad development; Mesenchymal to 
epithelial transition; Metanephric mesenchyme development; 
Negative regulation of transcription, DNA-templated; 
Positive regulation of heart growth; Positive regulation of 
metanephric ureteric bud development; Substantia nigra 
development; Thorax and anterior abdomen determination 
Na(+)/H(+) exchange 
regulatory cofactor NHE-RF1 






cell projection  
Scaffold protein that connects plasma membrane proteins 
with members of the ezrin/moesin/radixin family and thereby 
helps to link them to the actin cytoskeleton and to regulate 
their surface expression. Necessary for recycling of 
internalized ADRB2. Was first known to play a role in the 
regulation of the activity and subcellular location of 
SLC9A3. Necessary for cAMP-mediated phosphorylation 
and inhibition of SLC9A3. May enhance Wnt signaling. May 
participate in HTR4 targeting to microvilli (By similarity). 
Involved in the regulation of phosphate reabsorption in the 
renal proximal tubules. Involved in sperm capacitation. May 
participate in the regulation of the chloride and bicarbonate 
homeostasis in spermatozoa. 
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GUCA1B protein (Fragment) 8.6 14.21 3.386 23.03 2.169 cytoplasm structural molecule activity 







Activation Of Signaling Protein Activity Involved In 
Unfolded Protein Response 
Aspartate aminotransferase, 
mitochondrial 
47.5 8.67 2.487 5.45 20.27 
mitochondria; 
cytoplasm 
Catalyzes the irreversible transamination of the L-tryptophan 
metabolite L-kynurenine to form kynurenic acid (KA). Plays 
a key role in amino acid metabolism. Important for 
metabolite exchange between mitochondria and cytosol. 
Facilitates cellular uptake of long-chain free fatty acids. 
Isoform 1 of Eukaryotic 
translation initiation factor 
5A-1 
16.8 4.73 39.559 19.42 57.631 






pore complex   
mRNA-binding protein involved in translation elongation. 
Has an important function at the level of mRNA turnover, 
probably acting downstream of decapping. Involved in actin 
dynamics and cell cycle progression, mRNA decay and 
probably in a pathway involved in stress response and 
maintenance of cell wall integrity. With syntenin SDCBP, 
functions as a regulator of p53/TP53 and 
p53/TP53-dependent apoptosis. Regulates also 
TNF-alpha-mediated apoptosis. Mediates effects of 
polyamines on neuronal process extension and survival. May 
play an important role in brain development and function, 
and in skeletal muscle stem cell differentiation. Also 
described as a cellular cofactor of human T-cell leukemia 
virus type I (HTLV-1) Rex protein and of human 
immunodeficiency virus type 1 (HIV-1) Rev protein, 





Summarization of methyltransferases of SILAC PD 




(kDa) Score Coverage # Proteins 
# Unique 
Peptides 
# Peptides # PSMs Area Heavy/Light 
P1 target proteins : keyword methyltransferase 
IPI00872909.1 
Isoform 2 of Putative ribosomal RNA 
methyltransferase NOP2 
88.9 4.67 3.34% 3 1 2 2 2.55E+07 15.297 
IPI00217686.4 Putative rRNA methyltransferase 3 96.5 13 4.37% 1 2 3 4 1.58E+07 1.083 
IPI00909681.1 Serine hydroxymethyltransferase 47.8 24.8 21.63% 18 7 7 7 4.87E+07 0.581 
IPI00025039.1 rRNA 2'-O-methyltransferase fibrillarin 33.8 2 5.30% 1 1 2 3 3.03E+07  
IPI00411680.11 
Isoform 1 of 
Protein-L-isoaspartate(D-aspartate) 
O-methyltransferase 
24.6 6.47 13.22% 4 1 2 2 8.58E+07  
P2 target proteins : keyword methyltransferase 
IPI00217686.4 Putative rRNA methyltransferase 3 96.5 13.48 3.90% 1 3 3 4 6.56E+06 0.777 
IPI00909681.1 Serine hydroxymethyltransferase 47.8 11.97 11.16% 18 4 4 4 3.06E+07  
IPI00335589.5 RNA methyltransferase-like protein 1 47 0 4.76% 1 1 2 3 2.48E+07  
IPI00922359.1 Protein-L-isoaspartate O-methyltransferase 20.7 5.12 8.85% 4 1 1 1 7.84E+07  
IPI00332367.1 
Isoform 3 of Histone-lysine 
N-methyltransferase, H3 lysine-36 and H4 
lysine-20 specific 





Total proteins showed in both P1 and P2 PD large scale SILAC samples 
(Highlighted in red: proteins showed SILAC ratio; Highlighted in blue: proteins showed SILAC ratio >2) 
 
Description P1 P2 Total 
P1 P2 
M.W.(kDa) 
Score Heavy/Light Score Heavy/Light 
IPI00411704.9_Isoform 1 of Eukaryotic translation initiation 
factor 5A-1 
1 1 2 4.73 39.559 19.42 57.631 16.8 
IPI01014561.1_Uncharacterized protein 1 1 2 17.47 8.775 14.5 2.355 18.8 
IPI00032137.2_Alpha-actinin-3 1 1 2 12.35 7.831 8.19  
103.2 
IPI00304589.5_Isoform 1 of 182 kDa tankyrase-1-binding 
protein 
1 1 2 17.14 5.144 7.98 
 
181.7 
IPI00457184.5_5 kDa protein 1 1 2 6.85 4.222 8.35 4.751 5.3 
IPI00964535.1_Uncharacterized protein 1 1 2 58.2 4.059 67.44 3.104 24.1 
IPI00011876.3_cDNA FLJ59758, highly similar to 
S-methyl-5-thioadenosine phosphorylase 
1 1 2 25.78 3.913 14.67 
 
33.2 
IPI00910786.2_Uncharacterized protein 1 1 2 11.57 3.727 5.07  
26 
IPI00748354.1_Isoform 1 of Mitochondrial intermembrane space 
import and assembly protein 40 
1 1 2 8.83 3.45 4.41 1.087 16 
IPI00930614.1_GUCA1B protein (Fragment) 1 1 2 14.21 3.386 23.03 2.169 8.6 
IPI00056357.3_UPF0556 protein C19orf10 1 1 2 10.57 3.306 10.5 2.347 18.8 
IPI00221325.3_E3 SUMO-protein ligase RanBP2 1 1 2 12.93 3.077 16.36 0.305 358 
IPI00021263.3_14-3-3 protein zeta/delta 1 1 2 81.76 3.038 66.07 1.248 27.7 
IPI00008918.1_Isoform Beta of LIM domain and actin-binding 
protein 1 
1 1 2 47.81 2.99 37.39 1.472 85.2 
IPI01022048.1_Uncharacterized protein 1 1 2 37.54 2.983 27.57  
41.7 
IPI00013895.1_Protein S100-A11 1 1 2 104.41 2.967 71.66 1.71 11.7 
IPI00032140.4_Serpin H1 1 1 2 20.57 2.906 15.51 2.192 46.4 
IPI00470590.3_splicing factor 3A subunit 1 isoform 2 1 1 2 49.19 2.893 31.41 2.084 81.6 
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IPI00646304.4_Peptidyl-prolyl cis-trans isomerase B 1 1 2 56.22 2.872 44.81 1.606 23.7 
IPI00013297.1_28 kDa heat- and acid-stable phosphoprotein 1 1 2 26.42 2.861 26.46 2.899 20.6 
IPI00291510.3_Inosine-5'-monophosphate dehydrogenase 2 1 1 2 11.33 2.857 15.48  
55.8 
IPI00412714.3_Isoform 4 of Plasminogen activator inhibitor 1 
RNA-binding protein 
1 1 2 32.53 2.836 39.17 2.076 42.4 
IPI00922081.1_Fructose-bisphosphate aldolase 1 1 2 75.14 2.791 61.33  
31.1 
IPI00001589.1_Mitochondrial import inner membrane 
translocase subunit Tim13 
1 1 2 16 2.774 6.72 
 
10.5 
IPI00872684.2_cDNA FLJ54141, highly similar to Ezrin 1 1 2 73.82 2.755 59.36 1.246 65.5 
IPI00299024.9_Isoform 1 of Brain acid soluble protein 1 1 1 2 17.68 2.726 9.8 3.467 22.7 
IPI00104050.3_Thyroid hormone receptor-associated protein 3 1 1 2 24.22 2.702 31.6 3.175 108.6 
IPI00010404.1_Splicing factor 3B subunit 5 1 1 2 3.93 2.683 6.04 1.119 10.1 
IPI00003527.5_Na(+)/H(+) exchange regulatory cofactor 
NHE-RF1 
1 1 2 14.56 2.627 10.29 2.362 38.8 
IPI00303722.5_Protein FAM136A 1 1 2 13.37 2.574 7.94 1.446 15.6 
IPI00062884.4_src substrate cortactin isoform b 1 1 2 12.07 2.556 10.67 1.3 57.4 
IPI00419585.9_Peptidyl-prolyl cis-trans isomerase A 1 1 2 160.15 2.507 157.76 2.113 18 
IPI00005511.1_PHD finger-like domain-containing protein 5A 1 1 2 22.65 2.497 11.33 1.108 12.4 
IPI00180240.2_Thymosin beta-4-like protein 3 1 1 2 36.32 2.497 27.27 2.209 5.1 
IPI00018206.4_Aspartate aminotransferase, mitochondrial 1 1 2 8.67 2.487 5.45 20.27 47.5 
IPI00552131.1_cDNA FLJ60021, moderately similar to Protein 
transport protein Sec61 subunit alpha isoform 1 
1 1 2 7.34 2.47 3.15 1.224 18 
IPI00917605.1_Uncharacterized protein 1 1 2 8.86 2.459 9.19 1.79 11.3 
IPI00292387.6_Isoform Alpha of Nucleolar and coiled-body 
phosphoprotein 1 
1 1 2 36.39 2.382 38.31 1.881 73.6 
IPI00218988.4_Isoform 2 of Adenylate kinase 2, mitochondrial 1 1 2 99.8 2.369 95.72 1.072 25.6 
IPI00298547.3_Protein DJ-1 1 1 2 56.29 2.366 50.82 1.346 19.9 
IPI00924819.3_Protein 1 1 2 7.61 2.366 7.67 2.305 7.8 
IPI00219301.7_Myristoylated alanine-rich C-kinase substrate 1 1 2 53.06 2.334 30.4 1.825 31.5 
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IPI00298057.3_Periplakin 1 1 2 16.64 2.24 10.41  
204.6 
IPI00010471.6_Plastin-2 1 1 2 16.41 2.239 14.94 1.573 70.2 
IPI00297579.4_Chromobox protein homolog 3 1 1 2 24.38 2.21 21.24 1.242 20.8 
IPI00382733.2_Isoform 3 of Leucine-rich repeat 
flightless-interacting protein 1 
1 1 2 21.5 2.203 6.78 1.682 82.6 
IPI01015029.1_Uncharacterized protein 1 1 2 2.42 2.201 3.21  
6.3 
IPI00216492.1_Isoform 2 of Heterogeneous nuclear 
ribonucleoprotein H3 
1 1 2 25.69 2.148 25.74 1.289 35.2 
IPI00012074.3_Isoform 1 of Heterogeneous nuclear 
ribonucleoprotein R 
1 1 2 41.15 2.111 38.15 1.456 70.9 
IPI00844040.2_cDNA FLJ59759, highly similar to Protein SET 1 1 2 10.57 2.111 20.69 0.576 31.1 
IPI00000335.1_Histidine triad nucleotide-binding protein 2, 
mitochondrial 
1 1 2 14.04 2.079 14.33 1.805 17.2 
IPI00909207.1_cDNA FLJ60461, highly similar to 
Peroxiredoxin-2 
1 1 2 61.96 2.073 70.15 1.683 20.1 
IPI00829824.1_PRKCSH protein (Fragment) 1 1 2 26.7 2.056 23.29 1.799 20.3 
IPI00430813.3_Isoform 2 of Cellular nucleic acid-binding protein 1 1 2 15.78 2.027 7.56  
18.7 
IPI00010740.1_Isoform Long of Splicing factor, proline- and 
glutamine-rich 
1 1 2 101.3 2.02 95.65 1.269 76.1 
IPI00296713.4_Isoform 1 of Granulins 1 1 2 16.73 1.989 9.63  
63.5 
IPI00479997.4_Isoform 1 of Stathmin 1 1 2 26.47 1.979 32.73 1.368 17.3 
IPI00983028.1_Uncharacterized protein 1 1 2 3.56 1.935 3.97 1.611 15.3 
IPI00024920.1_ATP synthase subunit delta, mitochondrial 1 1 2 9.05 1.934 3.64  
17.5 
IPI00017341.3_SF3A2 protein (Fragment) 1 1 2 9.3 1.913 4.48  
51.4 
IPI00015077.1_Eukaryotic translation initiation factor 1 1 1 2 5.6 1.91 5.65 1.806 12.7 
IPI00966238.2_cDNA FLJ51907, highly similar to Stress-70 
protein, mitochondrial 
1 1 2 270.41 1.896 216.88 0.999 72.4 
IPI00032460.3_U6 snRNA-associated Sm-like protein LSm2 1 1 2 3.75 1.884 8.46 1.724 10.8 
IPI00011229.1_Cathepsin D 1 1 2 39.46 1.876 24.62 0.564 44.5 
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IPI00333215.1_Isoform 1 of Transcription elongation factor A 
protein 1 
1 1 2 17.42 1.864 10.78 0.88 33.9 
IPI00291006.2_Malate dehydrogenase, mitochondrial 1 1 2 387.5 1.862 284.37 0.892 35.5 
IPI00005087.1_Tropomodulin-3 1 1 2 25.15 1.84 7.52  
39.6 
IPI00759832.1_Isoform Short of 14-3-3 protein beta/alpha 1 1 2 53.97 1.84 48.32 1.525 27.8 
IPI00893062.1_X-ray repair complementing defective repair in 
Chinese hamster cells 6 
1 1 2 4.9 1.817 5.23 
 
64.2 
IPI00967330.1_Uncharacterized protein 1 1 2 5.46 1.815 5.08 1.257 26.9 
IPI00940851.1_ELAV-like protein 1 1 1 2 27.41 1.768 36.77 1.957 36.1 
IPI00641287.1_serine/arginine-rich splicing factor 11 isoform 2 1 1 2 16.21 1.737 18.76 1.329 53.4 
IPI00967744.1_Uncharacterized protein 1 1 2 17.38 1.73 13.16 1.432 8.6 
IPI00782992.3_Isoform 1 of Serine/arginine repetitive matrix 
protein 2 
1 1 2 49.44 1.714 24.93 1.569 299.4 
IPI00644556.2_Uncharacterized protein 1 1 2 3.99 1.708 5.06 1.845 5.9 
IPI00029557.3_GrpE protein homolog 1, mitochondrial 1 1 2 24.06 1.697 16.06 1.111 24.3 
IPI00855957.3_Isoform 2 of Far upstream element-binding 
protein 2 
1 1 2 51.77 1.672 50.28 0.386 72.9 
IPI00793319.1_Uncharacterized protein 1 1 2 4.78 1.656 4.61 1.478 19.5 
IPI00946474.1_Uncharacterized protein 1 1 2 2.94 1.656 2.97 0.42 7.8 
IPI01012004.1_cDNA PSEC0175 fis, clone OVARC1000169, 
highly similar to Protein disulfide-isomerase A3 
1 1 2 144.61 1.655 142.37 1.553 54.1 
IPI01012026.1_Uncharacterized protein 1 1 2 19.43 1.636 2.11  
215.2 
IPI00028109.1_Protein dpy-30 homolog 1 1 2 37.66 1.63 46.9 1.361 11.2 
IPI00939560.1_thioredoxin domain-containing protein 5 isoform 
3 
1 1 2 21.12 1.629 27.31 1.243 36.2 
IPI00020956.1_Hepatoma-derived growth factor 1 1 2 10.15 1.622 7.64 0.945 74.3 
IPI01018333.1_Isoform 1 of Hepatoma-derived growth 
factor-related protein 2 
1 1 2 10.15 1.622 7.64 0.945 74.3 




component of 2-oxoglutarate dehydrogenase complex, 
mitochondrial 
1 1 2 13.89 1.573 8.9 0.621 48.7 
IPI00060181.1_EF-hand domain-containing protein D2 1 1 2 28.49 1.53 38.81 2.614 26.7 
IPI00742682.2_Nucleoprotein TPR 1 1 2 70.07 1.53 62.7 1.015 267.1 
IPI00025086.4_Cytochrome c oxidase subunit 5A, mitochondrial 1 1 2 11.64 1.513 3.63  
16.8 
IPI00216691.5_Profilin-1 1 1 2 139.03 1.508 124.62 1.21 15 
IPI00013894.1_Stress-induced-phosphoprotein 1 1 1 2 86.16 1.503 100.89 0.99 62.6 
IPI00893737.1_Protein 1 1 2 4.28 1.479 4.14 0.934 5.7 
IPI00021785.2_Cytochrome c oxidase subunit 5B, mitochondrial 1 1 2 3.19 1.465 6.17 0.854 13.7 
IPI00021812.2_Neuroblast differentiation-associated protein 
AHNAK 
1 1 2 332.26 1.451 285.93 0.807 628.7 
IPI00554722.1_Isoform 3 of 4F2 cell-surface antigen heavy chain 1 1 2 17.4 1.441 7  
61.8 
IPI00301058.5_Vasodilator-stimulated phosphoprotein 1 1 2 19.05 1.431 12.55  
39.8 
IPI00797270.4_Isoform 1 of Triosephosphate isomerase 1 1 2 254.69 1.421 278.72 1.027 26.7 
IPI00013122.1_Hsp90 co-chaperone Cdc37 1 1 2 42.29 1.395 34.81 1.13 44.4 
IPI00419473.5_Isoform 2 of Transcription factor BTF3 1 1 2 19.69 1.381 10.04 2.468 17.7 
IPI00009659.3_Regulation of nuclear pre-mRNA 
domain-containing protein 1B 
1 1 2 23.34 1.369 18.37 1.079 36.9 
IPI00465248.5_Isoform alpha-enolase of Alpha-enolase 1 1 2 166.67 1.35 186.96 1.083 47.1 
IPI00385834.3_Isoform 2 of KH domain-containing, 
RNA-binding, signal transduction-associated protein 1 
1 1 2 33.13 1.348 33.02 1.203 45.8 
IPI00419258.4_High mobility group protein B1 1 1 2 56.46 1.348 39.94 0.999 24.9 
IPI00937615.2_Elongation factor 1-gamma 1 1 2 22.44 1.301 11.83 0.736 50.1 
IPI00029744.1_Single-stranded DNA-binding protein, 
mitochondrial 
1 1 2 67.02 1.3 71.21 0.961 17.2 
IPI00219219.3_Galectin-1 1 1 2 53.57 1.279 34.73 0.782 14.7 
IPI00010414.4_PDZ and LIM domain protein 1 1 1 2 37.06 1.269 25.5 8.302 36 
IPI00009771.6_Lamin-B2 1 1 2 33.31 1.268 42.68 0.923 69.9 
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IPI00795292.1_Isoform 3 of Nucleoside diphosphate kinase B 1 1 2 84.62 1.262 72.16 1.001 30.1 
IPI00955815.2_pyruvate dehydrogenase E1 component subunit 
alpha, somatic form, mitochondrial isoform 4 precursor 
1 1 2 3.54 1.261 6.22 0.698 40.2 
IPI00001639.2_Importin subunit beta-1 1 1 2 13.02 1.258 9.79 0.297 97.1 
IPI00911038.2_apoptotic chromatin condensation inducer in the 
nucleus isoform 3 
1 1 2 31.02 1.234 16.92 1.816 147.3 
IPI00395674.1_Isoform SM-B of Small nuclear 
ribonucleoprotein-associated proteins B and B' 
1 1 2 15.21 1.223 10.79 0.667 23.6 
IPI00220740.1_Isoform 2 of Nucleophosmin 1 1 2 312.48 1.215 269.05 0.823 29.4 
IPI00465439.5_Fructose-bisphosphate aldolase A 1 1 2 153.22 1.199 151.31 0.891 39.4 
IPI00642944.1_Uncharacterized protein 1 1 2 43.15 1.199 40.55 0.763 67.9 
IPI00550363.3_Transgelin-2 1 1 2 32.93 1.184 27.64 0.88 22.4 
IPI00010214.1_Protein S100-A14 1 1 2 10.43 1.168 10.4 0.629 11.7 
IPI00219754.1_Isoform 2 of Liprin-alpha-1 1 1 2 9.86 1.159 8.19 1.187 133.9 
IPI00759715.1_Isoform Cytoplasmic of Fumarate hydratase, 
mitochondrial 
1 1 2 9.86 1.159 33.76 0.591 50.2 
IPI00953109.2_Isoform 6 of Filamin-B 1 1 2 9.86 1.159 41.44 1.107 271.2 
IPI00737545.4_Pseudopodium-enriched atypical kinase 1 1 1 2 1.94 1.133 12.45 0.847 193 
IPI00093057.6_Coproporphyrinogen-III oxidase, mitochondrial 1 1 2 13.84 1.109 8.77  
50.1 
IPI00940673.2_cDNA FLJ36348 fis, clone THYMU2007025, 
highly similar to TRANSKETOLASE 
1 1 2 93.01 1.105 79.07 1.343 58.9 
IPI00002966.2_Heat shock 70 kDa protein 4 1 1 2 55.89 1.088 33.89 1.244 94.3 
IPI00217686.4_Putative rRNA methyltransferase 3 1 1 2 13 1.083 13.48 0.777 96.5 
IPI00304925.5_Heat shock 70 kDa protein 1A/1B 1 1 2 114.96 1.08 124.75 0.495 70 
IPI00003362.3_78 kDa glucose-regulated protein 1 1 2 311.66 1.078 326.1 0.909 72.3 
IPI00644576.1_Uncharacterized protein 1 1 2 91.18 1.074 76.44 0.709 276.4 
IPI00398776.3_Isoform 7 of Plectin 1 1 2 331.9 1.035 280.18 0.486 512.3 
IPI00179964.5_Isoform 1 of Polypyrimidine tract-binding protein 
1 
1 1 2 59.33 1.023 64.98 0.792 57.2 
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IPI00021828.1_Cystatin-B 1 1 2 22.29 1.015 14.62 0.415 11.1 
IPI01015060.1_39S ribosomal protein L12, mitochondrial 1 1 2 22.88 1.015 4.01 0.535 21.3 
IPI00017963.1_Small nuclear ribonucleoprotein Sm D2 1 1 2 20.34 1.012 12.49 0.739 13.5 
IPI00027230.3_Endoplasmin 1 1 2 82.74 1.011 65.1 0.609 92.4 
IPI01014727.1_cDNA FLJ51983, highly similar to 
Phosphoglycerate mutase 1 
1 1 2 19.12 1.011 20.38 0.657 27.1 
IPI00220362.5_10 kDa heat shock protein, mitochondrial 1 1 2 139.6 1.007 122.74 0.592 10.9 
IPI00218733.6_Superoxide dismutase [Cu-Zn] 1 1 2 67.34 0.981 50.91 0.888 15.9 
IPI00646689.1_Thioredoxin domain-containing protein 17 1 1 2 2.68 0.979 5.36 0.813 13.9 
IPI01013681.1_Uncharacterized protein 1 1 2 9.36 0.976 2.63 1.023 116.7 
IPI00003865.1_Isoform 1 of Heat shock cognate 71 kDa protein 1 1 2 230.48 0.974 217.4 0.713 70.9 
IPI00939159.6_Adenylyl cyclase-associated protein 1 1 2 12.43 0.97 11.98 0.444 47.1 
IPI01014951.1_Uncharacterized protein 1 1 2 7.62 0.968 4.14  
162.5 
IPI00004656.3_Beta-2-microglobulin 1 1 2 28.93 0.963 33.02 0.919 13.7 
IPI00216770.1_Isoform 2 of 26S protease regulatory subunit 6B 1 1 2 9.06 0.955 8.77 0.573 43.5 
IPI01011685.1_Uncharacterized protein 1 1 2 13.97 0.955 26.12 0.745 31.4 
IPI00029631.1_Enhancer of rudimentary homolog 1 1 2 5.67 0.931 1.96  
12.3 
IPI00514561.1_cDNA FLJ54552, highly similar to 
Heterogeneous nuclear ribonucleoprotein K 
1 1 2 167.78 0.924 119.06 2.211 47.5 
IPI00554648.3_Keratin, type II cytoskeletal 8 1 1 2 235.39 0.918 247.01 0.652 53.7 
IPI00004902.1_Isoform 1 of Electron transfer flavoprotein 
subunit beta 
1 1 2 15.6 0.914 12.33 
 
27.8 
IPI00013917.3_40S ribosomal protein S12 1 1 2 34.79 0.911 32.42 0.551 14.5 
IPI00178440.3_Elongation factor 1-beta 1 1 2 32.04 0.907 30.75 0.138 24.7 
IPI00176637.5_Eukaryotic translation initiation factor 2 subunit 
2-like protein 
1 1 2 16.12 0.905 9.15 0.38 37.8 
IPI01022933.1_Uncharacterized protein 1 1 2 35.83 0.893 29.79 0.474 15 




IPI00023640.3_Programmed cell death protein 5 1 1 2 12.81 0.887 3.15  
14.3 
IPI00218918.5_Annexin A1 1 1 2 121.43 0.884 94.85 0.233 38.7 
IPI00337736.1_Isoform 2 of Kinectin 1 1 2 9.75 0.881 10.01  
149.5 
IPI00647168.1_Ribosomal protein L11 1 1 2 4.12 0.877 3.84  
14.9 
IPI00025512.2_Heat shock protein beta-1 1 1 2 54.08 0.876 41.48 0.612 22.8 
IPI00026519.1_Peptidyl-prolyl cis-trans isomerase F, 
mitochondrial 
1 1 2 10.38 0.869 8.63 1.148 22 
IPI00015842.1_Reticulocalbin-1 1 1 2 5.56 0.859 5.21 0.637 38.9 
IPI00383296.5_Isoform 2 of Heterogeneous nuclear 
ribonucleoprotein M 
1 1 2 53.36 0.859 70.95 0.869 73.6 
IPI00843765.1_Isoform 3 of Spectrin alpha chain, brain 1 1 2 20.05 0.853 17.3 0.337 282.1 
IPI00029356.1_Isoform 2 of Non-structural maintenance of 
chromosomes element 4 homolog A 
1 1 2 2.96 0.85 2.86 0.625 35.8 
IPI00607577.2_superoxide dismutase [Mn], mitochondrial 
isoform B precursor 
1 1 2 13.34 0.845 15.76 0.404 20.7 
IPI00221222.7_Activated RNA polymerase II transcriptional 
coactivator p15 
1 1 2 17.04 0.83 22.98 0.742 14.4 
IPI00217975.4_Lamin-B1 1 1 2 97.71 0.785 101.88 0.468 66.4 
IPI00003438.2_DnaJ homolog subfamily C member 8 1 1 2 6.5 0.77 4.52 0.601 29.8 
IPI00658199.3_Uncharacterized protein 1 1 2 2.56 0.761 5.22 0.464 9.5 
IPI00014230.1_Complement component 1 Q 
subcomponent-binding protein, mitochondrial 
1 1 2 12.25 0.758 9.33 0.464 31.3 
IPI00020194.1_Isoform Short of TATA-binding 
protein-associated factor 2N 
1 1 2 15.42 0.751 15.99 1.022 61.5 
IPI00908881.3_Glucose-6-phosphate isomerase 1 1 2 14.49 0.749 8.87 0.292 60 
IPI00880007.2_Microtubule-associated protein 1 1 2 10.31 0.738 10.32 1.36 245.3 
IPI00646767.1_24 kDa protein 1 1 2 4.38 0.736 2.37  
23.9 
IPI00889196.2_Putative cytochrome b-c1 complex subunit 
Rieske-like protein 1 
1 1 2 11.62 0.728 8.38 
 
30.8 
IPI00006196.3_Isoform 2 of Nuclear mitotic apparatus protein 1 1 1 2 36.25 0.724 32.01 0.076 236.4 
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IPI00000874.1_Peroxiredoxin-1 1 1 2 98.37 0.722 106.07 0.445 22.1 
IPI00220834.8_X-ray repair cross-complementing protein 5 1 1 2 7 0.717 7.93 0.447 82.7 
IPI00895865.1_electron transfer flavoprotein subunit alpha, 
mitochondrial isoform b 
1 1 2 11.59 0.686 5.83 0.305 30 
IPI00396378.3_Isoform B1 of Heterogeneous nuclear 
ribonucleoproteins A2/B1 
1 1 2 236.87 0.678 240.97 0.491 37.4 
IPI00915452.4_Uncharacterized protein 1 1 2 96.4 0.675 96.26 0.428 128.6 
IPI00290460.3_Eukaryotic translation initiation factor 3 subunit 
G 
1 1 2 7.43 0.67 7.96 0.372 35.6 
IPI00908723.1_cDNA FLJ61039, highly similar to Stomatin-like 
protein 2 
1 1 2 13.32 0.659 18.33 0.38 33.3 
IPI00816063.1_Isoform 2 of 60S ribosomal protein L12 1 1 2 7.99 0.658 4.45 0.278 14.2 
IPI00031812.3_Nuclease-sensitive element-binding protein 1 1 1 2 58.8 0.646 48.58 0.479 35.9 
IPI00219097.4_High mobility group protein B2 1 1 2 26.56 0.606 21.93 0.641 24 
IPI00456695.1_Isoform 2 of 26S proteasome non-ATPase 
regulatory subunit 1 
1 1 2 5.03 0.596 2.89 0.546 102.2 
IPI00642213.1_Uncharacterized protein 1 1 2 36.92 0.596 35.07 0.787 24.7 
IPI00008527.3_60S acidic ribosomal protein P1 1 1 2 18.93 0.594 12.07 0.246 11.5 
IPI00552768.1_Uncharacterized protein 1 1 2 3.57 0.582 4.65 0.462 9.4 
IPI00909681.1_Serine hydroxymethyltransferase 1 1 2 24.8 0.581 11.97  
47.8 
IPI00479722.2_Proteasome activator complex subunit 1 1 1 2 5.06 0.578 9.34 0.363 28.7 
IPI00981395.1_cDNA FLJ53442, highly similar to Poly 
(ADP-ribose) polymerase 1 
1 1 2 34.82 0.573 20.49 0.757 111.1 
IPI00830039.1_Isoform 2 of Splicing factor U2AF 65 kDa 
subunit 
1 1 2 6.45 0.568 7.26 0.444 53.1 
IPI00020599.1_Calreticulin 1 1 2 6.28 0.561 6.47 0.879 48.1 
IPI00011200.5_D-3-phosphoglycerate dehydrogenase 1 1 2 14.22 0.553 18.64 0.247 56.6 
IPI01014382.2_Uncharacterized protein 1 1 2 9.48 0.552 6.98 0.176 54.3 
IPI00976562.1_cytochrome b-c1 complex subunit 7 isoform 2 1 1 2 12.98 0.55 6.79 0.25 10 
281 
 
IPI00304692.1_Heterogeneous nuclear ribonucleoprotein G 1 1 2 21.48 0.548 20.99 0.452 42.3 
IPI01013559.1_cDNA FLJ58502, highly similar to Protein 
disulfide-isomerase A6 
1 1 2 22.72 0.532 23.09 0.34 47.8 
IPI00022774.3_Transitional endoplasmic reticulum ATPase 1 1 2 79.19 0.53 64.07 0.314 89.3 
IPI00604620.3_Nucleolin 1 1 2 230.09 0.53 207.04 0.452 76.6 
IPI00788837.2_cDNA FLJ54752, highly similar to 
Poly(rC)-binding protein 2 
1 1 2 19.53 0.529 14.78 0.238 29.7 
IPI00010796.1_Protein disulfide-isomerase 1 1 2 27.35 0.523 28.68 0.612 57.1 
IPI00941747.1_Calnexin 1 1 2 33.95 0.522 33.84 0.634 67.5 
IPI00009904.1_Protein disulfide-isomerase A4 1 1 2 13.77 0.496 7.53  
72.9 
IPI00883857.2_Isoform Long of Heterogeneous nuclear 
ribonucleoprotein U 
1 1 2 38.09 0.496 45.14 0.606 90.5 
IPI00747810.3_52 kDa protein 1 1 2 20.82 0.476 17.3  
52.2 
IPI00106668.5_perilipin-3 isoform 3 1 1 2 10.97 0.472 4.61  
45.8 
IPI00916802.1_Uncharacterized protein 1 1 2 33.03 0.463 25.59 0.406 41.8 
IPI00374151.1_thioredoxin-dependent peroxide reductase, 
mitochondrial isoform b 
1 1 2 41.4 0.444 29.43 0.475 25.8 
IPI00008438.1_40S ribosomal protein S10 1 1 2 5.77 0.442 5.96 0.317 18.9 
IPI00218993.1_Isoform Beta of Heat shock protein 105 kDa 1 1 2 35.99 0.439 27.98  
92.1 
IPI00008529.1_60S acidic ribosomal protein P2 1 1 2 56.86 0.433 43.84 0.327 11.7 
IPI00644810.1_Uncharacterized protein 1 1 2 2.9 0.433 6.73 0.27 36.2 
IPI00016610.2_Poly(rC)-binding protein 1 1 1 2 34.32 0.423 37.96 0.263 37.5 
IPI00412771.1_CD2-associated protein 1 1 2 8.1 0.413 11.6  
71.4 
IPI00784154.1_60 kDa heat shock protein, mitochondrial 1 1 2 596.14 0.407 533.82 0.286 61 
IPI00910683.2_cDNA FLJ59557, highly similar to 
2-oxoglutarate dehydrogenase E1 component, mitochondrial 
1 1 2 6.48 0.39 6.86 
 
99 
IPI00186290.6_Elongation factor 2 1 1 2 73.81 0.382 64.76 0.205 95.3 
IPI00878876.1_Uncharacterized protein 1 1 2 46.47 0.364 38.81 1.493 13.3 
IPI00009866.7_Isoform 1 of Keratin, type I cytoskeletal 13 1 1 2 36.78 0.338 55.24 0.175 49.6 
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IPI00386621.3_CALM3 protein 1 1 2 22.16 0.333 24.26 0.319 16.5 
IPI00031522.2_Trifunctional enzyme subunit alpha, 
mitochondrial 
1 1 2 27.54 0.311 15.23 0.211 82.9 
IPI00984945.1_EF-Hand type domain containing protein 1 1 2 3.22 0.311 7.78 0.253 36.2 
IPI00396321.1_Leucine-rich repeat-containing protein 59 1 1 2 90.59 0.309 69.44 0.222 34.9 
IPI00465294.2_Cell division cycle 5-like protein 1 1 2 12.32 0.297 9.56 0.34 92.2 
IPI00021187.4_Isoform 1 of RuvB-like 1 1 1 2 14.98 0.296 7.94 0.191 50.2 
IPI00794461.1_Histone H2B type 1-N 1 1 2 73.94 0.293 86.95 0.31 18.8 
IPI00642982.1_Lon protease homolog 1 1 2 11.49 0.289 5.27 0.11 85.6 
IPI00396485.3_Elongation factor 1-alpha 1 1 1 2 121.3 0.279 133.68 0.229 50.1 
IPI00479186.7_Isoform M2 of Pyruvate kinase isozymes M1/M2 1 1 2 171.34 0.26 153.21 0.177 57.9 
IPI00910515.1_cDNA FLJ59603, highly similar to 
Serine/threonine-protein phosphatase 2A 65 kDa regulatory 
subunit A alpha isoform 
1 1 2 10.16 0.249 4.77 0.203 17.3 
IPI00471928.6_ATP synthase subunit alpha 1 1 2 63.95 0.247 57.2 0.206 54.5 
IPI01020686.1_Uncharacterized protein 1 1 2 75.29 0.246 96.98 0.05 48.5 
IPI00215790.6_60S ribosomal protein L38 1 1 2 1.91 0.244 2.03  
8.2 
IPI00419833.9_Histone H2B type 1-K 1 1 2 65.22 0.239 67.07  
13.9 
IPI00020928.1_Transcription factor A, mitochondrial 1 1 2 12.04 0.234 12.11 0.082 29.1 
IPI01011344.1_Uncharacterized protein 1 1 2 167.05 0.228 133.53 0.224 37.4 
IPI00024993.4_Enoyl-CoA hydratase, mitochondrial 1 1 2 42.89 0.216 30.67 0.074 31.4 
IPI00386208.1_Gastric-associated differentially-expressed 
protein YA61P 
1 1 2 14.42 0.194 19.03 0.189 14.9 
IPI00783097.4_Glycyl-tRNA synthetase 1 1 2 0 0.182 2.93  
83.1 
IPI00942853.2_RNA binding motif protein 39 1 1 2 19 0.179 17.49 0.068 36.7 
IPI00783271.1_Leucine-rich PPR motif-containing protein, 
mitochondrial 
1 1 2 22.79 0.175 18.18 0.21 157.8 




IPI00784295.2_Isoform 1 of Heat shock protein HSP 90-alpha 1 1 2 54.91 0.172 77.01 0.213 84.6 
IPI00908410.1_cDNA FLJ56566, highly similar to Small 
glutamine-rich tetratricopeptiderepeat-containing protein A 
1 1 2 9.74 0.17 7.94 
 
31.4 
IPI00019502.3_Isoform 1 of Myosin-9 1 1 2 70.33 0.167 83.7 0.165 226.4 
IPI01009326.1_cDNA FLJ53379, highly similar to T-complex 
protein 1 subunit theta 
1 1 2 14.78 0.164 15.03 0.145 57.6 
IPI00217475.2_Isoform 3 of Gamma-interferon-inducible protein 
16 
1 1 2 9.94 0.161 9.31 0.171 75.9 
IPI00015953.3_Isoform 1 of Nucleolar RNA helicase 2 1 1 2 28.27 0.158 27.13 0.139 87.3 
IPI00376215.2_Isoform 2 of DNA-dependent protein kinase 
catalytic subunit 
1 1 2 10.22 0.142 13.34 
 
465.2 
IPI00217467.3_Histone H1.4 1 1 2 28.04 0.133 29.56 0.127 21.9 
IPI00445401.4_Isoform 2 of E3 ubiquitin-protein ligase HUWE1 1 1 2 14.76 0.133 18.85 0.208 479.9 
IPI00103521.1_Stonin-2 1 1 2 1.75 0.125 1.76 0.171 101.1 
IPI00026087.1_Barrier-to-autointegration factor 1 1 2 10.3 0.103 17.48 0.114 10.1 
IPI00103467.5_Aldehyde dehydrogenase X, mitochondrial 1 1 2 10.96 0.099 8.31 0.167 57.2 
IPI00414676.6_Heat shock protein HSP 90-beta 1 1 2 2.96 0.068 2.15  
38.1 
IPI00807498.1_CCDC6 protein (Fragment) 1 1 2 2.96 0.068 2.15  
38.1 
IPI00977430.1_cDNA, FLJ79286, highly similar to T-complex 
protein 1 subunit gamma 
1 1 2 13.52 0.052 15.12 
 
55.6 
IPI00015018.1_Inorganic pyrophosphatase 1 1 2 19.82 0.042 10.4 0.101 32.6 
IPI00843996.1_cDNA FLJ52832, highly similar to Splicing 
factor, arginine/serine-rich 3 
1 1 2 21.74 0.031 14.97 
 
14.2 
IPI00217468.3_Histone H1.5 1 1 2 48.81 0.03 47.38 0.021 22.6 
IPI00893541.1_14 kDa protein 1 1 2 47.97 0.029 11.7  
14.6 
IPI00893703.1_Uncharacterized protein 1 1 2 2.94 0.029 3.07 0.019 21.3 
IPI00013847.4_Cytochrome b-c1 complex subunit 1, 
mitochondrial 
1 1 2 13.78 0.026 17.72 0.016 52.6 




IPI00293276.10_Macrophage migration inhibitory factor 1 1 2 25.22 0.018 26.09 0.02 12.5 












































IPI00007188.6_ADP/ATP translocase 2 1 1 2 11.96  
8.98 0.212 32.8 
IPI00007248.6_Pleckstrin homology domain-containing family A 
member 6 






























































































































IPI00022648.2_Eukaryotic translation initiation factor 5 1 1 2 4.43  
2.24 0.107 49.2 












IPI00026271.5_40S ribosomal protein S14 1 1 2 2.72  
6.08 0.057 16.3 








IPI00026546.1_Platelet-activating factor acetylhydrolase IB 
subunit beta 







IPI00026781.3_Fatty acid synthase 1 1 2 16.65  
17.11 0.234 273.3 
IPI00026848.3_Alpha-2-macroglobulin receptor-associated 
protein 





















IPI00028376.1_Mitochondrial import inner membrane 
translocase subunit Tim8 A 









IPI00031107.1_Isoform 2 of Hydroxysteroid dehydrogenase-like 
protein 2 
1 1 2 4.49 
 
4.28 0.224 37.3 








IPI00033561.3_Isoform 1 of RNA-binding protein with 
serine-rich domain 1 
1 1 2 6.25 
 
4.2 0.502 34.2 
IPI00060627.2_Coiled-coil domain-containing protein 124 1 1 2 6.79  
10.58 0.344 25.8 
IPI00103636.1_Isoform 2 of WAP four-disulfide core domain 
protein 2 





















IPI00177716.7_Isoform HMG-Y of High mobility group protein 
HMG-I/HMG-Y 





IPI00177817.4_Isoform 2 of Sarcoplasmic/endoplasmic 
reticulum calcium ATPase 2 





IPI00179700.3_Isoform HMG-I of High mobility group protein 
HMG-I/HMG-Y 





IPI00187011.4_Zinc finger CCCH domain-containing protein 4 1 1 2 9.28  
9.52 1.151 140.2 
287 
 








IPI00216393.1_Isoform Non-brain of Clathrin light chain A 1 1 2 8.9  
12.96 0.784 23.6 








IPI00218319.3_Isoform 2 of Tropomyosin alpha-3 chain 1 1 2 125.28  
117.56 1.948 29 




IPI00218435.1_Isoform 2 of U4/U6 small nuclear 
ribonucleoprotein Prp4 





IPI00218547.1_Isoform Short of Delta-1-pyrroline-5-carboxylate 
synthase 









IPI00219330.2_Isoform 5 of Interleukin enhancer-binding factor 
3 









IPI00219483.1_Isoform 2 of U1 small nuclear ribonucleoprotein 
70 kDa 









IPI00219866.2_Isoform 2 of Zinc finger Ran-binding 
domain-containing protein 2 









IPI00220447.2_cDNA FLJ50614, highly similar to 
Transformer-2 protein homolog 































IPI00293254.1_Isoform EWS-B of RNA-binding protein EWS 1 1 2 11.54  
15.21 5.506 61.2 




IPI00294398.2_Isoform 1 of Hydroxyacyl-coenzyme A 
dehydrogenase, mitochondrial 

















IPI00302047.3_cDNA FLJ77737, highly similar to Homo sapiens 
calpastatin (CAST), transcript variant 3, mRNA 





IPI00304596.3_Non-POU domain-containing octamer-binding 
protein 









IPI00333010.9_Calcium homeostasis endoplasmic reticulum 
protein 

























IPI00384556.1_Ribosomal RNA upstream binding transcription 
factor (Fragment) 









IPI00385786.3_cDNA FLJ35170 fis, clone PLACE6012942, 
highly similar to SPLICING FACTOR, 
ARGININE/SERINE-RICH 2 



























IPI00412579.6_60S ribosomal protein L10a 1 1 2 5.67  
10.89 0.131 24.8 
IPI00412643.1_Isoform 2 of Serine/arginine-rich splicing factor 
10 









IPI00451437.1_Isoform 3 of Zinc finger CCCH 
domain-containing protein 14 









IPI00455134.1_Isoform 2 of Heterogeneous nuclear 
ribonucleoprotein A3 
1 1 2 96.14 
 
89.88 1.536 37 
IPI00455383.4_Isoform 2 of Clathrin heavy chain 1 1 1 2 6.9  
2.19 0.11 187.8 








IPI00465070.7_Histone H3.1 1 1 2 36.7  
42.7 0.053 15.4 




IPI00478236.3_GTP:AMP phosphotransferase, mitochondrial 
isoform c 

























IPI00556297.1_Arginine/serine-rich splicing factor 6 variant 
(Fragment) 









IPI00640037.2_cDNA FLJ38496 fis, clone FELIV1000137, 
highly similar to 60S RIBOSOMAL PROTEIN L5 



























IPI00646047.1_cDNA FLJ43095 fis, clone CORDB2000541, 
highly similar to F-actin capping protein subunit beta 













IPI00739902.2_Isoform 2 of Melanoma inhibitory activity 
protein 3 

































IPI00796776.2_cDNA FLJ54081, highly similar to Keratin, type 
II cytoskeletal 5 









IPI00797941.3_cDNA FLJ57770, moderately similar to 
ADP-ribosylation factor 3 





IPI00829896.1_Hemoglobin Lepore-Baltimore (Fragment) 1 1 2 2.07  
7.38 2.613 11.5 




















IPI00852988.1_ubiquitin fusion degradation protein 1 homolog 
isoform B 







IPI00872952.1_Ubiquinol-cytochrome c reductase hinge protein, 
isoform CRA_c 

















IPI00902463.1_cDNA FLJ46898 fis, clone UTERU3022168, 
highly similar to Protein FAM62A 





IPI00902640.1_cDNA FLJ32326 fis, clone PROST2004332, 
highly similar to Brain-specific angiogenesis 
inhibitor1-associated protein 2 





IPI00902976.1_cDNA FLJ37504 fis, clone BRAWH2017103, 
highly similar to ATPase WRNIP1 





IPI00903112.1_cDNA FLJ36533 fis, clone TRACH2004428, 
highly similar to Lactotransferrin (Fragment) 





IPI00903143.1_cDNA FLJ44205 fis, clone THYMU3001379, 
highly similar to 116 kDa U5 small nuclear ribonucleoprotein 
component 





IPI00909083.1_eukaryotic peptide chain release factor 
GTP-binding subunit ERF3A isoform 2 





IPI00909134.1_cDNA FLJ58513, highly similar to 
Mitochondrial-processing peptidase subunit beta, mitochondrial 





IPI00909622.1_cDNA FLJ58787, highly similar to Cleavage 
stimulation factor 64 kDa subunit 
1 1 2 19.52 
 
12.14 1.271 58.6 
IPI00909657.1_cDNA FLJ50378, highly similar to 
Phenylalanyl-tRNA synthetase alpha chain 









IPI00910461.1_cDNA FLJ52962, highly similar to 
Ribulose-phosphate 3-epimerase 









IPI00910524.1_cDNA FLJ56243, highly similar to 
Melanoma-associated antigen 4 











Eukaryotic translation initiation factor 3 subunit 1 
IPI00910779.1_cDNA FLJ52141, highly similar to 14-3-3 
protein gamma 

















IPI00916535.1_prolyl 4-hydroxylase subunit alpha-1 isoform 3 
precursor 













IPI00922068.1_Isoform 5 of Insulin-like growth factor 2 
mRNA-binding protein 2 
1 1 2 6.07 
 
10.93 0.133 54.7 
IPI00922554.1_cDNA FLJ51996, highly similar to 
Deoxyribonuclease-2-alpha 

























































IPI00969132.1_Isoform 8 of Disintegrin and metalloproteinase 
domain-containing protein 15 







IPI00978796.1_17 kDa protein 1 1 2 6.58  
73.2 1.84 16.8 




















IPI00983652.2_cDNA FLJ61021, highly similar to Far upstream 
element-binding protein 1 





















IPI01010654.1_cDNA FLJ57899, highly similar to Mitotic 
checkpoint protein BUB3 









IPI01010852.1_cDNA FLJ57121, highly similar to 
Heterogeneous nuclear ribonucleoprotein F 





IPI01010990.1_cDNA FLJ53478, highly similar to 
Galectin-3-binding protein 





IPI01011079.1_cDNA FLJ54262, highly similar to 
N-acetylglucosamine-6-sulfatase 





IPI01011882.1_cDNA FLJ50515, highly similar to Dihydrolipoyl 
dehydrogenase, mitochondrial 









IPI01011998.2_cDNA FLJ52138, highly similar to NADH 
dehydrogenase (ubiquinone) 1 alpha subcomplex subunit 8 



















IPI01014777.1_cDNA FLJ53007, highly similar to UBA/UBX 
33.3 kDa protein 
1 1 2 2.49 
 
4.28 0.099 22.9 
















IPI01015765.1_cDNA FLJ57240, highly similar to Mitochondrial 
proteins import receptor 





IPI01020986.1_Uncharacterized protein 1 1 2 6.14  
6.06 0.104 13.8 
IPI01021182.1_Uncharacterized protein 1 1 2 7.5  
7.4 1.51 41.4 
IPI01021487.1_protein phosphatase 1 regulatory subunit 12A 
isoform b 









IPI01021673.1_Uncharacterized protein 1 1 2 5.42  
6.17 0.153 14.5 
























IPI01022580.1_14 kDa protein 1 1 2 2.77  
3.22 
 
14.1 
 
